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Abstract 
This thesis describes the incorporation of heterocycles as part of an a-amino acid side-chain. 
Two methods were adopted. The first involved the alkylation of a pseudoephednne 
glycinamide enolate using haloalkanes. The method was validated by making the naturally 
occurring amino acid phenylalanine. Subsequently naphthyl-, pyridyl-, biphenyl- and 
isoxazolyl- groups were successfully incorporated into the amino acid side chain. The 
enantiomeric excess of the product amino acids was found to be moderate (10-87%) due to 
poor diastereoselectivity in the key alkylation step. Moreover, the strict experimental 
conditions required for the alkylation reaction were found to be difficult to reproduce. 
Attempts to apply this enolate anion strategy to the incorporation of nucleic acid bases 
utilising an analogous purine electrophile failed, the reaction leading only to elimination. 
Thus, amino acids that carry a nucleic acid base in the side chain were synthesised by an 
alternative method. In this, N-(2-iodoethyl)- and N-(3-iodopropyl)-pyrimidines and purines 
underwent stereoselective conjugate radical addition with an optically active oxazolidinone 
acceptor derived from (R)-5’-methylcysteine to give syn-adducts. Hydrolysis of the 
oxazolidinone adducts followed by deprotection afforded the desired amino acids carrying 
pyrimidine- (thymine, uracil) and purine- (adenine, guanine) containing side chains. The 
enantiomeric excesses, which reflect the diastereoselectivity of the radical addition step, were 
found to be between 85 and 89%. 
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CHAPTER 1 
INTRODUCTION 
1.0 Introduction 
The synthesis of non-proteinogenic a-amino acids in enantiomerically pure form is an 
important goal because of their increasing role in biology and chemistry'. They are present 
in natural and pharmacologically active compounds. The presence of these amino acids as 
residues in peptides can render such peptides resistant to enzymatic degradation. These 
non-proteinogenic amino acid residues also have conformation-inducing properties in 
designed peptides and proteins*. According to the substitution pattern at the a-position, 
they can be classified as mono- and diakylated a-amino acids. a-Substituents include allyl, 
aryl, vinyl and heterocyclic groups, the latter class being particularly attractive because of 
the hydrogen bonding possibilities that can create a lot of diversity in biological activity. 
This introduction will therefore outline some background regarding the biological 
significance of certain classes of heterocyclic amino acids. Further, to give a wider 
perspective to the synthetic methodologies that we employed to assemble our unusual 
amino acids, we will also review briefly the more important strategies available in the 
literature to date. Except where the methodology or examples are directly relevant to the 
work in this thesis, we have limited the discussion to heterocyclic amino acids. 
1 
1.1 Objectives 
The goal of this work was the synthesis of novel nitrogen-containing heterocyclic amino 
acids, of the general structure 1.1 shown below, that can be incorporated into important 
biologically active targets. 
1.1 
At the outset, we decided to use and develop existing synthetic methodologies rather than 
develop a new methodology. One requirement we made of the chosen methodology was 
that it should be stereoselective, in contrast to the less challenging strategy that employs an 
already existing stereocentre in the amino acid backbone. A further requirement of this 
work was to choose a methodology that would permit a variation of the distance between 
the heterocycle and the amino acid backbone. 
We decided to focus our attention towards nitrogen- and oxygen- containing heterocycles. 
Amongst the simplest heterocyclic cores are the pyridyl, 1.2, and isoxazolyl, 1.3, rings; 
synthetically, these represent a simple challenge, as no protecting group would be required. 
1.2 1.3 
2 
Moreover, many of the simpler precursors are commercially available. Having assessed the 
viability of the route using these, we could then extend the method to other, perhaps more 
interesting, heterocycles such as those derived from pyrimidine, 1.4, and purine, 1.5. 
1.4 1.5 
The biological relevance of those chosen targets is discussed in the next section. 
1.2 Heterocyclic a-amino acids 
The twenty main naturally occurring a-amino acids are the fundamental building blocks of 
peptides, proteins and other natural products. Consequently, they fulfil fundamentally 
important roles in biology and chemistry such as structural (e.g. muscle), recognition (e.g. 
receptors), communication (e.g.  hormones, neurotransmitters), transformation (e.g. 
enzymes) and regulation ( in~ul in)~.  Amongst these twenty natural amino acids, histidine 
and tryptophan are the only two that bear a heterocyclic side chain. 
m -  ' f /__(YCo2H 
(S)-Tryptophan (S)-Histidine 
Tryptophan is important as the major precursor of the nicotinamide nucleotide coenzymes, 
NAD and NADP, and in the central nervous system as the precursor of the transmitter 
serotonin (5-hydroxytryptamine). The indole nucleus of tryptophan is also present in many 
fungal toxic peptides such as phalloidin and amanitin4. 
3 
The imidazole group in histidine is essential for the biological activity of a variety of 
enzymes, including the serine and cysteine proteases'. In the active centre, the histidine 
residue may serve as both donor and acceptor in hydrogen-bonding interactions, and it can 
also promote proton transfer by a general acid-base catalysis. Moreover, the imidazolyl 
nitrogen atoms are making histidine an efficient nucleophile both for acyl transfer reactions 
and for coordination to metals. Modification of the histidine residue in peptides can 
produce dramatic changes in biological activity (see section 2.2). 
In the following sections, the focus will be first on the role of heterocyclic amino acids as 
natural products, then on the introduction of such heterocyclic amino acids into peptides, 
and finally we will discuss briefly the recent advances concerning the manipulation of 
heterocyclic amino acids in relation to DNA. 
1.2.1 Heterocyclic amino acids as natural products 
The synthesis of natural products is one of the most important and challenging areas in 
organic chemistry. Many natural products contain amino acids. 
For example, excitatory amino acids (EAA) are known to mediate synaptic excitation, and 
therefore nerve signal transmission, by binding to EAA receptors6. EAA receptors can be 
divided into two main classes, namely, the ionotropic glutamate receptors containing the 
AMF'A ((S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid), KA (kainic 
acid) and NMDA (N-methyl-D-aspartic acid) receptors, and the metabotropic glutamate 
receptors containing ACPD (l-aminocyclopentane-1,3-dicarboxylic acid), group I, group II 
and group 111 receptors. 
4 
NMDA (S) -AMPA Kainic acid 
All these receptors are potential targets for therapeutic intervention in a number of 
diseases, such as Alzheimers and schizophrenia7. Consequently, compounds capable of 
activation of excitatory amino acid receptors (agonists) have potential as drugs for these 
disorders. One recent example displaying activity at iGlu-Rs (agonist for non-NMDA 
glutamate-type receptors), is the natural amino acid dysiherbaine 1.6, isolated from the 
Micronesian marine sponge Dysidea herbacea by Sakai and co-workers in 19978. 
1.6 
A synthesis of this challenging natural product target which contains six chiral centres, has 
recently appeared (Scheme l.l)9. In the penultimate step, the centre that becomes the chiral 
centre at the a-position in the amino acid is generated as a 1:l mixture of epimers of 
separable nitriles. 
5 
i) EDC, HOBt, DMBNHz (86%) 
NHDMB 
¡i) Oso,, acetone, NalO, (99%)- 
H 
i) K,CO,, acetone 
6 M HCI, (99%) 
DMB - (-)-dysiherbaine ¡i) TMSCN, Znl,, 
O 
50% + epimer at position 2 
Scheme 1.1 
The AMPA receptor is selectively activated by (S)-AMPA, and the synthesis of 
heteroarylalanine analogues of AMPA 1.7 that could serve as receptor ligands has been 
accomplished'' 
U: 
6 H,N COzH 
1.7 
Although these (S)-AMPA analogues have shown full agonist activity, no simple SAR 
correlations were found. Further development of amino acids containing isoxazole, 
aromatic or heteroaromatic rings is therefore still necessary to provide potential candidates 
as AMPA receptor agonists. 
The synthesis of kainic acid analogues is also an intense area of research and it has been 
suggested that they may have a useful role in the treatment of epilepsy''. Many analogues 
of the natural product acromelic acid A 1.8 have shown some activity". 
6 
One further naturally occurring heterocyclic excitatory amino acid that has received a lot 
of attention is quisquaiic acid. This activates metabotropic glutamate Group I receptor6, 
Quisqualic acid 
Apart from compounds that act at glutamate receptors, other natural amino acids such as 
the pyridyl derivative azatyrosine 1.9 and the dihydropyridyl derivatide mimosine 1.10 
have been observed to display antibiotic, wool growth hormone and pollen growth 
inhibition a~t iv i ty '~ .  Lathyrine 1.11, a pyrimidine-containing a-amino acid, and 
discadenine 1.12 (isolated from Dicryostelium di~coideum'~),  a purine-containing a-amino 
acid, also display biological activity. 
HO q 
H2NAC02H H2NAC02H 
1.9 1.10 
/ t 
/- 
HN 
1.11 1.12 
1.2.2 Heterocyclic a-amino acids as natural amino acid replacements 
We have seen that natural heterocyclic a-amino acids, as well as synthetic analogues, have 
biological activity in their own right. However they can also induce biological activity 
when incorporated into natural or designed peptides. For example, pyridyl amino acids 
1.13 serve as a replacement of histidine and phenylalanine in numerous biologically active 
compounds. Indeed, it is well known that pyridylalanines and substituted analogues exhibit 
diverse pharmacological effects when introduced into biological systemsI5. 
1.13 
More precisely, in angiotensin I1 (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-) the replacement of 
the histidyl residue by basic, neutral, acidic, and aromatic residues gave analogues with 
low biological activity. Therefore, the structural features of histidine, namely the electron 
rich aromatic ring and the two heterocyclic nitrogens was studied in more detailI6. 
Replacement of histidine by 2-(pyridyl)-(S)-aIanine 1.14 and 2-(imidazolyl)-(S)-alanine 
1.15 revealed that the pyrrolic NH is necessary for the interaction of angiotensin II with its 
receptor, the pyridine nitrogen N9 playing a minor role. 
8 
@:"" 
1.14 1.15 
1.2.3 Heterocyclic a-amino acids and DNA 
The most important molecular recognition event in Nature is the base-pairing of nucleic 
acids, which guarantees the storage, transfer and expression of genetic information. 
H 
.- 
*.-- *.- 
- - -  -.-- __.-- "-.- O 
Thymine 
N 
Cytosine 
/ 
Guanine Adenine 
Figurel.l/Nucleobase recognition by Watson-Crick hydrogen bonding 
Highly specific recognition is a result of specific base-pairing between the purine and 
pyrimidine nucleobases, guanine with cytosine and adenine with thymine (Figure 1 .i). 
These interactions between the nucleic acid bases are responsible for the helical structure 
of DNA. One way to disrupt this helical structure and the base stacking is to introduce 
intercalating agents that could intercalate between the nucleic acid bases and interact with 
the strands of DNA. Another way is to introduce oligonucleotide derivatives which mimic 
the DNA structure. Finally, a more recent approach that has led to a new and rapidly 
expanding field of research, namely peptide nucleic acids (PNA), will be treated. 
9 
1.2.3.1 Intercalating agents 
The primary mode of noncovalent binding of small molecules to DNA and RNA is 
intercalation and groove binding. Intercalators are molecules that bind to DNA by insertion 
of an aromatic moiety between the stacked base pairs of double helical DNA. 9- 
Anilinoacridine-4-carboxamides 1.16, for example, have shown binding to DNAI7. In the 
intercalation complex, acridine substituents at the 4- and 9- positions are located in the 
major and minor grooves with the acridine chromophore sandwiched between base pairs. 
These compounds allow for base-specific groove binding by the substituents to occur. The 
ability of intercalators to direct functionality into both the major and minor grooves of 
nucleic acids makes them good candidates for selective ligands able to provide molecular 
recognition. In particular, acridines have been shown to be potent inhibitors of the cancer 
chemotherapy target topoisomerase II'*. 
Groove binding -
1 Intercalation 
N 
H' ' R' - 
Groove binding 
1.16 
Interestingly, several non-natural amino acids carrying large aromatic groups such as 2- 
anthrylalanine 1.17, 2-pyrenylalanine 1.18 and 1-pyrenylalanine 1.19 have been 
10 
successfully incorporated into proteins via the ribosomal system''. It has been shown that 
success in the incorporation depends on the amino-acid used together with recognition by 
the ribosomal A-sitezo. 
H,N 
1.17 
9 \ /
I 
", 1.18 1.19 
The incorporation of these amino acids could be translated into conformational changes in 
the protein, enzymes or binding site. One can well imagine designing proteins 
incorporating amino acids containing large side chains in order to target particular 
functions or genetic disorders at the desired site. 
1.2.3.2 Antisense oligonucleotides 
Zamecnick and Stephenson were the first to propose, in 1978, the use of synthetic 
oligonucleotides for therapeutic purposes" in the inhibition of a virus in a cell culture. The 
inhibition is based on the specific Watson-Crick base pairing between the heterocyclic 
bases of the antisense oligonucleotide and of the viral nucleic acid. In order to meet these 
inhibition requirements, it is necessary for normal oligonucleotides to be chemically 
modified. We briefly describe below such modifications. 
11 
Backbone modifications 
DNA structure can be modified at the phosphate backbone level. Phosphorothioate 
oligonucleotides (Figure 1.2) are those in which one (or more) oxygen atom has been 
replaced by sulfur and selenium". 
I l l I O 
b B  O b B  o"" 
I I -o-p=o 
l l I I O 
o\.*' b B  '&Bo\.-' o"' '&B o"' 
I -o-p=o 
O."' 
I -s-p=o -s-P=s 'Se-P=O 
o,.*' 0." 
I 
I 
'Se-P=O 
I I -s-p=o -s-p=s 
l l I I 
DNA Phosphorothioate oligonucleotides 
Figure 1.2 Replacement of oxygen atoms in the phosphate backbone of DNA 
Indeed, this modification made the oligonucleotides more stable towards degradation by 
enzymes (nucleases). However, it was found that the binding affinity to mRNA was poor. 
Base modifications 
To increase binding affinity and specificity to a complementary nucleic acid sequence, 
oligonucleotides can also be modified by incorporating 'unnatural' heterocyclic bases. 
Most of the reported modifications have concentrated on analogues of the purines and 
pyrimidines that are the principal bases of nucleic acid. 
There are four principal sites for modification of the pyrimidine ring: C-2, C-4, C-5 and C- 
6. 1.20. 
12 
c-4 
1.20 
Modifications at C-2 interfere with the hydrogen bonding that is essential for 
complementary base pairing, and these are therefore unfavourable. Modifications at C-4 
include OCalkylthymine 1.21, N4-methoxycytosine 1.22, N4-methylcytosine 1.23, and 
pyridopyrimidine 1.24. The latter modification, 1.24 (which also involves C-5 
modification), resulted in a stabilised duplex due to stronger hydrogen bonding than the 
natural cytosinez3. 
1.21 1.22 1.23 1.24 
Modifications at C-6 showed that 6-substituted 5-azacytosines, such as 6-hydroxy- 1.25 
and 6-amino-5-azacytosines 1.26 could serve as 'universal' bases in that they hydrogen 
bond with guanine, thymine and uracil with equal efficiency. 
"2 I 
1.25 1.26 
Uracil 1.27, a pyrimidine base found in RNA that can hydrogen bond with adenine, has 
also been the subject of modification. In particular, derivatives 1.28 can also be obtained 
having a halogen atom at the C-5 position. Oligomers containing these halogenated uracil 
13 
derivatives have been shown to form a more stable duplex than the oligomers containing 
uraciiZ4. 
1.27 1.28 
The main problem with the above modifications is their lack of specificity. This has 
prevented them from being used in antisense (&NA targeting) studies. 
N-7 C-6 
t t 
c-8 _ _ _ _ _  + ( r J + - - - N - 1  
N \. I r  -- c-2 
N-3 
1.29 
Modification of the purine moiety 1.29 has produced analogues that are able to form a 
more stable duplex than their natural counterparts. As an example, incorporation of the 2- 
aminoadenine 1.30 into oligonucleotides resulted not only in enhanced binding to DNA but 
also in more specific base pairing via the additional H-bond that is formed between the 2- 
amino group of 1.30 and the 2-oxo group of thymine. 
14 
ThymineiAdenine Thymine/2-aminoadenine (1.30) 
In addition, C-8 modification has provided analogues such as 8-hydroxyadenine 1.31, 8- 
methoxyadenine 1.32, 8-hydroxyguanine 1.33, and 8-methoxyguanine, 1.34 that possess an 
increased resistance to enzymes that cleave nucleic acids at phosphodiester bondsz5 
(nucleases). 
1.31 1.32 1.33 1.34 
1.2.3.3 Peptide nucleic acid technology 
Peptide nucleic acids (PNA) have emerged as a new class of therapeutic agents, designed 
to inhibit expression of genetic information both as antisense (&NA targeting) and 
antigene (DNA targeting) agents. Peptide nucleic acids are being developed to target a 
particular gene responsible for a genetic defect. Preventing its expression, by interfering 
with the transcription of a particular sequence, is a much more efficient way of intervening 
than targeting the genetically defective protein itself. 
In order to be ideal therapeutic agents, small oligonucleotide sequences must fulfil at least 
three fundamental requirements: first, they must bind to target mRNA or DNA according 
to Watson-Crick base pairing; second, they must be sufficiently robust both inside and 
15 
outside the cell environment; and third, they must be able to reach the site of action, just as 
for any other drug. Natural oligonucleotides themselves have a high affinity for DNA as 
they bind to DNA via Watson Crick base pairing, but they are easily degraded by cellular 
enzymes. Consequently, they are unsuitable as therapeutic agents. It is therefore necessary 
to introduce chemical modification for the purpose of intact delivery to the site of action. 
The group of Nielsen in the early 1990's reported an entirely different approach towards 
improving binding affinity to complementary nucleic acid, increasing biological stability, 
and improving cellular uptake. PNA represents a very dramatic deviation from the natural 
DNA structure since the entire phosphodiester backbone has been replaced by a 
pseudopeptide backbone. In this approach, the sugar-phosphate backbone is replaced by an 
N-(2-aminoethyl)glycine-based polyamide structure 1.35, in which each subunit 
incorporates one of the naturally occuring nucleic acid bases attached to the polyamide 
backbone via a modified acetyl group. From a chemical point of view, PNA is a hybrid 
between an oligonucleotide (nucleobases) and a protein (backbone) and therefore shows 
properties from both categories. 
B B 
1.35 
Nielsen discovered that these PNAs bind with higher affinity to complementary nucleic 
acids than their natural counterparts and obey the Watson-Crick base pairing rules. An 
advantage of PNAs over oligonucleotides is that the polyamide backbone is not recognised 
by either nucleases or proteases and is therefore not cleaved. However a major limitation 
of PNAs from the perspective of their use as therapeutic agents is their poor solubility in 
aqueous medium. In addition, being achiral, they bind to complementary DNA in both 
parallel (PNAíS'DNA) and antiparallel (PNAí3'DNA) modes. In an attempt to impart 
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discrimination between parallel and antiparallel modes of binding, chirality was introduced 
into PNA molecules either by linking amino acidsz6, peptides or oligonucleotides at the 
terminus or by incorporation of chiral amino acids in place of glycine into the PNA 
backbone. Of course, symmetry can also be introduced into PNA through incorporation of 
cyclic amino acids into the PNA backbone. 
Incorporation of cyclic amino acids into the PNA backbone 
Kumar and Ganesh" have employed PNA monomers containing stereospecific chemical 
modifications. They envisaged introducing chirality into the backbone by synthesising the 
modified proline unit 1.36. 
1.36 
Comparison of this with the generalised PNA structure reveals the a-carbon of the glycine 
unit and the ß-carbon of the adjacent ethylenediamine unit are bridged via a methylene 
group. The precursors required for such oligomers are the 4-(WS)-amino-Na-(A/G/C~- 
ylacetyl)-2-(R/S)-prolines containing two asymmetric centers at C-2 and C-4 1.37. 
Naturally occumng trans-4-hydroxyproline has been manipulated to access ali four 
stereoisomers and has proved to be a useful starting material to synthesise such 
conformationally constrained PNA monomers. Oligomerisation of the four possible 
diastereoisomers has led to polychiral PNA having wide conformational diversity in the 
backbone. 
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A similar strategy was later employed by Lowez8 utilising 4-hydroxyproline to synthesise 
HO 
PNA monomers in which the nucleobase is positioned at C-4 of the pyrrolidine ring 1.38. 
Y 
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Y 
NH 
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1.39 1.38 
This chiral PNA, based on a glycyl-($proline skeleton, was shown to interact strongly 
with complementary DNA and RNA; however, it had poor solubility in aqueous media, 
making biological studies difficult. Lowe therefore synthesised a variantz9 that utilised a 
hydrophilic N-aminoethylproline backbone, 1.39. This was readily soluble in aqueous 
medium and exhibited a strong interaction with oligoribonucleotides but not with 
oligodeox yribonucleotides. 
Another class of peptide nucleic acid monomer containing a cyclic system has been 
synthesised by Nielsen3' (Scheme 1.2). The monomer has conformational restriction and 
the carbocyclic ring was also designed to increase the lipophilicity of the monomer. The 
monomers having a chiral backbone were prepared using the commercially available cis or 
trans isomers of 1,2-diaminocyclohexane. One amino group was protected as its Boc- 
derivative, the other was alkylated with methyl bromoacetate. The desired monomers 
i 8  
containing a chirai backbone were obtained by coupling to carboxymethyl functionalised 
purine or pyrimidine followed by basic ester hydrolysis. 
OH 
D - i) BOCZO, 
¡i) Methyl bromoacetate 
Scheme 1.2 
PNA containing amino acid having side chains 
1.40 
PNAs containing (R)-monomers (R-PNAs) 1.40 have been found to bind to the 
complementary antiparallel DNA with greater stability than do the corresponding (S)- 
PNAs3'. The synthesis was effected using a similar strategy as in Scheme 1.2 but using 
lysine instead of glycine. The observed enantioselectivity has been explained in terms of 
preferential PNA helicity induced by the configuration of the stereogenic centre. 
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PNA with a nucleobase-bearing amino acid 
A final category of modification, in which we have been particularly interested, is that in 
which the nucleobase is incorporated as part of a side chain of an a-amino acid 1.41. 
Nielsen's PNA 1.41 
Taddei and co-workers have designed these building blocks in an attempt to enhance the 
rigidity of the PNA backbone, which is supposed to be one of the factors responsible for 
the binding of PNA to DNA. Taddei chose to prepare the self-complementary 
oligonucleotide ATATATAT 1.4232. 
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The polypeptide backbone was composed entirely of a-amino acids and the distance 
between the nucleobases was the same as in the originai PNA devised by Nielsen. Glycine 
was chosen as the spacer so that the structure would not be complicated by additional 
chirality. Lysine was chosen at the N-terminus to increase the solubility in aqueous media 
of this relatively low polarity structure. This PNA was indeed found to mimic DNA by 
forming a duplex with itself through Watson Crick base-pairing. However, the thermal 
stability of this complex was found to be lower than that of analogous PNA systems. 
However, the small number of bases employed in the structure and the fact that the semi- 
rigid peptide backbone may have some difficulty in adopting the double helical structure in 
solution may account for this low thermal stability. Nevertheless, it was demonstrated that 
a real chiral peptide nucleic acid with a structural backbone analogous to that of natural 
peptides could be prepared and that this product had some properties of typical nucleic 
acids. 
Y a m a ~ a k i ~ ~  observed stable complex formation between dinucleotide analogues and 
complementary natural polynucleotides; again these dinucleotide analogues (eg. 1.43). 
contain a true peptide backbone. 
1.43 
Indeed, he found that even these small dinucleotide-containing molecules showed good 
ability to form triplex structures. Moreover, analogues containing variation of the (alkyl) 
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substituent at the a-position of the spacer amino acid unit showed very similar potency. A 
modification at this position with heterocycle-containing amino acids may be feasible to 
increase further the stability of the complexes or to modulate the DNA recognition ability. 
1.3 Targets 
The aim of the present work was to synthesise heterocyclic a-amino acids by selecting a 
stereoselective method of assembling amino acids and to apply it to targets such as those 
described in the previous section. More specifically our targets included cyclic and 
heterocyclic a-amino acids. Examples of this type included simple aryl groups such as 
naphthyl, 1.44, and biphenyl, 1.45, which could potentially serve as intercalating agents, 
and which were also used to test the synthetic method because the precursors do not 
necessitate any protecting group. 
1.44 1.45 
After establishing confidence in the method, we envisaged extending it to heterocycles 
containing one (pyndyl, 1.46) or two (isoxazole, 1.47) heteroatoms in the ring system 
(potential excitatory amino acid mimics) and then moving to the more challenging target, 
which constitute the main core of this thesis. In particular, our attention was focused on 
amino acids carrying heterocycles such as purine, 1.48 and pyrimidine, 1.49, that contain 
two or more heteroatoms, for potential PNA application. These more valuable targets 
require manipulation of protecting groups so as to allow access to the desired molecules. 
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1.4 Strategies for assembling amino acids 
To meet the demand for enantiomerically pure a-amino acids with specific non- 
proteinogenic functional groups, a large number of synthetic methods has been developed. 
For convenience, we have divided these into two main categories. The most synthetically 
challenging of these involves the asymmetric attachment, 1.50, of either a nucleophilic or 
an electrophilic group to the a-carbon of a glycine equivalent. The second strategy 
involves attachment of the heterocycles at a bond beyond Cp (see 1.50) to a chiral 
substituted glycine derivative. 
o 
> r  
8 '. 
1.50 
The large number of synthetic methods available for the synthesis of enantiomerically pure 
amino acids is a reflection of the biological and chemical significance of such compounds. 
This section will focus on retrosynthetic strategies, highlighting those that have been 
employed in the most recent examples. 
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1.4.1 Attachment of heterocyles to a glycine equivalent 
Retrosynthetic analysis involves seven different disconnections of the carbon-carbon bond 
at the asymmetric centre (Figure 1.2). Indeed the reaction of an electrophile or nucleophile 
in a stereoselective manner has been demonstrated to be most effective for the synthesis of 
heterocyclic amino acids. This is a very popular approach as it offers significant flexibility 
in the type of a-amino acid that can be produced. One of the main disadvantages of this 
method is that very often a chiral auxiliary is required to induce or create the 
stereochemistry at the a-centre. The harsh conditions often required to cleave the chiral 
auxiliary, and a requirement for purification to remove traces of chiral auxiliary, can limit 
the use of such approaches. 
Nucleophilic alkylation 
I
Electrophilic alkylation 
 
Nucleophilic amination 
Electrophilic amination 
'JOH I
"2 
H"' 
Nucleophilic carboxylation 
I 
Electrophilic carboxylation 
 
Homolytic alkylation - 
Figure 1.2 
dOH ,.s. - 
NH2+ 
R 
H. NH2 
\ 'C02H 
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Each disconnection will now be discussed in turn and illustrated. 
1.4.1.1 Nucleophilic alkylation 
Nucleophilic alkylation 
'f&OH , /  
I$''. NH2 "2 
H"' 
Scheme 1.3 
This method has received limited attention as the number of functional groups compatible 
with an organometallic nucleophile is restricted. One of the most thoroughly studied 
glycine cation equivalents is the 3-bromooxazinone 1.51 34,35 . 
- I  
"2 
1.51 1.52 1.53 
Scheme 1.4 
This has been successfully substituted with retention of configuration by malonate, alkyl 
zinc halides and cuprates (Scheme 1.4). 
Using chiral esters as electrophilic glycine templates can also provide a-amino acids in 
high enantiomeric excess. When 8-phenylmenthyl ester 1.54 was used as the auxiliary, the 
a-bromoglycinate 1.55 was prepared as a single stereoisomer by reaction with N- 
bromosu~cinimide~~ (Scheme 1.5). 
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1.56 
Scheme 1.5 
This intermediate was then reacted with a Grignard reagent to form first an imine that was 
stereoselectively attacked by a second equivalent of Grignard reagent to give 1.56. 
Subsequent acid cleavage of the ester afforded the a-amino acids. 
1.4.1.2 Electrophilic alkylation 
Electrophilic alkylation 
R* . 
"8' 
OH 
"2 
"2 
Scheme 1.6 
This strategy will be discussed in more detail in the next chapter, as one of the methods 
utilised in this thesis involves electrophilic alkylation of a glycine enolate equivalent. 
1.4.1.3 Nucleophilic amination 
O I l  Nucleophilic amination 
Scheme 1.7 
The generation of a-amino acids by introduction of the N H 2  group through the use of 
nucleophilic aminating agents is generally based on S N ~  displacement, the chirality being 
developed prior to nucleophilic amination. Versatile intermediates for this procedure are 
chiral epoxides (e.g. 1.57). Benzylamine, for example, can act as an efficient nucleophilic 
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aminating agent for the formation of optically pure cl-amino acids viu intermolecular 
reaction with a suitable epoxide37 (Scheme 1.8). 
PhCH2NH2 
* no 
NaOWH20, 89% 
Reflux 
HO% 
66% 
1.57 bh 
Scheme 1.8 
1.4.1.4 Electrophilic amination 
dOH 
H' + "2 
Electrophilic amination 
I
H\\"' ,i- R J  
Scheme 1.9 
Another direct approach to a-amino acids is the amination of enolates with electrophilic 
reagents. A promising electrophilic amination reagent, which has been introduced by 
Evans et and has been used mainly for the preparation of complex amino acids 
(Scheme l.lO), is triisopropylbenzenesulfonyl azide. 
- 0  n ! ?  
i) KN(SiMe3),, 1.1 equiv. 
Ar 
KOAc Ar? OCH2Ph 
NHBoc 
Scheme 1.10 
27 
Oppolzer et al. have disclosed another procedure for enantioselective electrophilic 
amination of enolates based on the N-acylcamphorsultam 1.59 as chiral template and using 
1-chloro-1-nitrosocyclohexane 1.60 as the nitrogen electrophile (Scheme 1.1 1)39 
HCi I\ 'NOH 1) Zn 
2) LiOH 
- 
O 
Scheme 1.11 
1.4.1.5 Nucleophilic carboxylation 
R 
'CO2H 
Nucleophilic carboxylation \ 
OH p.'' NH, 
"2 
Scheme 1.12 
This approach is usually associated with the Strecker reaction (Scheme 1.13) that typically 
utilises stereochemically pure carbohydrate-derived amines (1 .61)40. The nucleophilic 
carboxylate synthon in the Strecker synthesis is the cyanide ion. Stereocontrol can be 
expected by incorporating chirality in the aldehyde, the amine, and the nucleophile or by 
using a chiral catalyst. 
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i )  RCHO, AcOH 
¡ i )  Me3SiCN, SnC4 * 
Strecker NH 
!-CN 
1.61 d" 
d.e 90% 
Scheme 1.13 
The key step in the Strecker reaction relies on the nucleophilic addition of cyanide ion to 
the C=N bond of an imine, the nitrile functionality being then converted into the carboxylic 
acid, generally by acid hydrolysis. Some asymmetric versions of this reaction have been 
described giving a-amino acids with an enantiomeric excess of up to 99% (Scheme 
1.  14)4'. 
(N Il 
92% e.e. 60% 99% e.e. 
Scheme 1.14 
1.4.1.6 Electrophilic carboxylation 
+ 
I 
Electrophilic carboxylation 
"2 "2 
Scheme 1.15 
Fournet et recently described the synthesis of enantiomerically pure a-amino acids by 
carboxylation (COZ gas) of N-(a-1ithioalkyl)oxazoiidinone (1.63) reagents obtained by the 
tin-lithium exchange of N-(a-stanny1alkyl)oxazolidinones 1.62 (Scheme 1.16). This 
extended a method originally designed for methionine to other amino acids and was 
applied to the synthesis of S-leucine, S-alanine and S-homocysteine in ca. 80% yield and 
with enantiomeric excesses superior to 90%. 
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Scheme 1.16 
1.4.1.7 Homolytic alkylation 
'JOH H\\' "2 
Homolytic alkylation 
L
Scheme 1.17 
The asymmetric formation of a-amino acids by reaction of stannanes with a chiral a- 
bromo glycine ester (1.64) is one of the radical strategies that has been reported43344 
(Scheme 1.18). 
&o%NHBoc B@nR [ao% NHBoc 
H Br 1.64 
* &o&NHBoc 
R 
Scheme 1.18 
The general radical strategy will be discussed in more detail in Chapter 3 since we have 
used such an approach to make our heterocyclic amino acids. 
This brief overview demonstrates the approaches that have been used to generate 
stereoselectively a chiral centre at the a-carbon atom. The remainder of this introduction 
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will detail an alternative strategy that involves the construction of a-amino acids by 
modification of the side chain of a readily available a-amino acid, retaining the level of 
stereochemical purity. 
1.4.2 Attachment of heterocycles to substituted glycine 
Work in this area has concentrated on the formation of the Cp-C, bond from electrophilic, 
nucleophilic and radical based synthons (Scheme 1.19) that are. generated from alanine, 
serine, cysteine or aspartic acid and this will constitute the first sub-section of this survey. 
In a second sub-section, we will concentrate on the synthesis of a-amino acids by 
formation of bonds beyond C,. 
B 
fJy 
H,N a coon 
H2N 1 COOH 
Electrophilic alanine 
H2N 1 COOH ' I  n2&coon 
Nucleophilic alanine Radical alanine 
Scheme 1.19 
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1.4.2.1 Electrophilic alanine 
/R - 
Scheme 1.20 
The two most common ß-cationic a-amino acid synthetic equivalents are derived from 
serine and cysteine. This concept is most readily realised by substitution of the serine OH- 
function after suitable activation. To avoid competing elimination, Vederas and coworkers 
have prepared the ß-lactones 1.66 by Mitsunobu esterification from N-Boc-serine4’ 1.65 
(Scheme 1.21). 
1.65 1.66 
Scheme 1.21 
Substituted alanines were obtained with various heteronucleophiles. Heating with 
phosphites resulted in an Arbusov-like substitution to ß-phosphoalanine 1.6746. The 
nucleophilic substitution can also be effected with ammonia, giving access to 2.3- 
diaminopropanoates 1.6S4’, but a competitive reaction occurs which is the formation of the 
serine amide resulting from the attack at the carbonyl group. By using cyanide ion as the 
nucleophile, the resulting ß-cyano amino acid derivative could be hydrolysed to the 
aspartate 1.6948. 
1.67 1.68 1.69 
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Heterocyclic amino acids can be obtained by a Lewis acid catalysed alkylation of the 
aziridine carboxylate 1.70 with various indoles to yield substituted tryptophans 1.7149 
(Scheme 1.22). 
x - q  
H k y o R 1  R3 b x-\ W O R '  NHC02R2 
/ 
03 Lewis Acid N 
R3 OR2 
1.70 1.71 
Scheme 1.22 
Baldwin and co-workers have used the serine sulfamate 1.72 as a substitute for aziridine 
carboxylate in substitutions with a variety of nucleophiles, incuding cyanide, pyrazole, and 
malonates0 (Scheme 1.23). 
o. J N Z  ' -b [RrhFoR2] - Nu +OR2 NHR' 
Scheme 1.23 
o/Sc'O 
1.72 
1.4.2.2 Nucleophilic alanine 
dR 
HzN 1J COOH 'HzN 1 COOH 
Scheme 1.24 
The polarity of the serine side-chain can be reversed from electrophilic to nucleophilic by 
utilisation of sulfone or phosphonium functionalities. For example, Itaya and co-workers5' 
have shown that the phosphonium chloride 1.73 can be prepared in 59% yield from 
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S-serine, and that the stereochemical integrity is retained completely upon reaction with n- 
BuLi and benzaldehyde (Scheme 1.25). 
CI‘ 
1.73 
Scheme 1.25 
Jackson et al. have reported the preparation of ß-iodoalanine 1.74 and on the use of the 
corresponding Reformatsky reagent (Scheme 1.26). Aromatic iodides can also be used; for 
example, the pyridine analogue of phenylalanine, 1.75, was obtained in moderate yield”. 
Various acid chlorides have also been coupled using catalytic palladium, an example being 
the glyceric acid derivative 1.7653. 
COzBn 
C02Bn - 
ZnlCulPd NHBoc Pd 
1.75 1.74 1.16 O NHBoc 
Scheme 1.26 
1.4.2.3 Radical alanine synthetic equivalent 
R 
HzN 1’ COOH ‘ 
Scheme 1.27 
54SS.56 The Cp radical can be obtained by photolysis of the Barton ester of aspartic acid 1.77 
or from homolytic cleavage of a ß-haloalanine 1.78 with a tin radical. 
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Scheme 1.28 
Radical traps include electrophilic olefins 1.79 that give adducts 1.80 in good yields. 
The radical addition can also occur in an intramolecular fashion (Scheme 1.29). Treatment 
of an N-allyl or N-propargyl-ß-haloalanine (1.81) derivative with tributyltin hydride leads 
to proline derivatives (1.82)". 
Br 
Bu,SnH 
I l  
'N'C02CH2Ph SO h I * 
1.81 
Scheme 1.29 
1.4.2.4 Bond formation beyond C, 
6OiPh 
1.82 
Figure 1.2 
(S)-Pyroglutamic acid 1.83 can serve as a building block to effect transformations beyond 
C, and Murray has utilised the lactam 1.84 to prepare a range of pyrrolidoness8. Each 
diastereoisomer of 1.84 was further elaborated to give a range of heterocyclic amino acids. 
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Scheme 1.30 
Taylor has used a borane methodology based on allylglycine 1.86, and has carried out a 
hydroboration-Suzuki cross-coupling sequence using a range of unsaturated halidess9. 
Scheme 1.31 
Another starting template for the synthesis of heterocyclic a-amino acids by construction 
of bonds beyond C., is the vicinal tricarbonyl 1.87, which is easily accessible from glutamic 
(n=2) or aspartic acids (n=i). Reaction of 1.87 with ethylenediamine (Scheme 1.32) gave 
the desired pyrazine substituted amino acid 1.8860. A cyclocondensation with 1,2- 
diaminobenzene resulted in conversion to the quinoxaline substituted a-amino acids 1.89. 
The 1.2.4-triazine 1.90 was also achieved in good yield by reaction with S-methyl 
isothiosemicarbazide. No investigation of potential racemisation during the 
cyclocondensation was reported. 
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Scheme 1.32 
Baldwin er al!' have used a propargyl functionality 1.91, created from aspartic acid:' to 
synthesise a range of non-proteinogenic heterocyclic amino acids (Scheme 1.33). 
1.93 O 
Scheme 1.33 
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1.5 Summary 
The aim of this project was the synthesis of unnatural heterocyclic a-amino acids. Indeed, 
first, they represent important targets as some are present as natural products. We have 
shown that the heterocycle itself is the key that can govern the activity in a peptide unit and 
in many cases the heterocycle is responsible for the binding to the substrate. Moreover, the 
synthesis of amino acids is important for the design of DNA mimics. More recently nucleic 
acid bases bearing amino acids have attracted a lot of attention in the design of novel 
peptide nucleic acids. The methods to synthesise heterocyclic amino acids are numerous 
and are governed by the structure of the heterocycle. In this work, we have chosen first to 
use an anionic route and secondly a radical method, this will constitute the two main 
chapters of this thesis. 
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CHAPTER 2 
A GLYCINE ENOLATE APPROACH 
2.1 Methods available 
As outlined in the generai introduction, one possibility for retrosynthetic disconnection at 
the a-carbon of amino acids corresponds to the introduction of the complete side chain R 
by electrophilic attack on a glycine enolate (Scheme 2.1). 
?iR8 
/N\ 
R'rOR. 
dN- 
/ 
R+ 
D 
Scheme 2.1 
This approach will now be elaborated further, with an overview of the most important 
methods available, and with highlights of their respective advantages and weaknesses. 
2.1.1 Bis-lactim ethers 
The introduction of the chiral bis-lactim ether, e.g 2.4, as a glycine enolate equivalent was 
made by Schöllkopf and coworkers63. This method, useful for the preparation of a large 
variety of amino acids, is based on the metallation and subsequent alkylation of the bis- 
lactim ether 2.4 (Scheme 2.2). 
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Scheme 2.2 
The general procedure involves formation of the chiral piperazinedione 2.3 and subsequent 
bis-lactim ether formation with trimethyloxonium tetrafluoroborate. The most popular and 
extensively studied bis-lactim ether is that derived from S-valine and glycine. Metallation 
of the bis-lactim ether with butyllithium in THF at low temperature and subsequent 
alkylation with a variety of electrophiles gives the anti-adducts 2.5 with a high degree of 
stereoselectivity. Hydrolysis of the heterocycle using dilute hydrochloric acid furnishes the 
new amino acid methyl ester 2.6 (usually the @)-enantiomer) and (8-valine methyl ester 
which must be separated. 
Several other bis-lactim ethers have been prepared following this standard protocol 
including systems derived from (S)-0,O-dimethyl-a-methyldopa nd glycine 2.7, (S)- 
valine and alanine 2.8, (S)-terr-leucine and glycine 2.9, (S)-leucine and (3)-leucine 2.10, 
(S)-isoleucine and glycine 2.11 (Scheme 2.3). 
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2.10 
Employing the Schöllkopf template 
2.1 1 
Scheme 2.3 
4, Hopkins et al. prepared ovothiol AM found 
in the eggs of certain marine invertebrates, via alkylation using N-methyl-4-(p- 
methoxybenzylthio)-5-chloromethylimidazole, chromatographic separation of the 5:l 
anri:syn mixture of diastereoisomers and hydrolysis of the bis-lactim ether 2.12 (Scheme 
2.4). 
Me 
e H 
c - 1. aq. HCI 
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HZN 
MeO 
HS anisole 
2.4 CI 2.12 2.13 
Scheme 2.4 
Although, the bis-lactim ether method provides a powerful and versatile tool for preparing 
a large array of a-amino acids, a weakness of the method is the difficulty encountered in 
the hydrolysis of the denvatised bis-lactim ethers first to the amino acid methyl esters and 
subsequently, under harsher conditions, to the free amino acids. 
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2.1.2 Asymmetric enolate alkylation of Schiff bases 
One of the first reports on the stereoselective alkylation of glycine imines was that by 
Yamada et al. in 197665. in this strategy, Scheme 2.6, condensation of (lS,2S,5S)-2- 
hydroxy-2,6,6-trimethylbicyclo[3.1.l]heptan-3-one 2.14 with glycine rerr-butyl ester in the 
presence of BF,-Et,O gave the ketimine 2.15. Treatment with 2 equivalents of LDA in 
THF led to the chelated dilithio species 2.16, and subsequent alkylation proceeded 
stereoselectively to give 2.17. Hydrolysis of the ketimine with aqueous citric acid in THF 
provided the tert-butyl esters 2.18 that could be cleaved to the free amino acids. 
2.14 2.15 2.16 
2.17 2.1 8 2.14 
Scheme 2.6 
McIntosh and coworkers66 have used use a similar strategy based on camphor-derived 
imines of glycine (Scheme 2.7). Camphor itself was found to be too sterically hindered to 
condense directly with glycine esters to form the Schiff base; instead the more reactive 
thione 2.19 was used. Conversion of the intermediate imines 2.21 to the tert-butyl esters 
2.22 required hydroxylamine, as steric hindrance makes hydrolysis of the camphor imine 
difficult. However, the inconsistent stereoselectivity, which is dependent on the structure 
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of the electrophile, and the tricky final cleavage of the hindered imine are factors which 
have limited the application of this method. 
Scheme 2.7 
2.1.3 Oxazolidinones and imidazolidinones 
The use of the oxazolidinone system is exemplified by compound 2.23 which can be 
prepared from (S)-proline and pivaldehyde6’ (Scheme 2.8). Here, the stereogenic centre of 
proline controls the stereoselectivity in the formation of the C-2 stereogenic centre of the 
oxazolidinone. Treatment of 2.23 with LDA in THF afforded the planar enolate 2.24 that 
has lost the chirality associated with the proline ring. However, the enolate underwent 
highly diastereoselective alkylation controlled by the tert-butyl group with retention of 
configuration. 
o Hür 
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Scheme 2.8 
The imidazolidinone approach is illustrated in Scheme 2.968. Pivalyl imines 2.28 of amino 
acid N-methylamides readily form the anti-imidazolidinone 2.29 upon treatment with 
methanolic HCI followed by acylation with benzoyl chloride. The corresponding syn- 
isomers 2.30 are available by treatment of 2.28 with benzoic anhydride. 
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Valine, phenylglycine, phenylalanine, aspartic acid and glutamic acid have all been 
converted into the corresponding imidazolidinones. Alkylation of the enolates derived 
from these to afford 2.32 proceeded in good yield and with excellent diastereoselectivity, 
(Scheme 2.10). However, a real disadvantage of these systems is the final hydrolysis which 
requires severe conditions, typically 6 M hydrochloric acid in a sealed tube. 
Me 
I 
Me 9.....<y I 9y>;
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2.31 2.32 2.33 
Scheme 2.10 
Significantly, the corresponding glycine derivatives have also been examined69. Alkylation 
of the enolate derived from 2.34 proceeded with high stereoselectivity to afford 2.35. 
Ci-HSNVC02Me - MeNH$EtOH &$O LDPJTHF - *?jo 
-0 
eieclrophiie 
W O  
pivaidehyde 
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resoiutlon 
2.34 2.35 
Scheme 2.11 
It is thought that the enolate adopts a conformation that places the tea-butyl group in a 
pseudo-equatorial position, and that both nitrogen atoms are pyramidal with the lone pairs 
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pseudoaxial (Scheme 2.12). The combined steric effect of the tea-butyl group and the anti- 
stereoelectronic effect of the enamine favours the electrophilic attack anti to the teri-butyl 
goup.  
Me & 
COPh 
H 
Scheme 2.12 
The stereoselective functionalisation of these heterocycles via enolate methodology, has 
provided a useful and practical approach to the asymmetric synthesis of non-proteinogenic 
amino acids, again despite the somewhat harsh acidic conditions (6 M HCI) needed to 
provide the final amino acids. 
2.1.4 Pseudoephedrine amides 
In recent publications, Myers and  co-worker^'^ have described a method for the alkylation 
of amide enolates using pseudoephedrine as a chiral auxiliary (Scheme 2.13). 
Pseudoephedrine was N-acylated in high yield (90-95%) using carboxylic acid chlorides 
and anhydndes. After deprotonation with LDA (2 equiv.), these N-acylpseudoephedrine 
derivatives reacted efficiently with alkyl bromides or iodides in a highly stereoselective 
manner. Furthermore, a number of simple cleavage reactions, with recovery of the chiral 
auxiliary, demonstrated the synthetic potential of these pseudoephedrine amides. 
45 
m ; L R  R'X + QJ& LDA (2 equiv) LICI (6 equiv) 
I 
On cn, R' I On cn3 
8049% >99% d.e. 
Scheme 2.13 
Given that this process employs a stoichiometric amount of chiral auxiliary, it might 
appear to be non-competitive with asymmetric catalytic procedures (see Chapter 1) 
However, it is also important to consider (i) the low cost and (ii) the ready availability of 
both enantiomeric forms of pseudoephedrine, as well as (iii) the tendency of many 
Pseudoephedrine amides to be crystalline, thus making the compounds easy to handle and 
purify. Overall, the alkylation reactions are highly diastereoselective, and given that each 
of the synthetic manipulations may be executed without the use of protecting groups this 
approach is highly attractive. 
Myers has demonstrated (Scheme 2.14) that the pseudoephedrine-based methodology can 
be adapted for the synthesis of amino acids using pseudoephedrine glycinamide 2.3671,72. 
Such compounds can be alkylated at the a-carbon of the glycine moiety using similar 
conditions to those used for simple acyl groups. Diastereoselectivities of 95% have been 
reported. Formation of the desired amino acids 2.38 can be achieved with very high 
enantiomeric excess by cleavage of the amide bond under basic, acidic or neutral 
conditions. 
2.36 2.31 2.38 
Scheme 2.14 
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2.1.5 Summary 
As shown above, the alkylation of an a-carbon of an enolate derivative of glycine is one of 
the most direct, general and commonly used methods for the preparation of a-amino acids. 
We selected for our purposes (namely the synthesis of new heterocyclic amino acids) the 
method developed by Myers because of its potential advantages over other enolate 
procedures. These include the low cost and availability of both enantiomers of 
pseudoephedrine, the tendency of pseudoephedrine amides to be crystalline, the high 
diastereoselectivities of the alkylation reactions, and the facile removal of the chiral 
auxiliary (which can be recycled). Lastly, each synthetic manipulation could be done 
without the use of a protecting group on the amino of glycine. Using this route, unnatural, 
salt-free, amino acids can be prepared in three steps in good yields and in high 
enantiomeric excess. 
2.2 Results and discussion 
This discussion will focus on the results obtained using pseudoephedrine as a chiral 
auxiliary and a range of heterocyclic electrophiles to access unusual amino acids 
containing heterocycles in their side chain. We will present first our validation of the 
method and subsequently describe its application to the synthesis of unusual heterocyclic 
amino acids. The determination of the enantiomeric purity of these unusual amino acids 
will also be presented. 
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2.2.1 Validation of the method 
2.2.1.1 Pseudoephedrine glycinamide synthesis 
The synthesis of pseudoephednne glycinamide 2.36 was effected by direct condensation 
between (lR,2R)-pseudoephedrine and glycine methyl ester under basic conditions using 
a procedure developed by Myers7' (Scheme 2.15). 
O 
Pl FH3 * CIH.H2NJ OMe 
n-BuLi, LiCI I 
ÖH CH3 
(lR,ZR)-Pseudoephedrine 2.36 
Scheme 2.15 
An initial attempt to neutralise the hydrochloride salt of glycine methyl ester 
hydrochloride using triethylamine (1 equiv.) in dry diethyl ether resulted in the formation 
of unwanted side-products in the later alkylation reaction. However, we found that 
treatment of glycine methyl ester hydrochloride in dry diethyl ether with dry ammonia 
for 3-4 h, followed by filtration of the ammonium chloride and careful concentration of 
the ethereal solution afforded a sufficiently pure solution of the free glycine methyl ester. 
In our hands, this method gave good yields in the subsequent coupling reaction (typically 
70-80%). This coupling reaction is noteworthy in that the secondary amino group of 
pseudoephedrine was acylated by the carboxylic ester without any detectable competition 
from the amino group of glycine, thus obviating the need for protection of this 
functionality. The coupling protocol involved deprotonation of the hydroxyl group of 
pseudoephedrine (1 equiv.) with n-butyllithium (2.5M. 0.80 equiv.) in the presence of 
anhydrous lithium chloride (2 equiv.) in THF at 0°C and subsequent addition of the 
ethereal solution of glycine methyl ester (1.2 eq) in THF. It was noted that a high yield, 
typically 75%, was only obtained when rigorously anhydrous lithium chloride was used 
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and also when very slow addition of glycine methyl ester (typically over 1.5 h) was 
carried out. Lithium chloride is believed to have an accelerating effect on the rate of the 
reaction thereby preventing self-condensation of glycine methyl ester. This accelerating 
effect is thought to result from activation of glycine methyl ester by bidentate 
coordination to the lithium cation. This coordination is also considered to diminish the 
nucleophilicity of the glycine amino group consequently decreasing the formation of by- 
products. 
It is believed that this one step procedure of pseudoephedrine glycinamide formation 
proceeds by the initial transesterification of glycine methyl ester with the secondary 
hydroxyl group of pseudoephedrine, followed by a rapid O- to N-acyl transfer. 
Pseudoephedrine glycinamide was obtained first as the hydrate without any 
chromatography. Dehydration of pseudoephedrine glycinamide using anhydrous 
potassium carbonate and subsequent recrystallisation from toluene afforded anhydrous 
pseudoephedrine glycinamide. It is worth noting that failure to properly dehydrate 
pseudoephedrine glycinamide could lead to consumption of the strong base &DA) 
needed in the alkylation process to enolize pseudoephedrine glycinamide. In the 
anhydrous state, pseudoephedrine glycinamide is a stable white solid which was typically 
stored in vacuo in the presence of phosphorus pentoxide to absorb any moisture. 
2.2.1.2 Enolization of pseudoephedrine glycinamide 
A unique feature of the use of pseudoephedrine glycinamide 2.36 as a chiral glycine 
enolate is the fact that the primary amino group is not protected. This introduces a potential 
complication in the enolization procedure as three different acidic functional groups are 
present in the molecule, namely the secondary hydroxyl group, the glycine a-carbon and 
the primary amino group. It has been confirmed experimentally by others that 2.39 is the 
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kinetic product of the reaction with 2 equiv. of base (Scheme 2.16). However, if the 
reaction mixture is allowed to warm up to 0°C prior to the addition of alkylating agent then 
equilibration to a thermodynamically more stable enolate 2.40 occurs and the C-alkylated 
product 2.37 is observed instead of the N-alkylated product 2.41 (which is observed at - 
78°C). 
Q-,,YLNH~ N 
-78°C [ Q J ~ J , , N H L ~  - 0°C [ m y ~ N H z ]  bLi CHJ 
OH AH3 ÖLi CHS 
2.36 2.39 2.40 
0°C RX 1 -78'C RX 
Q , J ; ~ N H ,  
1 mNJ,KR 
OH AH3 dH LHa R 
2.41 2.31 
Scheme 2.16 
Decomposition occurs when excess base (> 2 equiv.) is used. For example, with 2.2 equiv. 
of LDA pseudoephednne glycylglycinamide and pseudoephedrine were isolated. This 
probably is a result of the combination of two molecules of the 0,N-dianion 2.39, or by 
nucleophilic attack of the trianion 2.42 on the 0.N-dianion 2.39. 
QJjV \ NHLI 
I 
OLi CH, 
2.42 
Myers suggested that this problem can be entirely avoided by using 1.95 equiv. of LDA 
and proposed the following protocol: slow, dropwise addition of a solution of lithium 
diisopropylamide (LDA) (1.95 equiv.) in THF to a slurry of 2.36 (1 equiv.) and anhydrous 
lithium chloride (6.00 equiv.) in 'IMF at 0°C. He has shown that the use of 1.95 equiv. of 
base (LDA) in the enolisation is essential to obtain a high yield of alkylated product. In our 
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hands, when more than 2 equiv. of base was present, free pseudoephedrine was liberated 
and the reaction mixture developed a distinct orange colour in contrast to the normal 
yellow colour of the enolate suspensions prepared with 1.95 equiv. of LDA. Consequently, 
we used this colour change to indicate when sufficient base was present, generally 
stopping the addition when the solution was still just yellow, even if this meant using less 
than the full amount of base calculated from its concentration. Thus, the typical procedure 
that we adopted involved formation of a slurry of pseudoephedrine glycinamide (1 equiv.) 
and flame dried lithium chloride (6 equiv.) at 0°C followed by slow addition of LDA at 
O T ,  and then after 30 min of stirring at O'C, by the addition of a solution of haloalkane 
(1.1-1.2 equiv.) in THF. 
2.2.1.3 Alkylation of pseudoephednne glycinamide 
It has been reported that simple non heterocyclic alkyl halides reacted efficiently and 
diastereoselectively with the enolate 2.40. In every case examined the sense of the 
stereochemical outcome was that outlined in Scheme 2.17. 
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Scheme 2.17 
This stereochemical outcome is the same as that observed in the alkylation of the simple 
N-acyl pseudoephedrine derivatives. A useful mnemonic for deriving the sense of 
induction in the alkylation reaction has the electrophile entering from the same face as the 
methyl group of the pseudoephedrine residue when the (Z)-enolate 2.40 is drawn in a 
planar extended conformation (Scheme 2.18). 
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Thus, alkylation of (S,S)-pseudoephedrine glycinamide provided (R)-amino acids and 
(R,R)-pseudoephedrine glycinamide gave (S)-amino acids. In some cases the 
diastereoselectivity was influenced by the nature of the leaving group; iodoalkanes 
provided the highest selectivities and chloroalkanes the lowest. 
2.2.1.4 Synthesis of phenylalanine 
Prior to applying the above method to the synthesis of previously unsynthesised amino 
acids, we decided to assess the validity of the method by using benzyl bromide as the 
electrophile (Scheme 2.19). This will ultimately afford the known amino acid, 
phenylalanine. 
b 
LiCi, LDA 
2.43 
I 
OH CH3 
2.36 
Scheme 2.19 
Particular care was taken to ensure the use of anhydrous reagents. All the reaction 
vessels were flame dried and cooled under a positive pressure of argon. Lithium chloride 
was dried under vacuum for 12 h, then prior to use flame dried and cooled again under a 
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positive pressure of argon. Using commercial LDA solutions was found to give poor 
yields in the alkylation step, so we used a freshly prepared solution of LDA made from 
freshly titrated (against diphenylacetic acid73) n-BuLi solution and freshly distilled 
diisopropylamine. The enolate was prepared by slow addition (30 min) of the LDA 
solution to a stirred slurry of (R,R)-pseudoephedrine glycinamide and LiCI at 0°C. 
Benzyl bromide was then added to the yellow enolate solution and the mixture stirred at 
0°C for 2 h. After work-up and chromatography, compound 2.43 was isolated in 62% 
yield. 
We noticed that, like most tertiary amides, 2.43 exhibited rotational isomerism about the 
N-C(0) bond and interconversion of isomers was slow on the NMR ( l H  and l3C) 
timescale (Figure 2.1 and 2.2). This is shown in particular, by the two N-CH3 signals at 
2.6 and 2.9 ppm in the 'H spectrum and 27.1 and 30.4 in the I3C spectrum. Using the 
integration of these peaks in the 'H spectrum, a rotamer ratio of 4 to 1 was found. 
Unfortunately, a variable temperature NMR experiment (2OOC to iOO°C) did not show 
peak coalescence. One further complicating factor was that the l H  NMR spectrum of 
2.43 exhibited the presence of both rotamers and diastereoisomers. Attempts to 
determine diastereoisomeric ratios by HF'LC (reversed phase C18 column) or by chiral 
GC (Chiral Sil Vai column post acetylation) proved unsuccessful as resolution of the 
peaks corresponding to the two potential diastereoisomers either in HPLC or GC could 
not be achieved. Compound 2.43 was therefore submitted directly to hydrolysis 
conditions (Scheme 2.20). 
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Myers observed that the products of alkylation are easily hydrolysed by refluxing in a 
slightly alkaline solution. However, we noted that the products resulting from the 
alkylation displayed some solubility in water and produces alkaline solutions, presumably 
due to the presence of the free amino group. Therefore, we found that simply heating an 
aqueous solution of the alkylated product in wateddioxane for 12h led to quantitative 
hydrolysis to afford the free amino acid together with pseudoephedrine. The latter was 
removed by extraction with DCM. Evaporation of the aqueous layers and subsequent 
trituration of the crude amino acid in ethanol served to remove any residual trace of 
pseudoephedrine. An advantage of using water is that the amino acid product does not 
require any desalting procedure such as ion exchange chromatography. 
Thus, pure phenylalanine 2.51 was isolated in 76% yield after the trituration procedure. 
Moreover, pure pseudoephedrine was also recovered from the organic phase in 70% 
yield. 
To assess the enantiomeric purity of the phenylalanine so-obtained, we decided to 
employ the NMR-based method of Mo~her’~. in this, 2-methoxy-2-phenyl-3,3,3- 
trifluoropropanoic acid (MTPA), or its chloride, MTPA-CI, of defined stereochemistry is 
coupled to the compound of unknown configuration to produce diastereoisomeric 
amides. The method consequently relies on the difference in the I9F NMR chemical shift 
of the trifluoromethyl group for both  diastereoisomer^^^. 
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The enantiomeric excess (e.e.) analysis was accomplished by esterifying 2.51 using a 
solution of HC1 in ethanol, followed by coupling of the phenylalanine ethyl ester 
hydrochloride to commercially available (R)-MTPA-C1 (Scheme 2.21) and subjecting the 
product 2.59 to ’9 NMR spectroscopy. 
2.51 2.59 
Scheme 2.21 
The ’% NMR spectrum (Figure 2.3) exhibited two singlets at 8~ -69.087 ppm for the 
major diastereoisomer and 8~ -69.141 ppm for the minor diastereoisomer. We related the 
ratio of these two diastereoisomers (calculated from the integration of each signal) with 
the e.e. of the original phenylalanine 2.51. An e.e. of 87 % was determined. Interestingly, 
Myers has quoted an e.e. of 99% for the same cornpo~nd’~. 
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To assess whether or not the integrity of the c h i d  center had been retained during the 
synthesis, we canied out some test experiments. 
First, commerciai (8-phenylalanine ethyl ester hydrochloride was coupled to (1R,2R)- 
pseudoephedrine using the same conditions as for the coupling with glycine. The 
resulting amide was then hydrolysed to give phenylalanine, which was subsequently 
esterified. Coupling to (R)-MTPA-CI and analysis by I9F NMR revealed only one signal 
at & -69.067 ppm (Figure 2.4). 
Second, (R)-phenylalanine was also coupled to ( 1S,2S)-pseudoephedrinedrine, the  hydrolysed 
and coupled to give a Mosher’s amide. The I9F NMR spectrum again showed only one 
singlet. The chemical shift of & -67.940 ppm was different from the minor isomer 
resulting from the alkylation (& -69.141 ppm), a difference probably due to the incorrect 
calibration of the instrument (Figure 2.5). 
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Thus, the integrity of the chiral centre appears not to be compromised in any of the 
hydrolysis, esterification and coupling steps. We, therefore concluded that the low e.e. 
obtained for compound 2.51 was only due to moderate diastereoselectivity in the 
alkylation step. This experiment also verified the finding that (R,R)-pseudoephedrine 
produces @)-amino acids. 
2.2.2 Aikylation using other electrophiles 
Next, we decided to extend the method to a wider range of electrophiles (2.60-2.66). 
Naphthyl systems 2.60 and 2.61 were chosen because they should have similar reactivity 
to the benzyl bromide used to test the method. Potentially, amino acids containing such a 
ring system could serve as intercalating agents. The pyridyl systems 2.62-2.64 are also 
commercially available and the corresponding amino acids could mimic histidine, for 
example. Electrophiles 2.65 and 2.66 are also commercially available. 
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The electrophiles were submitted to the alkylation conditions described above for benzyl 
bromide, and using (IR,2R)-pseudoephedrine glycinamide to try and produce (S)-amino 
acids (Scheme 2.22). 
1 
LiCI, LDA 
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Scheme 2.22 
The results of the alkylation reactions are displayed in the table shown below (Table 2.1). 
Electrophile Alkylated product Yield Amino Yield Pseudoephedrine 
(%) acid (%) recovered 
Benzyl bromide 2.43 62 2.51 76 70 
2.60 2.67 61 2.74 76 50 
2.61 2.68 33 2.75 74 58 
2.62 2.69 62* 2.76 59 
2.63 2.70 55* 2.77 49 
2.64 2.71 36* 2.78 40 
2.65 2.72 68 2.79 48 78 
2.66 2.73 97 2.80 59 62 
* crude yield 
Table 2.1 Product yields from the alkylation of pseudoephedrine glycinamide 
and from the hydrolysis of the alkylated products. 
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The alkylation reaction proceeded successfully for all the electrophiles selected; in 
moderate yield for electrophiles 2.60-2.65 (33% to 68%), and in nearly quantitative yield 
(97%) for the isoxazole electrophile 2.66. In generai, these compounds were sticky gums 
that could not be crystallised. For the pyridyl series the alkylated products could not be 
isolated in pure form for spectroscopic characterisation. Indeed, for this series we noted 
that the starting electrophiles rapidly decomposed both after neutralising the 
hydrochloride salt with triethylamine and when THF was removed to concentrate the 
solution prior to alkylation. Consequently, we decided to subject the alkylated products 
to hydrolysis directly without further purification. 
2.2.3 The unusual amino acids 
H,O, reflux + HO?"' + 
: NHCH3 
OH Dioxane R R 
2.61-2.13 2.14-2.80 pseudoephedrine 
Scheme 2.23 
A significant advantage of hydrolysing the alkylated products in an aqueous medium was 
that the free amino acid was retained in the aqueous phase while the pseudoephedrine co- 
product could be extracted into DCM. Thus, the desired amino acids were obtained by 
heating the alkylated products 2.67-2.73 (dissolved in minimal amount of dioxane) at 
reflux in water for 12 h (Scheme 2.23). Reactions were monitored by HPLC and reached 
completion after 12 h. A simple extraction with dichloromethane ensured removal of the 
chiral auxiliary. Further purification was achieved by trituration of the aqueous phase 
with ethanol to remove any residual pseudoephednne. In our hands, this procedure 
successfully provided the desired amino acids 2.74-2.80 with good purity and in 
moderate yield (40-76%) (Table 2.1). 
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2.74 2.75 2.76 2.77 2.78 
2.79 2.80 
It is worth mentioning that this hydrolysis procedure helped in the purification of the 
pyridyl amino acids 2.76-2.78. However, it was noticed that the pyndyl amino acids 
were somewhat soluble in ethanol, which may account for lower yields obtained for 
these compounds. 
2.2.4 Enantiomeric purity determination 
The amino acids were esterified and converted into their corresponding hydrochloride salt 
using acetyl chloride in ethanol (which generates HCI in situ). The coupling of the amino 
acids 2.74-2.80 to (R)-MTPA-C1 was accomplished in dichloromethane in the presence of 
an excess of base (Scheme 2.24). The absolute configuration of the chiral centre of a 
Mosher amide is of course identical with that of the Mosher acid chloride. However, the 
Cahn-Ing~ld-Prelong~~ descriptor changes because COCl has higher priority than CF in the 
chloride but CON has lower priority than CF in the amide. 
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The crude mixtures 2.81-2.87 so-obtained were analysed by I9F NMR. Each revealed the 
presence of two singlets corresponding to the two diastereoisomeric products. The 
diastereoisomeric excess (d.e.) for each amino acid was calculated using the integration 
traces for these signals. (see appendix). Again, the e.e. for each amino acid can be equated 
with these d.e. values (Table 2.2). These results represent the best e.e. values from several 
reactions carried out for each electrophile. 
Amino acid Mosher’s amide e.e. (%) 
2.74 2.81 87 
2.75 2.82 61 
2.76 2.83 10 
2.77 2.84 74 
2.78 2.85 68 
2.79 2.86 74 
2.80 2.87 74 
Table 2.2 Enantiomeric excesses determined for amino acids 2.74-2.80 
Unfortunately, these results were found to be very difficult to reproduce. One factor that 
may contribute to this is the determination of the end point for the addition of n-BuLi. 
Another is the physical state of the LiCl. It was found that drying lithium chloride under 
vacuum for 12 h and further flame drying had an effect on the yields obtained (higher) and 
also seemed to raise the enantiomeric excess of the amino acids. These conditions could 
not be identically applied in all cases. 
Nonetheless, several unusual interesting amino acids were produced with moderate e.e. 
using pseudoephedrine as a chiral auxiliary. With this relative success in mind, we decided 
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to extend further the use of pseudoephedrine as a chiral auxiliary to more complex 
heterocyclic amino acids. Amino acids bearing nucleic acid bases in their side chain 
seemed to be more valuable targets. 
2.2.5 Limitation of the enolate method 
We envisaged that the same methodology could be used for the synthesis of these amino 
acids bearing a nucleobase in the side chain. 
2.2.5. I N9-(2-Bromoethyl)-N6-aminopurine as electrophile 
Commercially available Nó-aminopurine (adenine) was chosen as the precursor for the 
synthesis of the halopurine electrophile 2.89; this required the use of protecting groups 
(Scheme 2.25). We decided to use a non-base sensitive protecting group to avoid 
deprotection by LDA in the alkylation step. Adenine was Boc-protected selectively at N-6 
in 75% yield using Boc-anhydride (1 equiv.). Nó-Boc-Adenine 2.88 was then alkylated at 
N-9 in 21 % yield under Mitsunobu conditions using 2-bromoethanol with diisopropyl 
azodicarboxylate and triphenylphosphine to give 2.89. Surprisingly, the Boc-group was 
lost during the Mtsunobu reaction, presumably upon product purification on the acidic 
silica gel. The desired purine electrophile 2.89 was submitted to alkylation in the usual 
way using (lR,2R)-pseudoephedrine glycinamide. However, the desired alkylated product 
was not isolated rather a mixture containing the elimination product 2.90 (77% 
spectroscopic yield) and the starting bromide 2.89 was recovered instead. Clearly, the 
strong base LDA (pK,>30) was able to deprotonate the acidic proton a to N-9 therefore 
promoting the elimination process. However, the presence of the adjacent electronegative 
ring N atom must also enhance the acidity of the a-proton given that we have successfully 
employed 1-(2-bromoethyl)naphthaIene 2.61 in this reaction. 
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Scheme 2.25 
2.2.5.2 N9-(2-Chloroethyl)-N6-(2-methylpropanoyl)adenine as electrophile 
We decided to examine whether or not a chloroethyl electrophile would enhance alkylation 
over elimination. A 2-methyl propanoyl protecting group at N-677 was also used in lieu of 
the Boc group (Scheme 2.26). 
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N9-(2-Chloroethy1)-~6-(2-methylpropanoy1)aminopurine 2.92 was synthesised in 71% 
yield according to a literature method7' (discussed in detail in Chapter 3) and subjected to 
the conditions for the alkylation of pseudoephedrine glycinamide. However, once again 
only the elimination product 2.93 together with the starting material 2.92, was isolated in 
77% (spectroscopic yield). 
2.2.6 Conclusion 
The pseudoephedrine glycine enolate method has been successfully extended to the 
synthesis of seven unusual heterocyclic amino-acids in good yield and moderate 
enantiomeric excess. However, despite significant effort, the e.e. of the new amino-acids 
were never as high as those claimed for Myers examples. It seems that stringently 
anhydrous conditions, together with less than 2.0 equiv. of LDA, are required for the 
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enolisationíalkylation step. Moreover, reproducibility for a given reaction (using exactly 
1.95 equiv. of LDA) was difficult to achieve. 
A serious disadvantage of the enolate route was that it could not be used to access 
heterocyclic amino acids bearing a nucleobase in the side chain. Here, competition 
between substitution and elimination completely favours the latter. 
Therefore, a new route using milder conditions was required if the synthesis of amino acids 
having nucleobases in the side chain was to be achieved. This new methodology, together 
with the results obtained, are discussed in the next chapter. 
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CHAPTER 3 
A RADICAL APPROACH 
3.1 INTRODUCTION 
It has been shown in Chapter 2 that in the application of the enolate approach to the 
synthesis of unnatural amino acids, we encountered some limitations when using base 
sensitive electrophiles where elimination could occur. To reach our goal of incorporating 
complex heterocycles into the side chain, a milder approach was required. It was 
anticipated that a radical approach would be more suitable. Indeed, over the last decade or 
so, chemists have exploited radical reactions to achieve transformations in a controlled 
manner, in good yield and with high regio- and stereoselectivity. Very often the reagents 
and reaction conditions used in free radical reactions are more compatible with the 
functional groups present (even without protection) and the stability of the compounds 
involved. This chapter will first extend the disconnection outlined in the introduction 
related to the formation of the C-C bond using a radical methodology (radical alanine 
synthetic equivalent), and will thus provide a general overview of the chemistry of radicais 
using both non-optically-active and optically-active dehydroalanine synthetic equivalents. 
We will then describe and demonstrate how we have successfully utilised an oxazolidinone 
derivative for the synthesis of optically active amino acids bearing nucleic acid bases 
(purines and pyrimidines) in their side chain. 
3.1.1 Non-optically active dehydroalanine 
Most intermolecular radical reactions of amino acid derivatives generate an a-centred 
radical, presumably as a result of the particular stability of this species. Many examples 
involve the introduction of an amino acid side chain, with formation of a carbon-carbon 
bond. If we disconnect the CB-C, bond, then we can conceive of a reaction involving 
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dehydroalanine (or equivalent) and a radical that could come from fragmentation of a C-X 
bond (Scheme 3.1). 
. R  u + RX u - HzN COzH HzN C0,H BY = 
Scheme 3.1 
Indeed, Crich7' has reported a mild method for the synthesis of a-amino acids by conjugate 
addition of free radicals to a protected dehydroalanine derivative. N-Trifluoroacetylamino 
acid methyl ester 3.2 were prepared by the addition of a cyclopropyl radical to N- 
tnfluoroacetyldehydroalanine methyl ester 3.1. The choice of trifluoroacetyl as the N- 
protecting group was guided by a desire to minimise any stabilization of the adduct radical, 
therefore promoting good chain-carrying properties and reducing dimensation, as well as 
by the ease of introduction and removal of this group. 
NaBH, 
3.1 F H g C I  - 
D' 
 coz^ F H g H  
Scheme 3.2 
The method proved applicable to the addition of primary, secondary as well as tertiary 
radicals, with moderate to good yields (30-85%) being achieved. Using this route, Crich 
was able to prepare the antifungal amino acid derived from 3.2 and isolated from the 
mushroom Amanita v i r g i n ~ i d e s ~ ~ .  
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A similar strategy was used by Kessler" to produce C-glycopeptides in yields up to 73% 
(Scheme 3.3). 
3.4 + 
R3HNAC02R4 
Bu3SnH/AIBN 
C02R4 -
3.3 3.5 3.6 
Scheme 3.3 
The sugar dehalogenated at C1 was isolated as a by-product. Interestingly, the C-glycosyl 
amino acid products were exclusively (>97%) of a-configuration at the anomeric centre of 
the sugar. In contrast to this high stereoselectivity at the sugar, final hydrogen transfer to 
C2 of the glycine backbone of the amino acid yielded mixtures of epimers 3.5 and 3.6. The 
possibility of increasing the diastereoselectivity was examined through chirality in the 
dehydro-amino acid building block without any real success. 
Martinez has extended the method to the use of polymer supports*', with the first synthesis 
of N-acetyl-a-amino acids by the addition of radicals to polymer supported 2- 
acetamidodehydroalanine (Scheme 3.4). Martinez outlined a three-step strategy. The amino 
acid 3.7 was anchored onto Wang resin (4-alkoxybenzyl alcohol polystyrene, 3.8) through 
the carboxylic acid function using a Mitsunobu method. Generation of radicals was 
accomplished using Giese's mercury method" in which a dropwise addition of an excess 
of sodium borohydride to a mixture of compound 3.9 and alkylmercury chloride generated 
the adduct 3.10. The product was then cleaved from the solid support using TFA, to yield 
the desired N-acetylamino acids 3.11. Of course, one advantage of this approach is that the 
excess reagents can easily be removed by washing the resin. 
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3.7 3.0 3.9 3.10 
A 
w AcHN COzH TFA 
3.11 
Scheme 3.4 
3.1.2 Oxazolidin-5-one as chiral dehydroalanine equivalent 
The synthesis of optically active amino acids using a radical method can be achieved by 
two separate approaches. The first is to use a chiral centre already present in the starting 
material and then generate a radical in the side chain; the second is to create the chiral 
centre at the a-carbon by stereoselective addition of a radical onto a dehydroalanine 
equivalent. In either method there is a need to direct the stereochemistry by H-atom 
capture on the carbon centred radical by steric influence of a neighbouring chiral center. 
One way of achieving this is normal asymmetric induction, another is the self-regeneration 
of chiral centress3. In the latter, a chirai centre, subsequently destroyed, is used to induce a 
new one, then this new chiral centre is used to induce chirality at the original centre. 
The oxazolidinone template is the most important tool for radical addition to form a C-C 
bond. In this section, first the synthesis of suitable oxazolidinones will be discussed and, 
second, recent successful applications of these to the synthesis of amino acids via radical 
methods will be reviewed. 
Oxazolidinone 3.12, made from (S)-alanine, afforded the bromo derivative 3.13 by radical 
bromination using NBS, and subsequent dehydrohalogenation with DBU gave the 
derivative 3.14 (Scheme 3.5)84. 
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3.12 3.13 3.14 
Scheme 3.5 
Later, Beckwith reported that the above procedure gave mixtures (Scheme 3.6) and he 
therefore devised an alternative method from which both enantiomers of 3.16 could be 
accessed in high enantiomeric purity8'. 
i) NBS,CCId, hv 
¡i) Nal, acetone 
3.15 3.17 
Scheme 3.6 
Thus, under photolytic conditions at ambient temperature using stringently purified NBS, 
followed by treatment with Na1 in acetone, the formation of the vinyl bromide 3.17 was 
suppressed to below 5%. 
This approach was extended by Crossley and Tansey to prepare the two diastereoisomeric 
oxazolidinones 3.18 and 3.19 and subsequently the enantiomer 3.14 (Schcrne 3.7)86. 
I) NBSIAIBN 
li) Küacetone 
Ph 
3.14 
Scheme 3.7 
The first radical addition onto the oxazolidinone dehydroalanine equivalent 3.14 was 
accomplished by Beckwith and Chai”. The oxazolidinone 3.14 and iodocyclohexane in 
benzene were irradiated with UV light at room temperature while tributyltin hydride and 
AIBN in benzene were added from a syringe pump; this gave a mixture of the two 
diastereoisomers 3.20 resulting from addition of the cyclohexyl radical onto the alkene 
acceptor of the dehydroalanine equivalent (Scheme 3.8). 
Q, - 
Bu3SnWAIBN 
Benzene 
73% anti produci d.e >75% 
3.14 3.20 
Scheme 3.8 
Similarly, the oxazolidinone 3.14 was treated with various iodoalkanes and tributyltin 
hydride yielding the anti diastereoisomers (assigned on the basis of n.0.e. experiments) as 
the major products (Table 3.1). 
Iodoalkane Major isomer %yield %d.e. 
Me1 Anti 60 42 
PhCHZI Anti 71 46 
‘BUI Anti 70 75 
Table 3.1 
In a later publication, Beckwith showed that the diastereoselectivity of the radical addition 
depends on the nature of the addend radical and on the N-protecting group”. Typically, N- 
benzoyloxazolidinones 3.14 (R=Ph) gave the anti products 3.20, whereas, the carbamates 
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(R=PhCH20, MeO, PhO) gave the syn products 3.20 with very high diastereoselectivity 
(Scheme 3.9). 
3.14 syn 3.20 
Scheme 3.9 
anti 3.20 
We describe in the next section our findings on the successful application of an oxazolidin- 
5-one to the synthesis of a range of a-amino acids containing different nucleic acid bases 
in their side chains. 
3.2 Results and discussion 
We proposed the disconnection strategy shown in Scheme 3.10, i.e. disconnection of the 
C(ß)-C(y) bond. This C(ß)X(y) identifies conjugate radical addition of a preformed 
radical containing the nucleic acid base onto a dehydroalanine acceptor as the appropriate 
C-C bond-forming reaction. The nucleic acid radical should be accessible from a 
haloalkylnucleobase, and the haloalkylnucleobases themselves viu C-N bond formation 
using a Mitsunobu procedure involving the nucleobases and commercially available 
haloalcohols. One advantage of this strategy is that the distance between the glycine 
backbone and the nucleobase can be varied by the choice of an appropriate haloalcohol. In 
adopting this strategy, we decided to synthesise a chiral dehydroalanine equivalent so that 
we could achieve stereoselective conjugate radical addition. 
13 
Scheme 3.10 
3.2.1 Synthesis of the chiral dehydroalanine equivalent 
The chiral dehydroalanine equivalent was synthesised from (R)-S-methylcysteine, an 
inexpensive, readily available amino acid, in four steps by adaptation of a published 
sequence to the N-benzoyl analogue (Scheme 3.11)s9. 
i) NaOH aq. 
ii) Bu'CHO, Dean-Stark 
w - "Y0 - H2N C 0 2 H  iii) PhCH,OCOCi ZNvo ZNvO 
(R)-S-Methylcysteine 
I 
BU' 
I 
BU' 3.21 
Ë u'
3.23 
Scheme 3.11 
The amino acid (R)-S-methylcysteine was stirred with one equivalent of aqueous sodium 
hydroxide to give the corresponding carboxylate. The water was removed and the salt dried 
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under vacuum. 2,2-Dimethylpropanal was then added and the mixture refluxed in hexane 
with azeotropic removal of water. The resulting Schiff base was treated with benzyl 
chloroformate to effect cyclisation. Attempts to purify the two diastereoisomeric 
methylthiomethyl compounds resulted in significant loss of material (these compounds 
proved inseparable). Indeed, it was found that the methylthiomethyl compounds rapidly 
oxidised on silica gel or in air to the corresponding sulfones 3.21 and 3.22. The 
diastereoisomeric ratio of synlanri methylthiomethyl products could be measured by 
determining the ratio of the integrals for the SMe singlets at 6 2.10 pprn (major 
diastereoisomer) and 6 2.02 ppm (minor isomer) prior to oxidation. Typically, a ratio of ca. 
8 to 1 was found. 
We therefore decided to carry out only a rapid extraction procedure to remove any excess 
benzyl chloroformate and to perform the next oxidation step, directly on the semi-crude 
material. Oxidation was achieved by dropwise addition of a solution of the 
diastereoisomeric methylthiomethyl compounds in acetonitrile to an aqueous solution of 
Oxone@. The reaction was monitored by 'H NMR spectroscopy using the SMe peaks of the 
thioether starting material and sulfone product. The sulfones were extracted once the 
singlets at 6 2.10 ppm and 6 2.02 ppm corresponding to the thioether had disappeared and 
been converted into the singlets at 6 2.87 (minor diastereoisomer) and 6 3.09 pprn (major 
diastereoisomer) corresponding to the S02Me of the sulfones 3.21 and 3.22. The synlanti 
ratio of the two diastereoisomeric sulfones was determined by measuring the ratio of 
integrals for these two S02Me peaks. As expected, and confirming our findings for the 
methylthiomethyl compound diastereoisomers, we found a ratio of ca. 7 to 1. This ratio did 
not vary significantly from experiment to experiment, and did not depend on the scale of 
the reaction. The two diastereoisomeric sulfones were easily separated by column 
chromatography on silica gel. The overall yield of the sulfones was ca. 57%. We were also 
able to crystallise the major diastereoisomer from hexane to further ensure 
diastereoisomeric purity. 
15 
To determine the relative stereochemistry at the C2 and C4 positions of the oxazolidinone 
ring in the sulfones, n.0.e. studies were performed. The results are shown in Table 3.2 
Signal irradiated Signal enhanced 
C&S02Me But (2.18%) 
B"' C&S02Me (1.12%) 
"yo Hf H, H4 (1.18%), Bu'(6.88%) 
Bu' 
H4 H2 (0.92%), CH2S02Me (4.58%) 
Table 3.2 
irradiation of the & proton gave a small enhancement of the HZ proton (0.92%) but no 
enhancement of the tert-butyl group. irradiation of the HZ proton gave also a small 
enhancement of & (1.18%) but no enhancement of the C&SOzMe protons. Moreover, 
irradiation of the tert-Bu group gave an enhancement of the C&S02Me (1.12%). 
Irradiation of the C&SOZMe gave also an enhancement of the fert-Bu group (2.18%). 
These mutual enhancements, despite being small, showed that the major isomer obtained 
was syn. This result was in accord with that of Pyne who found that under similar 
conditions other common a-amino acids (e.g. alanine) gave mixtures of syn and anzi 
oxazolidin-5-ones in which the syn isomer was predominantg9. 
Similar n.0.e experiments were also conducted with the minor sulfone diastereoisomer 
3.22 (Table 3.3). 
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H2 = , 
BU 
Signal irradiated Signal enhanced 
CH2S02Me H4 (14%) 
Bu' Hz (1.94%), % ( O S % )  
H2 Bu' (8.47%) 
H4 Bu' (2.33%), CH2S02Me (7.41%) 
Table 3.3 
Irradiation of the terr-Bu group gave a weak enhancement of & (0.55%) and, irradiation of 
& gave an enhancement of rerr-Bu (2.33%). Unfortunately, there was no enhancement 
between CHZSOzMe and Hz. Nevertheless, enhancement between & and rerr-Bu was 
strong enough to conclude that they were syn to each other. In other words, the minor 
sulfone diastereoisomer 3.22 had anti stereochemistry. 
The final reaction involved an elimination in the presence of a strong hindered base 
(Scheme 3.12). DBU was added dropwise to a solution of the syn-sulfone 3.21 in 
dichloromethane at OOC. In the procedure reported by Pyne and coworkers, similar sulfones 
were treated with DBU for 30 min to effect the elimination reaction. We found, like 
Mackay9', that the reaction was essentially completed after 5 min and that longer times led 
to some product decomposition. After a conventional extraction procedure the crude 
product was passed through a short-path silica column to remove excess unreacted DBU. 
S02Me 
syn sulfone Chiral dehydroalanine equivalent 
3.21 3.23 
Scheme 3.12 
The desired chiral template was then further purified by recrystallisation from hexane and 
obtained in 96% yield. In the 'H NMR spectrum, the disappearance of the S02Me singlet 
at 6 3.09 ppm and of the a-CH doublet of doublets at 4.9 ppm, and the appearance of a 
singlet at 6 5.7 ppm integrating to two protons corresponding to the alkene protons, 
indicated that we had indeed effected the required elimination to afford the (S)- 
oxazolidinone. The (R)- enantiomer would be available either from unnatural (S)-S- 
methylcysteine, or from the anti-sulfone. 
3.2.2 Alkylation of nucleic acid bases 
In the past few years, the Mitsunobu reaction has become an important regiospecific 
method (N1 for pyrimidine and N9 for purines) for the coupling of haloalcohols with 
nucleic acid bases under mild conditions. For example, it has recently been demonstrated 
that N3-benzoyluracil and N3-benzoylthymine undergo N1 alkylation with non-hindered 
alcohols9'. The N1 alkylation of N4-benzoylcytosine usually leads to a mixture of N1 and 
U2 alkylated products92. Nevertheless, it seemed that the Mitsunobu reaction could be used 
as a general approach to access haloalkyl pyrimidines and purines. In the following 
sections, we explain how we have used Mitsunobu conditions and appropriate protecting 
groups to synthesise the desired radical precursors. 
3.2.2.1 Synthesis of haloalkylpyrimidines 
Synthesis of N3-benzoylthymine 
When thymine was stirred with a large excess of benzoyl-chloride (2.2 equiv.) in a mixture 
of acetonitrile-pyridine at room temperature for 12h (Scheme 3.13), it was converted into 
the NI ,N3-dibenzoyl de r i~a t ive~~ .  The crude diprotected product was treated directly with 
a solution of potassium carbonate in dioxane-water. Selective N1 deprotection afforded the 
M-benzoylated thymine 3.24 containing traces of unreacted thymine. Thymine could be 
removed by column chromatography on silica gel but routinely the crude material was 
used directly without any further purification. This reaction was scaled up to 5 g thymine 
without any major noticeable decrease in yield (67%). 
PII',? 
A N  
Kzc03 BZ-CI P h ' N y  -"9 - 
O A N  O A N  O H  
Ph 3.24 
n 
Thymine 
Scheme 3.13 
The NMR spectroscopic data for our sample of N3-benzoylthymine 3.24 was in 
accordance with those quoted by R e e ~ e ~ ~ .  Thus, the NH signal of our material appeared at 
6 11.36 ppm (lit.93 6 11.2 ppm). In the I3C NMR spectrum, the C-5 carbon of our sample 
appeared at 6 107.90 ppm (lit?3 6 107.87 ppm). Our material also gave a satisfactory 
accurate mass from mass spectroscopic analysis (231.0769 for C&1&03). 
M-Benzoylthymine 3.24 is known to undergo N1 alkylation under Mitsunobu conditions. 
For example, Lucas9' has found that cyclopentanols alkylate N3-benzoylthymine at N1. 
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We decided to employ the same conditions but using 2-bromoethanol as the alkylating 
agent. 
Synthesis of N3-benzoyl-Nl-(2-bromoethyl)thymine and N3-benzoyl-N1-(2- 
iodoethy1)thymine 
N3-Benzoylthymine 3.24 was stirred with triphenylphosphine and 2-bromoethanol in 
dioxane at O°C (Scheme 3.14). Since the reaction was exothermic, it was decided to add 
the diisopropylazodicarboxylate (DIAD) at O°C via syringe pump over 30 min. It was 
found that such slow addition increased the yield of the reaction over simple dropwise 
addition. The reaction was then left to warm up to room temperature and stirred overnight 
to yield a clear solution. 
Purification by column chromatography gave the desired N1 bromoalkylated compound 
3.25 as a white solid in 89% yield. It should be noted that no other alkylated compound 
(e.g. 0 2  alkylation) was detected upon analysis of the reaction mixture. 
I I 
3.24 Br 3.25 I 3.26 
Scheme 3.14 
In the course of our studies, these results were supported by S ~ h e i n e r ~ ~  who observed only 
N1 alkylation under Mitsunobu conditions using bis-l,3-tntyloxy-2-propanol as the 
alkylating agent. The bromo derivative 3.25 was heated at reflux with an excess of sodium 
iodide in dry acetone to give 3.26 in 95% yield. As expected, an upfield shift of the CH2X 
was observed in the 'H N M R  spectrum, from 6 3.64 ppm in the starting material to 6 3.40 
ppm in the desired product. 
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Synthesis of N3-benzoyl-N1-(3-bromopropyl)thymine and N3-benzoyl-N1-(3- 
iodopropy1)thymine 
The Mitsunobu reaction was again carried out using 3.24 but substituting 3-bromopropan- 
1-01 for 2-bromoethanol (Scheme 3.15). The crude product was purified by column 
chromatography to give the desired N1 alkylated product 3.27 as a white solid in 92% 
yield. Compound 3.27 was then converted into its iodo derivative 3.28 by heating at reflux 
in the presence of an excess of sodium iodide in dry acetone overnight. In the 'H Nh4R 
spectrum, the triplet signal corresponding to the CH2Br at 6 3.91 pprn in the starting 
material was observed to shift upfield to 6 3.21 ppm. In the same way, the corresponding 
carbon signal in the I3C NMR spectrum shifted from 6 29.34 pprn in the starting material 
to S 1.62 pprn in the product. 
o 
3.24 I 3.21 Br 
Scheme 3.15 
(, 3.28 
Synthesis of N3-ben~oyluracil~~ 
The same protecting group strategy as for thymine was also employed for uracil. Uracil 
was stirred with 2.2 equiv. of benzoyl chloride in acetonitrile-pyridine (512, v/v) at room 
temperature overnight (Scheme 3.16). It was noted that the addition of benzoyl chloride 
was exothermic. Benzoyl chloride was therefore added at 0°C via syringe pump over 1 h. 
After evaporation of the solvent the crude diprotected product could either be purified by 
column chromatography on basic alumina or treated with potassium bicarbonate as for 
diprotected thymine. Serendipitously, we found that the purification by column 
chromatography on basic alumina led to the desired removal of the protecting group at 
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position N1 in good yield (3.29). This method was preferred for larger scale preparations 
because of the higher purity of the sample obtained. In the 'H NMR spectrum of our 
sample the NH signal at 6 11.17 pprn also matched that reported by R e e ~ e ~ ~  (6 11.16 pprn). 
In the 13C spectrum, the C5 carbon had 6 100.13 pprn (6 100.08 pprn reported by Reese"). 
Uracil PhAO 3.29 
Scheme 3.16 
N3-Benzoyluracil 3.29 was then submitted to Mitsunobu conditions, first using 2- 
bromoethanol as alkylating agent. 
Synthesis of N3-benzoyl-NI -(2-bromoethyi)uracil and N3-benzoyl-NI -(2-iodoethyi)uracil 
N3-Benzoyluracil 3.29 was stirred with triphenylphosphine and 2-bromoethanol in dry 
dioxane at 0°C (Scheme 3.17). DIAD was then added dropwise over 1 h using a syringe 
pump. The cloudy mixture was stirred overnight to give a clear yellow solution. The 
desired N1-alkylated compound 3.30 was easily purified by column chromatography on 
silica gel using an hexanekthyl acetate system as eluent (82% yield). Again, no 0 2  
alkylated compound was detected in the mixture. Compound 3.30 was then easily 
converted into its iodo counterpart 3.31 by heating at reflux in acetone in the presence of 
sodium iodide to yield the desired compound (96% from the bromo derivative 3.30). 
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3.29 Ar 3.30 i 3.31 
Scheme 3.17 
Synthesis of N3-benzoyl-NI-(3-bromopropyl)urucil and N3-benzoyl-N1-(3- 
iodopropy1)uracil 
The Mitsunobu conditions were used to alkylate the N1 nitrogen of N3-benzoyluracil using 
3-bromopropan-1-01 as the alkylating agent (Scheme 3.18). The reaction was carried out in 
the same way as for 2-bromoethanol. The desired bromo product 3.32 was isolated in 84% 
yield after purification by flash chromatography. Compound 3.32 was then converted into 
the iodo compound 3.33 by refluxing it with excess sodium iodide in dry acetone (96% 
yield from 3.32). The upfield shift to 6 3.14 ppm of the triplet signal in the 'H NMR 
spectrum for the CH2X protons in the product compared with 6 3.44 ppm in the starting 
material confirmed that the reaction had indeed been successful. 
3.29 3.32 \, 3.33 Br 
Scheme 3.18 
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Synthesis of N4-benzoy-NI -(3-bromopropyl)cytosine, and N4-benzoyl-N1-(3- 
iodopropy1)cytosine 
A search for a protecting group for the N4 exocyclic amino group in cytosine revealed that 
N4-benzoylcytosine was commercially available. It was therefore decided to try the usual 
Mitsunobu conditions on N4-benzoylcytosine (Scheme 3.19). 
"WBr PhBP, DIAD 
Dioxane 
\/ ~ 
/\ 
H 
Br 
Scheme 3.19 
An Nh4R analysis of the reaction mixture revealed a very complex mixture of products 
and the absence of the desired product. It was later found in the literature that N4- 
benzoylcytosine undergoes alkylation on the oxygen of the ring carbonyl group. Thus, 
Lucas9* has observed that, regardless of the temperature (OOC, -78°C) or steric constraints 
(bulky alcohol or not), 02-alkylation was preferred. Scheiner has also obtained 
predominantly 02-alkylated products94 (Scheme 3.20). 
OTr OTr 
+ 
OTr OTr 
80% 20% 
Scheme 3.20 
With these examples, it became clear to us that Mitsunobu-type conditions could not be 
used to alkylate cytosine. Consequently, we decided to attempt other literature methods to 
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access the desired N1 haloalkylated cytosine. One well known method for alkylation of 
cytosine is to use a silyl group to both protect the cytosine carbonyl group and direct the 
attack at the electrophilic centre adjacent to the acetate (Scheme 3.21). 
&r 
Scheme 3.21 
Despite several attempts, this method was not successful in our case. Chug' has alkylated 
cytosine under similar conditions, but using a precursor containing a much more 
electrophilic centre due to the three neighbouring oxygen atoms (Scheme 3.22). 
Ph K 
N 3  Ph TMSOTf - A 
H 0 "  
Scheme 3.22 
In search for an alternative strategy, we found that K e e ~ e ~ ~  had alkylated cytosine at the N1 
position using 6-bromohexan-1-01 without the use of any protecting group for the 
exocyclic amine functionality (Scheme 3.23). Indeed, one advantage of this method is that 
there is no need for the removal of a protecting group. 
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Scheme 3.23 
Further, we anticipated that the free amine would be compatible with the subsequent 
radical addition. Consequently, we adopted this method. Thus, NaH was added portionwise 
to cytosine in DMF (Scheme 3.24). After 1 h at room temperature, the solution became 
clear and 3-bromopropan-1-01 (0.5 equiv) was added dropwise to the solution. The mixture 
was stirred overnight at room temperature, quenched with methanol and the crude product 
was submitted to column chromatography. Due to the free amine group, triethylamine was 
required in order to elute the compound. The desired product 3.34 was isolated in 65% 
yield as a white solid. The presence of a singlet at 6 7.06 ppm integrating to two protons 
demonstrated that the free amine had not been alkylated. The chemical shift in the 'H 
NMR spectrum of the triplet signal corresponding to the NCHz (6 3.74 ppm) in our sample 
was very close to the triplet in Keese's product (6 3.73 ~ p m ~ ~ ) .  A triplet integrating to one 
proton at 3.44 ppm corresponded to the OH in the side chain. The accurate mass also gave 
satisfactory results (274.1 194 for CldH15N303). 
"2 I 
O #  
H w B r  
* 
NaH 
DMF 
Cytosine 
Scheme 3.24 
We then needed to convert the alcohol into the corresponding bromo compound. An 
obvious reagent for this is phosphorus tribromide. This reaction was carried out by 
dropwise addition of phosphorus tribromide to a stirred solution of the alcohol in 
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dichloromethane at -10°C. Monitoring the reaction by HPLC revealed the presence of 
numerous products, none of which could be isolated pure. It was then decided to use 
milder brominating conditions. We therefore selected the NBS/triphenylphosphine system. 
NBS was slowly added portionwise to a stirred solution of tnphenylphosphine and alcohol 
3.34 in dichloromethane (Scheme 3.25). The reaction mixture was stirred overnight after 
which time tlc showed no traces of starting material. 
Ph3P, NBS 
'/e 
DCM 
I 
Scheme 3.25 
The crude product was purified by column chromatography using 10 % solution of acetic 
acid in methanol, but unfortunately the product isolated was the cyclised compound 3.36. 
We observed a disappearance of the OH and NH2 singlets at 4.61 and 7.06 ppm 
respectively in the product 3.36. Presumably the presence of the lone pair of electrons on 
the exocyclic nitrogen promotes cyclisation (Scheme 3.26). 
NBS, P h P  
DCM 
+ A 
3.36 
Scheme 3.26 
It appeared, then, that the use of a protecting group on the amino group would be necessary 
so we decided to repeat these reactions using N4-benzoylcytosine (Scheme 3.27). 
Alkylation afforded a crude product that was purified by column chromatography on silica 
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gel to give the desired N1 alkylated cytosine 3.37 which gave satisfactory spectroscopic 
analysis. 
- NaH,H-Br 
I I 
DMF 
H 
Conversion of 
( 3.38 
Br 
LI 3.39 
Scheme 3.27 
; 01 group to Br was carried out using NBS iphenylphosl ¡ne in 
dichloromethane, and after purification by flash chromatography the desired product 3.38 
was isolated in 72% yield (Scheme 3.27). The disappearance of the OH triplet at 6 4.65 
pprn and of the CH20H quartet at 6 3.47 pprn in the 'H NMR spectrum and the appearance 
of triplet at 6 3.50 ppm confirmed that the required conversion had indeed been 
accomplished. 
The final step in the synthesis of our precursor for radical addition was the conversion of 
the bromopropyl cytosine derivative 3.38 into the iodo compound 3.39. Again, this was 
easily achieved in the usual manner by heating the bromo compound 3.38 with an excess 
of sodium iodide at reflux in dry acetone. We noticed the usual upfield shift in the 'H 
NMR spectrum of the triplet corresponding to the CH2X from S 3.47 ppm in 3.38 to 6 3.25 
ppm in 3.39. In the 13C NMR spectrum the signal shifted from 6 31 ppm in the starting 
material to 6 19.03 in the product, in agreement with all the other iodo precursors. 
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3.2.2.2 Synthesis of haloalkylpurines 
Synthesis of N6-(2-methylpropanoyl)adenine 
As described in Chapter 2, Shevlin has used the 2-(methyl)propanoyl group as a protecting 
group for adenosine analogues77. 
Adenine 2.91 
Scheme 3.28 
We therefore chose to employ the same protection and prepared the corresponding N6-(2- 
methylpropanoy1)adenine 2.91 (Scheme 3.28). 6-Aminopurine (adenine) was stirred at 
reflux in DMF for 6 h with a three fold excess of 2-methylpropanoyl anhydride. The 
solution turned dark orange. After removal of the DMF under reduced pressure the yellow 
solid residue was refluxed in EtOWH20 (111). The reaction was stopped when the tlc 
showed that all diprotected (N6 and N9) adenine had been converted into the mono- 
protected compound 2.91. The solvent was then evaporated and the yellow crude product 
dried over P205. The resulting solid which contained a substantial amount of adenine was 
further purified by column chromatography (DCMMeOH, 911). This reaction could be 
performed on a large scale (up to 10 g adenine) without decrease in the yield (typically 
70%). 
As we had observed for N3-benzoyluracil, it was also found that the 2-methylpropanoyl 
group at position N9 could also be removed during column chromatography on basic 
alumina. 
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Synthesis of N9-(2-bromoethyl)-N6-(2-methylpropanoyll)adenine and N9-(2-iodoethyl)- 
N6-(2-methylpropanoyl)adenine 
As S h e ~ l i n ~ ~  had used Mitsunobu conditions to alkylate the N9 position of N6-(2- 
methy1propanoyl)adenine with 2-chloroethanol, we adopted an identical procedure using 2- 
bromoethanol (Scheme 3.29). 
NHCOCHMe2 NHCOCHMq NHCOCHMe2 
N k ,  HOmB' Nal, acetone 
'., Dioxane 
I 2.91 3.40 Br 3.41 
Scheme 3.29 
Again, it was noted that when the addition of DIAD to compound 2.91 was performed at 
room temperature over 5 min, the reaction was exothermic and the yield of the alkylated 
product 3.40 was also lowered (typically <SO%). Care had to be taken with the purification 
by column chromatography as the desired product 3.40 eluted very close to 
triphenylphosphine. To remove any residual traces of phosphine oxide the product was 
further purified by crystallisation from ethanol to yield 76% of 3.40. The spectroscopic 
data of this bromo derivative were very similar to those of the chloro derivative of Shevlin. 
The bromoalkylated base was easily converted into the iodo compound 3.41 (86% from 
3.40) by refluxing 3.40 with an excess of sodium iodide in dry acetone in the dark. In the 
'H NMR spectrum we observed a characteristic shift of the CH2X protons (triplet) from 6 
3.79 in 3.40 to 6 3.63 ppm in 3.41. The accurate mass (360.0315 for CiiH1dN50) also 
confirmed that we have indeed incorporated an iodine atom into the molecule. 
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Synthesis of N9-(3-bromopropyl)-N6-(2-methylpropanoyl)adenine and N9-(3-iodopropyl)- 
N6-(2-methylpropanoyl)udenine 
The Mitsunobu reaction was carried out between 2.91 and 3-bromopropan-1-01 (Scheme 
3.30) to yield 3.42 (76%). Traces of triphenylphosphine oxide could be removed entirely 
by crystallisation from toluene. As previously described, the corresponding iodo derivative 
3.43 was obtained in 81% yield by heating the bromo-derivative 3.42 at reflux overnight 
with excess sodium iodide in dry acetone. In the 'H NMR spectrum, a shift in the signal for 
the CH2X protons was observed from 6 3.37 ppm in the starting material to 6 3.12 pprn in 
the product. In the I3C Nh4R spectrum, the signal for the carbon of the CH2X system 
moved from S 31.70 pprn in the starting material to 6 1.65 ppm in the product. The 
accurate mass also confirmed the structure of compound 3.43. 
NHCOCHMe, NHCOCHMe, NHCOCHMe, 
Ho\/\/Br PhSP,DIAD "%Y "al, acetone 4 
"i Dioxane 
2.91 3.42 \ Br 3.43 \, 
Scheme 3.30 
Synthesis of N2-acetyl-06-[2-(4-nitrophenyl)ethyl]guanine 
While the reaction of adenine with ethylene carbonate in refluxing DMF is reported to give 
the desired N9-(2-hydroxyethyl)adenine in good yield, hydroxyethylation of guanine 
generates predominantely 7-substituted guanine9'. A literature search revealed that one of 
the commonly used approaches to 9-substituted guanine derivatives relies on the 
construction of the purine base step by step starting from 2-amino-4,6- 
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dichloropyrimidine”. It was obvious that this reaction involved too many steps. In 1992, 
Benner and co-workers reported a convenient building block for the synthesis of analogues 
of guanosine9’. In their work, N2-(2-methylpropanoyI)-O6-[(4-nitrophenyl)ethyl]guanine 
3.44 was used in the Mitsunobu reaction with sugars to produce exclusively N9-substituted 
guanosines. 
Shevlin, in trying to make the above precursor, noted that treatment of N2-(2- 
methylpropanoy1)guanine with acetic anhydride repeatedly generated a mixture of N9- 
acetyl-N2-(2-methylpropanoyl)guanine together with N9jV2-diacetyl guaninelW. He 
therefore decided to use N9,AQ-diacetyI guanine instead of N9-acetyl-N2-(2- 
methylpropanoy1)guanine. N9,N2-Diacetylguanine was readily prepared from guanine in 
one step by treatment with a large excess of acetic anhydnde in refluxing DMF. Reaction 
of N9J2-diacetyl guanine with 2-(4-nitrophenyl)ethanol and subsequent hydrolysis in 
refluxing dioxane-water gave N2-acetyl-06-[2-(4-nitrophenyl)ethyl]guanine 3.44. 
\+ 
3.44 
-N*N i 
H2N H H 
Guanine iii) H20/dioxane, reflux 
Scheme 3.31 
In our hands, the diacetylated guanine produced under the same conditions as Shevlin was 
not purified but used directly in the next Mitsunobu step (Scheme 3.31). Thus, the 
unpurified diacetylated guanine was reacted with 2-(4-nitrophenyl)ethanol, 
triphenylphosphine and DIAD at room temperature overnight followed by reflux in 
dioxanelwater (111) for 1 h. Upon cooling, the yellow precipitate was filtered and washed 
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several times with dichloromethane to remove tnphenylphosphine oxide and any excess 
reagents. A pure sample of 3.44 was obtained in 53% yield by column chromatography on 
silica gel. The 'H Nh4R spectrum of a repeat reaction showed that that the crude product 
was pure enough (traces of phosphine oxide) to use it directly in the next step. 
Synthesis of N2-acetyl-N9-(2-bromoethyl)-O6-[2-(4-nitropheny~)ethyl~guunine and N2- 
ace~l-N9-(2-iodoethyl)-O6-[2-(4-nitrophenyl)ethyl]guunine 
Mitsunobu reaction of 3.44 with 2-bromoethanol in the usual way (Scheme 3.32) afforded 
3.45 in 67% yield after purification by column chromatography. With the aid of a 'H-'H 
COSY experiment the assignment of the four triplet CH2 signals [6 3.28 ppm (AICHz), 6 
3.95 and 4.55 ppm (NCH*CHzBr), 6 4.77 ppm (OCHz)] could be achieved without 
ambiguity. 
O/\/PNP O/\/PNP o-../PNP 
DMF, dioxane 
H H 
3.44 Er 'I 3.45 3.46 
Scheme 3.32 
The bromo derivative 3.45 was then converted into the iodo compound 3.47 in 85% yield 
using the standard method. The CH2X triplet in the 'H NMR spectrum again shifted from 6 
3.95 for 3.45 to 6 3.70 ppm in the product 3.46 which confirms the substitution. Moreover, 
the chemical shift in the I3C NMR revealed CH2X signal moved from 6 31.02 pprn in 3.45 
to 6 3.65 ppm in 3.46 and the correct accurate mass (397.0412 for C I ~ H ~ ~ I N ~ O ~ )  indicated 
that we had spthesised the desired iodoethyl guanine derivative 3.46 (Scheme 3.32). 
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3.2.2.3 Summary 
We have shown that all five 5 DNA bases could be alkylated regioselectively at the N1 
position for pyrimidines (thymine, uracil and cytosine) and at the N9 position for purines 
(adenine and guanine). We were able to introduce both two- and three-carbon spacers 
between the nucleobase and the carbon atom that will become the radical centre. With 
these radical precursors to hand, we needed both to generate the carbon-centred radical by 
homolysis of the weak carbon-iodine bond and to form, stereoselectively, a carbon-carbon 
bond by addition of the radical to the dehydroalanine equivalent. These results are 
developed in the next section. 
3.2.3 Radical addition 
Oxazolidine-5-ones (e.g. 3.14) have shown very good diastereoselectivity upon addition of 
a carbon-centered radical to the exocyclic double bondEE. We decided to use the Z-group to 
protect the ring nitrogen atom because it can be easily removed by hydrogenolysis in high 
yield. 
There are several methods available to generate the required carbon-centred radicals. 
Amongst the most important are the tributyltin hydride, the catalytic tin hydride, and the 
mercury methods"'. In our work only the former two methods of radical generation have 
been examined. The following is a short overview on C-C bond forming reactions that 
employ such tin-based methods. 
Radical reactions are usually chain processes, and a chain-camer radical is required. This 
is very commonly a trialkyltin radical. The generation of such radicals is commonly 
achieved using the initiation sequence shown in Scheme 3.33. Here, the formation of 
radicals is brought about by the thermolysis of azobis-(isobutyronitrile) (ALBN) (step 1). 
The correct choice of initiator is usually decided by the operating temperature and hence 
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by the appropriate half-life of the decomposition reaction; AIBN has a half-life of 2 h at 
80°C or 0.1 h at 100°C. 
CN CN 
AIBN 
Heat 
CN 
N2 + 
+ 
+ 
+ 
+ 
Bu3Sn * R' + Bu,SnX 
Bu3SnH * RH + Bu3Sn 
Scheme 3.33 
The AIBN-derived radical then abstracts a hydrogen atom from a tin hydride to form a tin- 
centered radical (step 2).  This trialkyltin radical generated by the initiator can abstract a 
halogen atom from the haloalkane, thereby producing the desired carbon-centered alkyl 
radical (step 3). The carbon-centered radical can then be reduced by hydrogen abstraction 
from another tin hydride molecule (step 4) or alternatively it could add to an alkene to 
extend the radical structure (step 5). The choice of the halogen in the haloalkane is 
important because the C-X bond dissociation energies (BDEs) are different: for C-CI, C-Br 
and C-I the BDEs are, respectively, 340, 290 and 220 Mmol-'. Thus iodoalkanes require 
little initiation. A trace of oxygen is sufficient to generate a tin-centered radical from the 
trialkyltin hydride by homolytic cleavage of the tin-hydrogen bond. Thereafter, almost 
every encounter between the trialkyltin radical and the iodoalkane is productive. 
A classic example of a synthetically useful process is the tributyltin hydride mediated 
cyclisation of the 5-hexenyl radical to form methylcyclopentane (Scheme 3.34). The 
BuiSn' radical abstracts the halogen atom to provide the 1-hexen-6-y1 radical. In a second- \ 
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order reaction, this radical can abstract a hydrogen atom from the tin hydnde reagent to 
afford the reduced product, 1-hexene, with concomitant regeneration of a tributyltin 
radical. Alternatively, the hexenyl radical can undergo a first order irreversible 5-exo-trig 
ring closure to form the cyclopentylmethyl radical. This latter radical can itself abstract a 
hydrogen atom from the tin hydride reagent to afford methylcyclopentane. Thus, the 
relative amounts of 1-hexene and methylcyclopentane are determined by the relative rates 
for the partitioning of the 1-hexen-6-y1 radical between cyclisation (kJ and hydrogen atom 
abstraction (kH[Bu3SnH]). Thus, the tin hydride concentration provides a variable by which 
the product distribution can be controlled. At a very high concentration (> 5 M), the 
unrearranged hex-1-ene product will predominate, whereas at low concentration (< 0.05 
M), the major product will be methylcyclopentane. 
bX + 
L. + 
¿I+ 
kx SñBy c 
kH H-SñBy -- 
A. + 
&H + 
X-SñBy 
SnBu, 
SñBU, 
Scheme 3.34 
Of course, these observations are also true for intermolecular addition of a carbon-centred 
radical to an alkene. By adjustment of the tin hydride concentration, a window of radical 
lifetime is obtained that allows for the slower addition to alkenes. One common technique 
used to maintain a low tin hydride concentration is the use of slow addition via syringe 
pump; this bypasses the need for a large volume of solvent as diluent. Another technique is 
-. 
96 
the in situ generation of tin hydnde; this enables low standing concentrations to be 
achieved. Whereas the tin hydride method requires stoichiometric amounts of tin reagent, 
the in situ generation of a tin hydride from the corresponding tin chloride is a catalytic 
procedure that was developed by Corey and Suggs'oz. In this procedure, as it is formed 
during the reaction, the tin chloride is reduced to the corresponding tin hydride using 
sodium borohydride or sodium cyanoborohydride. The tin hydride is then oxidised into the 
tin iodide (formed from the haloalkane) hence forming the desired carbon centred radical 
for radical addition. The so-formed tin iodide is further reduced to tin hydride and this 
completes the catalytic cycle. 
Both the tributyltin hydride and the catalytic tributyltin chloride method have been used in 
the present work. 
3.2.3.1 Thymine adducts 
The preparation of the thymine bromo- and iodo-ethyl 3.25 and 3.27, and -propyl 
derivatives 3.26 and 3.28 has been described above. The first reaction to be performed 
employed the bromoethyl derivative 3.25. Using this, we tried to generate the 
corresponding radical via catalytic formation of tributyltin hydride from the reduction of 
tributyltin chloride (0.2-0.3 equiv.) by sodium cyanoborohydride (Scheme 3.35) in the 
presence of the oxazolidinone 3.23. However, after 3h reflux in ethanol no addition 
product could be isolated. Indeed, the bromoethyl starting material was recovered in 82% 
yield. 
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Y+-- 
EtOH 
ÈI 
3.25 
i-s 
“y0 3.47 
BU‘ 
Scheme 3.35 
Consequently, we decided to repeat the reaction using the iodoethyl derivative 3.26. We 
also decided to adopt the conventional tin hydnde procedure (Scheme 3.36). 
P 
3.48 
3.23 BuSSnH, AIBN 
toluene 
I 
vo 3.26 3.47 ZN 
26% 
Scheme 3.36 
24% 
Tributyltin hydride was added viu syringe pump over 2 h to a refluxing solution of the 
iodoethyl compound 3.26, chiral template 3.23 and AIBN in toluene. The concentration of 
3.26 was calculated to be roughly 0.01M so as to minimise formation of the reduction 
product. Gratifyingly, the desired adduct 3.47 was isolated after column chromatography in 
26% yield, although the reduction compound 3.48 was also isolated in 24% yield. The 
adducts were all 2,4-syn and this will be discussed later. 
To reduce the amount of 3.48 produced still further, rather than use impractical volumes of 
solvent (so as to run the reaction at low concentration). We decided to employ the catalytic 
tributyltin chloride method (Scheme 3.37). Thus, the chiral template 3.23 (2 equiv.), the 
iodoethyl thymine derivative 3.26, tributyltin chloride (0.2-0.3 equiv.), sodium 
cyanoborohydride (2 equiv.) and AIBN were stirred at reflux in tert-butanol for 16 h. 
98 
Work-up afforded 24% of the desired adduct 3.47 and also, unexpectedly, the 3- 
debenzoylated adduct 3.49; no reduction product was isolated. It would appear that the 
catalytic tin hydride method does indeed lower the relative amount of the reduction 
product and, more importantly, more than doubled the yield of the desired adduct (from 
26% to a combined yield of 54%). 
I 
3.26 
"yo 3.23 
BU' 
'BuOH 
3.47 ,,Y0 BU' 
+ 
3.49 zNYo But 
24% 30% 
Scheme 3.37 
It was decided to investigate further the debenzoylation process. The reaction was 
repeated, but reflux was continued for 40 h instead of 16 h. This resulted in complete 3- 
debenzoylation, the yield of 3.49 being 47%. 
We therefore attempted radical addition using the iodopropylthymine derivative 3.28 under 
identical conditions (Scheme 3.38). 
3.28 
"yo 3.23 
BU' 
Bu3SnCl,NaBH3CN, AIBN 
'BuOH 
3.50 3.51 
25% 21% 
Scheme 3.38 
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As expected, upon reaction at reflux for 40 h in the presence of 2.0 equiv of sodium 
cyanoborohydride, the 3-debenzoylated adduct 3.50 was isolated after column 
chromatography in 25% yield, although the 3-debenzoylated reduction product, 
propylthymine 3.51 was also isolated in 21% yield. 
Nevertheless, encouraged by these results, we decided to employ the radical addition using 
the uracil precursors. 
3.2.3.2 Uracil adducts 
As the Bu3SnCl/NaBH3CN (0.3/2 equiv.) method gave satisfactory results, this method 
was applied to the corresponding iodouracil precursors (Schemes 3.39 and 3.40). 
i 
"yo 3.23 
BU' 
Bu3SnCI,NaBH3CN, AiBN 
b 
3.52 "yò 3.53 'BuOH 
BU' 
Lo + 
3.s4ZNy0 
BU' _ _  
3.31 
t = 7 h  47% t = 7 h  46% k 7 h  0% 
t= 40 h 0% t= 40 h 51% 
Scheme 3.39 
Thus, from the iodoethyl starting material 3.31, the desired compound 3.52 was isolated in 
47% yield after reflux for 7 h in tert-butanol. The benzoylated reduced compound 3.53 was 
also formed in 46% yield. A second reaction involving reflux for 40 h gave as by now 
expected the 3-debenzoylated adduct 3.54 in 51% yield. 
A similar reaction involving the iodopropyluracil precursor at reflux for 8 h (Scheme 3.40) 
gave the desired adduct 3.55 in 21% yield and the reduction product 3.56 in 27% yield. 
Extended reaction time gave as expected the desired debenzoylated adduct 3.57 in 44% 
yield. 1-Propyluracil3.58, was also isolated as a reduction co-product in 51% yield. 
1 O0 
c 'BuOH ZNVO + 
3.58 I 3.33 3.55 Bu' 3.56 3.57 Bu' 1 
8h21% 8h27% 8 h 0 %  8 h 0% 
40h0% 40hO% 40h44% 40h51% 
Scheme 3.40 
In an attempt to improve the yield of the product 3.57 of conjugate addition, this reaction 
was repeated using an excess of chiral acceptor 3.23 (5.0 equiv.). The adduct 3.57 was 
isolated in 62% yield. Despite the improved yield, we concluded that the latter conditions 
were too wasteful of our valuable chiral oxazolidinone 3.23. 
3.2.3.3 An unexpected intramolecular radical addition 
Given that the use of 2 mol equiv. of sodium cyanoborohydride resulted in both radical 
addition and deprotection of the nucleic acid base, we decided to investigate the reaction 
using 0.3 mol equiv, keeping the amount of Bu3SnCI the same (3  equiv.). 
3.59 
The reaction mixture was refluxed for 30 min in tert-butanol, after which time 82% of the 
unreacted chiral template 3.23, along with 80% of the starting iodopropyl compound 3.33 
was recovered. Unexpectedly, we also isolated the bicyclic product 3.59 in 87% yield 
(based on recovered 3.33). In other words, essentially all the radical species resulting from 
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the homolytic cleavage of the weak iodine-carbon bond underwent intramolecular addition 
rather than intermolecular capture by the radical template. According to Baldwin's rules, 
the cyclisation is a 5-exo-trig process and therefore favoured. 
The reaction was repeated using tnbutyltin hydride and AIBN in the absence of any 
oxazolidinone 3.23. The bicyclic compound 3.59 was the only product isolated (53% yield) 
from this reaction. The probable mechanism for the intramolecular addition is shown 
below (Scheme 3.41)'03. 
r 
3.33 
ir 
L 
- 0  -".s A N  
3.59 
Scheme 3.41 
3.2.3.4 Sodium cyanoborohydride and deacylation 
To determine whether or not the deacylation was a radical-initiated process, compound 
3.25 was heated at reflux in tea-butanol with 1 equivalent of sodium cyanoborohydride. 
The debenzoylated product 3.60 was isolated, indicating that deacylation was more likely 
to be hydride-mediated, rather than a radical-mediated process (Scheme 3.42). It is 
believed that the benzoyl carbonyl group of compound 3.25 is out-of plane of the thymine 
ring and therefore is not really amide-like. This ketone-like carbonyl can therefore be 
reduced to the corresponding alcohol by sodium cyanoborohydride and can further 
collapse to give benzaldehyde and compound 3.60. 
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Scheme 3.42 
3.2.3.5 Cytosine adduct 
The radical addition reaction was also perîomed on the iodopropyl cytosine 3.39 (Scheme 
3.43). Unfortunately, the corresponding adduct 3.61 could not be separated from a mixture 
with, infer alia, the reduced cytosine starting material and unknown by-products. High 
resolution mass spectrometry verified the presence of 3.61 so the crude mixture containing 
the addition product was taken through to the next step (see section 3.2.4). 
3.39 
Bu3CnCI, NaBhCN, AIBN 
'BuOH 
Scheme 3.43 
3.2.3.6 Adenine adducts 
3.61 
Bu' 
In the purine series, the usual Bu3SnCI/NaBH3CN method was applied to the iodoethyl 
adenine compound 3.41 (Scheme 3.44). After 16 h reaction time a mixture of products 
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resulting from conjugate addition [40%; acylated 3.62 (26%) and deacylated 3.64 (14%)] 
and reduction [36%; acylated 3.63 (17%) and deacylated 3.65 (19%)] was obtained. 
BU' 
'BuOH 
I \  
"Y0 I 
BU' 
3.41 3.62 3.63 3.64 3.65 
Scheme 3.44 
The deacylated adduct 3.64 and acylated reduction product 3.63 were isolated as an 
inseparable mixture, the contents of which were quantified from the result of the 
subsequent hydrolysis step (see below). The compounds 3.62, 3.63, 3.64, 3.65 showed 
satisfactory spectral data. 
The iodopropyl derivative 3.43 similarly gave products of radical addition [22%; acylated 
3.66 (12%) and deacylated 3.68 (lo%)] along with reduced compounds [24%; acylated 
3.67 (11%) and deacylated 3.69 (23%)] (Scheme 3.45). 
NHCOCHMq 
'BuOH 
I ZNvO 
L 
BU' 3.67 3.43 3.66 
Scheme 3.45 
For comparison, we found that the Bu3SnH method when applied to iodopropyl compound 
3.43 led to the acylated adduct 3.66 in 23% yield and the reduction product 3.67 in 45% 
yield. 
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3.2.3.7 Guanine adduct 
Finally, conjugate addition between the guanine derivative 3.45 and the 
methyleneoxazolidinone 3.23 using the Bu3SnH method led to adduct 3.70 (21%) and 
reduction product 3.71 (20%) (Scheme 3.46). This conjugate addition reaction was also 
conducted using the catalytic tin chloride method in rert-butanol. Unfortunately, no 
addition product was detected. 
3.4s 
zv BU' 
3.70 3.71 
Scheme 3.46 
3.2.3.8 Diastereoselectivity of the radical addition 
A major goal of our work was to carry out the synthesis of amino acids in a stereoselective 
manner. In the above radical additions, only one diastereoisomer was detected in the 'H 
N M R  spectra. To determine the relative stereochemistry of the radical addition (syn or unti 
addition) of the purinyl and pyrimidyl radicals onto the electron deficient alkene of the 
oxazolidinone 3.23, we performed n.0.e. experiments on the radical adducts. The 
corresponding results for the three examples are presented in tables 3.4,3.5 and 3.6. 
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Ph 
\ 
Signal irradiated Signal enhanced 
Bu' H2 (2.61%), -2CH2CHzN (0.24%) 
H2 (1.26%), Bu' (5.12%) 
H2 (1.24%) H4 
Table 3.4 
Signal irradiated Signal enhanced 
Bu' 
HZ 
Hz (1.92%), C&C&CHZN (0.82%) 
H4 (0.94%), Bu' (3.52%) 
3.66 
Table 3.5 
*PNP 
P 
Signal irradiated Signal enhanced 
Bu' Hz (2.6%) 
3.70 
H4 (1.12%), Bu' (5.21%) 
Hz (1.63%) 
Table 3.6 
Since all of these n.0.e. experiments exhibited, inter alia mutual enhancement between C- 
2(H) and C-4(H), we concluded that the radical addition was syn to the C2 teri-butyl 
group. The rationale for this syn addition is outlined in Scheme 3.47. Addition of the alkyl 
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radical yields an aminoacyl radical intermediate that reacts with tributyltin hydride on the 
less hindered face of the oxazolidine. 
Bu' 
Scheme 3.47 
3.2.4 The Z-protected amino acids 
The chiral template was removed from the adduct oxazolidinones by base hydrolysis using 
LiOH in THFkizO at 0°C for 30 min (Scheme 3.48)'04. 
1 
Bu' 
Radical adducts 
LiOH-HZO 
b 
xo 
ZHN OH 
Z-amino acids 
Scheme 3.48 
A simple acidification of the crude mixtures using aqueous HCI, followed by extraction of 
the acids using ethyl acetate afforded the desired Z-protected amino acids 3.73-3.83. In the 
case of the guanine derivative 3.83 some solubility problems were encountered at the 
extraction stage, but these were overcome by using DCM. For the cytosine example 3.78, 
the crude product 3.61 from radical addition was used in the hydrolysis, unfortunately no 
pure Z-amino acid 3.78 was obtained and 3.78 was used as crude in the next step. Thus, the 
Z-protected amino acids were afforded in high yield (Table 3.7). 
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ZHN Lo OH 
ZHN OH 
3.72 3.73 3.74 3.75 
NHCOCHMe, 
ZHN OH 
3.76 3.77 3.78 3.79 
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Oxazolidinone adduct Z-amino acid Yield (%) Amino acids Yield (%) 
3.47 3.72 92 - 
3.49 3.73 96 3.84 14 
3.50 3.74 81 3.85 I9  
3.54 3.75 69 3.86 15 
3.55 3.76 96 - - 
3.57 3.77 52 3.87,3.88 90,88 
3.61 3.78 crude 3.89 - 
3.62 3.79 12 3.90 15 
3.64 3.80 87 - - 
3.66 3.81 89 3.91 61 
3.68 3.82 86 . 
3.70 3.83 87 - 
- : reaction not carried out Table 3.7 
3.2.5 The amino acids 
To afford the corresponding parent amino acid and to monitor the stereochemical integrity 
of the synthesis, the 2-protecting group was removed using catalytic hydrogenation with 
10% Pd on C (Scheme 3.49). 
H2, PCVC . 
EtOWH2O H2N OH 
Z-amino acids Amino acids 
Scheme 3.49 
Our initial attempts at hydrogenation using ethyl acetate as solvent were unsuccessful due 
to solubility problems with both the Z-protected and final amino acid. Similarly, glacial 
acetic acid and methanol were also tried, but with no success. 
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Eventually, it was found that a solution of ethanoiíwater in a ratio of 713 vlv gave the best 
results. Most of the Z-protected amino acids previously described were submitted to 
catalytic hydrogenation to afford the novel amino acids shown below. 
O 
Il 
O 8 Il O Il 
3.86 
NHCOCHM+ 
3.87 
IHCOCHM+ 
3.88 3.89 3.90 3.91 
In general, the catalytic hydrogenation proceeded in good yield, from 61% for 3.88 to 90% 
for 3.84. While the amino acid 3.87 was obtained after hydrogenolysis of the Z-amino acid 
3.77 after 5 h, it was found that prolonged hydrogenolysis of 3.77 for 16 h led to the 5,6- 
dihydrouracil amino acid 3.88 in 88% yield. 
3.2.6 Determination of stereoselectivity 
The enantiomeric excess of most of the amino acids was determined through the formation 
of the Mosher amide (Scheme 3.50). 
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i) EtOWAcCI 
D 
H2N OH ¡i) (R)-MTPA-CI 
Amino acids MTPA-amides 
Scheme 3.50 
The amino acids (50 mg) were first converted to their corresponding ethyl ester 
hydrochloride by slow addition of acetyl chloride to a solution of the amino acids in 
ethanol at 0°C. The crude ethyl ester hydrochlorides were then coupled to (R)-MTPA-CI 
(100mg) in DCM and excess triethylamine. The Mosher amides so-produced were isolated 
and characterised. Their structures are shown below. 
3.92 3.93 3.94 3.95 
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One problem we encountered was that some amino acids underwent diamide formation 
(e.g. 3.90 and 3.91, and 3.95). However, we found that this allowed us to cross check 
enantiomeric purity, because both monoamide and diamide were able to report on 
stereoselectivity. In the 'H NMR spectra of the Mosher amide derivatives a major and a 
minor diastereoisomer were observed in some cases. This was noted especially by the 
presence of a major and a minor singlet corresponding to the methoxy group of the Mosher 
amide. Subsequent analysis of the CF3 signals in the 19F NMR spectra (see appendix) 
revealed very good enantiomeric excesses for the amino acids 3.84 (85%), 3.85 (SE%), 
3.86 @E%), 3.87 (89%) and 3.91 (86%) (Table 3.8). In the case of the amino acid 3.91 the 
reaction to form the Mosher amide 3.98 removed the 2-methylpropionyl group from the N9 
of adenine, presumably by ethanolysis during esterification, leading to the diamide 
derivative. 
One outstanding issue remains for the synthesis of cytosinyl amino acid 3.89. We were 
unable to isolate the corresponding Mosher amide for spectroscopic identification, though 
an I9F NMR analysis of the crude amide revealed only two singlets and an e x .  of 81%. 
Amino acids Amides e.e. (%) 
3.84 3.92 85 
3.85 3.93,3.94* 88,88* 
3.86 3.95 88 
3.87 3.96 89 
3.89 3.97 81 
3.91 3.98 86* 
*ce. measured from corresponding diamide 
Table 3.8 
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3.2.7 Conclusion and further work 
The radical methodology has enabled us to make available a range of novel optically active 
pyrimidinyl and purinyl amino acids. Indeed, we have shown that pyrimidinyl (thymine 
and uracil) and purinyl (adenine and guanine) radicais could undergo diastereoselective 
conjugate addition onto an oxazolidinone acceptor. The Z-protected amino acids could be 
easily accessed in good yield by base hydrolysis of the oxazolidinone adducts. We were 
also able to vary the distance from the glycine backbone to the nucleic acid base. 
Moreover, the corresponding amino acids were synthesised with good enantiomeric purity 
(85 to 89 % e.e.). 
Work that remains outstanding from the current project is (1)  improvement in the yield of 
the amino acid bearing the cytosine nucleobase, (2) unmasking of the Z-protected guanine- 
containing amino acid to give the free amino acid, and (3) synthesis of the lower guanine- 
containing homologue that has a three-carbon spacer between the nucleobase and the 
amino acid backbone. 
Future developments of the project are as follows. Although we have found the conjugate 
radical addition to be general, the conditions of the radical addition nevertheless require 
detailed investigation to improve the ratio of the desired conjugate addition to unwanted 
reduced products. This could, for example, potentially be achieved by using a different 
radical initiator such as triethylborane in the presence of traces of oxygen. Another 
alternative would be to use different reducing agents like tris(trimethylci1yl)silane. It would 
also be interesting to replace the tin reagent by one containing another (semi)metal like 
germanium or mercury for example. There are various other radical generation protocols 
that might be explored. For example, the carbon-centred radical could be accessed viu 
xanthate esters, selenium-containing precursors or Barton esters. The downside of this 
approach would be that it would involve a revision of the precursor synthesis. 
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Another potential extension to this work could be to add a nitrogen-centred (or oxygen- 
centred) radical onto the dehydroalanine acceptor, hence forming a carbon-nitrogen or 
carbon-oxygen bond instead of a carbon-carbon bond. This option would lead to a one- 
carbon spacer between the nucleobase and amino acid instead of the three- or four-carbon 
spacers generated by the current work. 
Another, obvious extension of the work is to apply the radical addition to other 
heterocyclic precursors such as modified nucleobases (e.g.  06-methylguanine, thiouracil), 
(benz)imidazole, triazole, isoxazole, indole etc. 
Other nitrogen protecting groups such as Boc, Fmoc, benzoyl could be used in lieu of the 
Z-protecting g o u p  on the oxazolidin-5-one acceptor, thereby avoiding the hydrogenation 
step. 
The finding that N3-benzoyl-N1-(3-iodopropyl)uracil underwent intramolecular addition to 
form a bicyclic system could be exploited further by introducing more functional groups 
onto the radical precursor. This cyclisation could also be the basis for a cascade radical 
reaction leading to more complex fused ring systems. There is potential to develop this 
reaction into other natural product series away from the PNA area. 
Finally, short PNA’s could be designed from the synthesised amino acids bearing the 
nucleobases. Hybridisation studies using those new PNAs could then be canied out to 
study potential specific binding affinity with DNA or self-hybridisation. 
114 
CHAPTER 4 
EXPERIMENTAL 
Experimental 1 Glycine enolate approach 
General Melting points were determined using a Pye 290 melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a Perkin-Elmer 1710 FïIR 
spectrophometer. 'H NMR spectra were recorded in deuteriochloroform (unless otherwise 
stated) on JEOL LAMBDA300 or JEOL EX400 spectrometers at 300 or 400 MHz, 
respectively, and chemical shifts are quoted in parts per million (p.p.m) from 
tetramethylsilane as internal standard. Coupling constants (4, where appropriate, are 
quoted in Hz with the following multiplicities; s-singlet, d-doublet, t-triplet, q-quartet and 
m-multiplet. The prefix br-broad is used where applicable. 13C Spectra were recorded on 
the same instruments at 75 M H z  or 100 M H z ,  respectively, in deutenochloroform (unless 
otherwise stated) and chemical shifts are quoted in parts per million (p.p.m) from 
tetramethylsilane as internal standard. 19F spectra were recorded on a JEOL EX400 
spectrometer at 376 MHz using TFA as external standard. Low-resolution mass spectra 
were obtained using an AEI MS902 spectrometer in EI-positive mode. High-resolution 
EUCI mass spectra were performed by the EPSRC National Mass Spectrometry Service in 
Swansea. Microanalytical data were obtained from Medac Ltd., Brunei Science Centre, 
Englefield Green, Egham, TW20 OBZ. Solvents were dried and distilled immediatly before 
use: chloroform and DCM from CaH2, THF and toluene from K, using benzophenone as 
indicator; methanol and ethanol from Mg turnings and iodine. n-Butyllithium was titrated 
with diphenylacetic acid before use. Column chromatography was performed under 
medium pressure using silica gel (Kieselgel 60; 220-440 mesh). TLC analysis was carried 
out using Machery-Nagel Polygram SIL Gm254 plates on a plastic backing and visualised 
by ultraviolet light or aqueous potassium permanganate spray (KMn04: KzCO3: water, 
6:1:100, wlwlv). Organic extracts were dried over anhydrous MgS04. 
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General method for alkylation of pseudoephedrine glycinamide7' 
'R 
A freshly prepared solution of LDA (2M, 1.95 equiv.) in hexanes was added over 0.25- 
0.5h to a stirred slurry of anhydrous pseudoephedrine gly~inamide'~ (1.0 equiv.) and 
flame dried lithium chloride (6 equiv.) in THF under a positive argon atmosphere at 0°C. 
After stirring at 0°C for 0.5-lh, the haloalkane (1.1 equiv.) in THF was added dropwise. 
After 12h, hydrochloric acid (IM) was added to the solution, followed by ethyl acetate. 
The organic layer was extracted with a second portion of hydrochloric acid (1M). The 
aqueous extracts were combined, and the resulting solution was cooled in an ice bath and 
carefully basified to pH 14 by addition of 50% aqueous solution of sodium hydroxide. 
The basic aqueous solution was extracted with DCM. The combined organic extracts 
were combined and dried over potassium carbonate, filtered and concentrated in vacuo to 
provide the alkylated products. 
(lit, 2R, 2'S)-2'-Amino-3'-phenylpropanoylpseudoephedrine, 2.4372 
I 
LDA, LiCI 
OH CH, 
2.36 2.43 
Prepared as above using LDA (2M, 17.56 ml, 0.035 mol), (IR,2R)-pseudoephednne 
glycinamide (4g, 0.018 mol) and lithium chloride (4.58g. 0.108 mol) in THF (100 mi), 
together with benzyl bromide (3.39g, 0.02 mol) in THF (10ml). After 2h, hydrochloric 
acid (IM, 100ml) was added to the clear solution, followed by ethyl acetate (200ml). The 
116 
organic layer was extracted with a second portion of hydrochloric acid (lM, 1OOml). The 
aqueous extracts were combined, cooled, basified and extracted with DCM (3x80ml). 
Removal of the solvent provided a hydroscopic solid residue (3.458, 62%), Rf-0.53 
@CM:MeOH:Et3N, 9 0 5 5 ,  vlvlv); Found: M" (ES') 313.1908. ClgH~N202 requires: 
MH 313.1916; v,,/cm~' (KBr) 3300, 3250, 1625, 1500, 1450, 1400, 1300, 1100; & (4:l 
rotamer ratio, the asterisk denotes the minor isomer) 0.88 and 0.99* (3H, d, J 6.2, 
CHCHi), 2.6 and 2.9* (3H, s, NCH3), 2.7- 2.82 (2H, 2 x dd, J 13.2 and 7.2 , CHCHz), 
3.7 (lH, t, J 7.1, CHCHz), 4.3 and 4.45* (lH, d, J 6.6 , CHOH), 4.6 and 4.0* (lH, m, 
CHCH3), 7.0-7.3 (lOH, m, Ar); & 14.4 and 15.5* (CHCH3), 27.1* and 30.4 (NCH3). 
41.9* and 30.4 (CH2), 53.2 (CHCHz), 56.5 and 57.9* (CHCH3), 75.0* and 75.6 (CHOH), 
126.5, 126.6, 126.7, 126.8, 127.7, 128.2, 128.3, 128.4, 128.5, 128.6, 129.2, 129.4 (6 x Ar 
and 6 x Ar*), 137.5 and 138.4* (ArC), 141.7* and 142.0 (Arc), 175.2* and 176.2 
(C=O); d z  (CI) 313 (MHf, lOO%), 295 (40), 277 (25), 267 (15). 255 (60), 231 (30). 
( l R ,  2R, 2'S)-2'-Amino-3'-(1-naphthyl)propanoylpseudoeph~rine, 2.67 
m' / ÖH - CH, N I L N H ,  
LDA, LiCI 
2.36 2.67 
Prepared by the generai method, using (lR,2R)-pseudoephedrine glycinamide (2 g, 9 
mmol), LDA (8.78 ml, 18 mmol), lithium chloride (2.29 g, 54 mmol) and 1- 
(bromomethy1)naphthalene (1.67 g, 9.5 mmol). After the usual extraction, the yellow 
gum was purified by column chromatography @CM:MeOH:Et3N, 9 0 5 5 ,  v/v/v) to yield 
the title compound as a yellow hydroscopic gum (1.98 g, 61%). Found: MH' (ES') 
363.2076. C23H26N202 requires: MH 363.2072. v,,/cm~' (film) 3400, 3200, 2850, 1650, 
1300, 950; 0" (4:l rotamer ratio, the asterisk denotes the minor isomer) 0.90 and 1.0* 
(3H, d, J 4.9, CHCH3), 2.6 (3H, s, NCH3), 3.1 and 3.2 (2H, 2 x dd, J 5.4 and 9.9, 
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CHCHz), 3.8 and 3.9* (IH, t, J 5.4 ,CHCH2), 4.15* and 4.4 (lH, m, CHCHd, 4.1 and 
4.2* (lH, d, J6.7, CHOH), 6.9-7.9 (12H, m, Ar); SC 15.2 and 15.6* (CHCH,), 29.8* and 
30.8 (NCH3), 39.4 and 39.5* (CHz), 52.2 and 56.9* (CHCH2), 53.7 and 68.9* (CHCHj), 
75.6 and 75.5* (CHOH), 123.3, 123.4, 125.3, 125.4, 125.6, 126.1, 126.2, 126.3, 126.7, 
126.8, 127.4, 127.5, 127.7, 128.1, 128.3, 128.4, 128.8, 128.9, 131.9 and 132.0 (10 x Ar 
and 10 x Ar*), 132.2 and 133.6* (quaternary C), 133.8 and 134.2* (quaternary C), 135.1 
and 135.3* (quaternary C), 141.9 and 142.0* (quaternary C), 176.3* and 176.4 (GO); 
m/z (CI) 363 (m, loo%), 230 (20) and 166 (100). 
( lR,  2R, 2'S)-2'-Amino-4'-(1-naphthyl)butanoylpseudoephedrine, 2.68 
/ /  
LDA, LICI 
I e OH CH, 
OH CH3 
2.36 
Prepared by the general method, using (iR,2R)-pseudoephednne glycinamide (1.51 g, 
6.77 mmol), LDA (6.60 ml, 13.21 mmol), lithium chloride (1.73 g, 40.64 mmol) and 1- 
(2-bromoethyl)naphthalene (1.75 g, 7.45 mmol). After the usual extraction, the yellow 
hyàroscopic gum was purified by column chromatography (DCM:MeOH:Et3N, 90:5:5, 
vlvlv), to yield the title compound as yellow gum (0.85 g, 33%): vmaX/cm-l (film) 3400, 
3050, 3000, 1650, 1450, 1250,750; SH (4:l rotamer ratio, the asterisk denotes the minor 
isomer) 0.65* and 0.80 (3H, d, J 4.9, CHCH,), 1.6-1.75 (2H, m, CHz), 2.4 (3H, s, 
NCH3), 2.95-3.05 (2H, rn, Cif2) ,  3.40 and 3.65* (IH, m, CHCHz), 3.8* and 4.35 (lH, m, 
CHCH,), 4.4 (lH, m, CHOH), 7.0-7.35 (9H, m, Ar), 7.6 (lH, d, J5.4, Ar), 7.7 (lH, d, J 
5.4, Ar), 7.85 and 8.1* (IH, d, J5.4, Ar). S, 14.0 and 15.5* (CHCH,), 29.0 (CHZ), 31.0* 
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and 46.0 (NCH3), 35.0 and 36.0* (CHz), 51.0 (CHCH2). 63.0 and 75.0* (CHOH), 57.0" 
and 75.4 (CHCH3), 123.54, 123.69, 123.98, 125.35, 125.65, 125.72, 125.97, 126.05, 
126.19, 126.36, 126.65, 126.98, 127.46, 127.60, 127.82, 127.91, 128.13, 128.26, 128.48 
and 128.59 (10 x Ar and 10 x Ar*), 131.6 and 131.8* (quaternary C), 133.7 (quaternary 
C), 137.4 and 138.0* (quaternary C), 141.7* and 142.1 (quaternary C), 175.9* and 176.8 
(C=O); d z  377 (CI) (@, 70%), 355 (60) and 337 (80). 
(lR, 2R, 2'S)-2'-Amino-3'-(2-pyridyl)propanoylpseud~phedrine, 2.69 
CI 
2.69 / 
OH CH3 I ÖH CHS 
2.36 
LOA, LICI 
2-Chloromethylpyridine hydrochloride (5g, 30.5 mmol) and triethylamine (3.1 g, 30.5 
mmol) were stirred for 3 h at room temperature in dry THF (100 mi) under an 
atmosphere of nitrogen. The triethylamine hydrochloride salt was filtered off and the 
solution reduced to 20 ml in vucuo and used immediately in the alkylation. The alkylated 
compound was prepared following the generai method, using (lR,2R)-pseudoephedrine 
glycinamide (5.64 g, 25.4 mmol), lithium chloride (6.46 g. 152.4 mmol), IDA (24.4 ml, 
48.8 mmol) and 2-chloromethylpyndine (3.89 g, 30 mmol). The crude brown gum (6.2 
g) that was obtained was subjected several times to column chromatography 
(DCM:MeOH:EtjN, 90:5:5, v/v/v) to yield the title compound (4.95 g, 62%) which was 
used directly in the next step. 
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(lR, 2R, 2'S)-2'-Amino-3'-(3-pyridyl)propanoyIpseudoephedrine, 2.70 
CI 
m3 / OH : N  CH, I ,ìi,,NH2 &N .) mi\N OH CH, 
LDA, LICI 
2.36 2.70 / 
3-Chloromethylpyridine hydrochloride (3g, 18.3 mmol) and triethylamine (1.85 g, 18.3 
mmol) were stirred for 3 h at room temperature in dry THF (100 mi) under an 
atmosphere of nitrogen. The triethylamine hydrochloride salt was filtered off and the 
solution reduced to 20 ml in vucuo and used immediately in the alkylation. The alkylated 
compound was prepared following the general method, using (IR,2R)-pseudoephedrine 
glycinamide (3.4 g, 15.3 mmol), lithium chloride (3.89 g, 91.8 mmol), LDA (14.9 ml, 
29.8 mmol) and 3-chloromethylpyridine (2.33 g, 18.3 mmol). The brown gum that was 
obtained was subjected several times to column chromatography @CM:MeOH:Et-,N, 
90:5:5, v/v/v) to yield the title compound (2.65 g, 55%) which was used directly in the 
next step. 
(lR, ZR, 2'S)-Z'-Amino-3'-(4-pyridyl)propanoylpseudoeph~rine, 2.71 
CI 
I 
OH CH3 
LDA, LiCI 
2.36 2.71 
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4-Chloromethylpyridine hydrochloride (3g, 18.3 mmol) and triethylamine (1.85 g, 18.3 
mmol) were stirred for 3 h at room temperature in dry THF (100 mi) under an 
atmosphere of nitrogen. The triethylamine hydrochloride salt was filtered off and the 
solution reduced to 20 ml in vacuo and used immediately for the alkylation. The 
alkylated compound was prepared following the general method, using (1R,2R)- 
pseudoephedrine glycinamide (2.96 g, 13.3 mmol), lithium chloride (3.4 g, 80.2 mmol), 
LDA (13 ml, 26.0 mmol) and 4-chloromethylpyridine (2.04 g, 16.0 mmol). The black 
gum that was obtained was subjected several times to column chromatography 
(DCM:MeOH:Et3N, 90:5:5, v/v/v) to yield the title compound as a brown hydroscopic 
solid (1.5 g, 36%) which was used directly in the next step. 
(lR, 2R, 2'S)-2'-Amino-3'-(2-phenylphenyl)propanoylpseudoeph~~ne, 2.72 
Prepared following the general method using (lR,2R)-pseudoephedrine glycinamide 
(2.50 g, 11.3 mmol), lithium chloride (2.86 g, 67.5 mmol), LDA (10.9 ml, 21.8 mmol) 
and 2-phenylchloromethylbenzene (3.06 g, 12.4 mmol) to yield the title compound as a 
white hydroscopic powder (2.97 g, 68%). Found MH+ (ES') 389.2234. C Z ~ H ~ ~ N Z O Z  
requires: MH 389.2229. v,,,/cm-' (film) 3100, 3000, 1250, 750, 700; 6" (4:l rotamer 
ratio, the asterisk denotes the minor isomer) 0.60* and 0.90 (3H, d, J 4.9, CHCH3), 2.0 
(3H, s, NCH3), 2.4 and 2.8 (2H, 2 x dd, J 8.7 and 11.7, CHz), 3.3 and 3.4* (lH, m, 
CHCHz), 3.2 (lH, m, CHCH3), 4.40 (lH, d, J6.3, CHOH) 7.1-7.4 (14H, m, Ar); 6~ 14.1* 
and 14.2 (CHCH3). 31.0 (NCH3), 39.2* and 39.5 (CHCHz), 50.6* and 51.8 (CHCHz), 
74.8* and 75.0 (CHOH), 75.4 (CHCH3), 126.0, 126.1, 126.3, 126.8, 126.9, 127.2, 127.4, 
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127.5, 127.6, 128.2, 128.4, 128.6, 128.8, 129.1, 129.3, 130.2, 130.4, 130.5, 130.6, 131.0 
(10 x Ar and lox Ar*), 132.0 and 132.3* (quaternary C), 133.0 and 133.2* (quaternary 
C), 141.0 and 141.2* (quaternary C), 141.9* and 142.2 (quaternary C), 175.0* and 176.1 
(C=O); núz (CI) 389 (MW, 40%), 166 (100) and 58 (15). 
(lR, 2R, 2'S)-2'-Amino-3'-(3,5-dimethylisoxazol-4-yl)prop~oylpseudoephednne, 
2.73 
CI 
LDA, 
Prepared following the general method using (IR,2R)-pseudoephednne glycinamide 
(5.88 g, 26.5 mmol), lithium chloride (6.73 g, 159 mmol), LDA (25.8 ml, 51.6 mmol) 
and 4-(chloromethyl)-3,5-dimethylisoxazole (4.24 g, 29.1 mmol) to yield a white 
hydroscopic powder (8.46 g, 97%). Found: MH+ (ES') 332.1976. C L ~ H Z ~ N ~ O ~  requires: 
h4H 332.1974. vmX/cm.l (film) 3390, 2950, 2900, 1650, 1450, 1400, 1250, 1200, 1050, 
750, 700; 6" (4: 1 rotamer ratio, the asterisk denotes minor rotamer peaks) 0.66* and 0.77 
(3H, d, J 4.8, CHCH3), 2.05* and 2.1 (3H, s, isoxazole CH3), 2.15* and 2.25 (3H, s, 
isoxazole CH3), 2.35 and 2.45 (2H, 2 x dd appears as multiplets, CHCHz), 2.65 (3H, s, 
NCH3), 3.6 and 3.8* (IH, m, CHCHz), 4.3* and 4.4 (lH, d, J 6.6, CHOH), 4.64 (lH, m, 
CHCH3), 7.19-7.27 (5H, m, ArCH); 6~ 10.0 and 10.5* (isoxazole CH3), 11.0 and 11.5* 
(isoxazole C H 3 ) ,  14.0 and 14.5* (CHCH3). 28.0 and 28.5* (CHCHz), 31.0 (NCH3), 51.0 
and 51.5* (CHCH*), 55.8 (CHCH3), 75.0 and 75.5* (CHOH), 109.5 and 110.0* 
(quaternary AK), 126.3, 126.5, 126.6, 126.7, 126.9, 127.6, (3 x Ar and 3 x Ar*), 141.0 
and 141.5*, 159.0 and 159.5* , 166.0 and 166.5* (3 x quaternary Arc), 175.0* and 176.0 
(C=O); núz (CI) 332 (m, loo%), 166 (65), 112 (18), and 58 (20). 
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General method for the hydrolysis of alkylated pseudoephedrine glycinamide~’~ 
The alkylated pseudoephednne glycinamide was dissolved in the minimum volume of 
dioxane and water was added. The solution was then heated at reflux for 12h, cooled to 
20°C and diluted with water. This solution was extracted with DCM (2 x 25 mi). The 
combined organic extracts were extracted with water. The aqueous layers were combined 
and concentrated in vacuo to afford a white solid. The solid was triturated in ethanol to 
remove residual pseudoephedrine, filtered and dried in vacuo to give the free amino acid. 
The combined organic extracts were dried over potassium carbonate, filtered, and 
concentrated to afford pseudoephedrine. 
Phenylalanine, 2.51’’ 
w 2.43 2.51 
Prepared following the general method, using 2.43 (2g, 6.4 mmol) in dioxane (5ml) and 
water (25 mi). Work-up afforded the title compound (0.81g, 76%) and pseudoephedrine, 
(1.0g,70%);6H(D20)2.95and3.15(2H,2xdd,J8.0, 14.5and5.1,CH2),3.83(1H,dd, 
J 8.0 and 5.2, CHCHz), 7.16-7.26 (5H, m, Ar); 6~ @ 2 0 )  37.15 (CHz), 56.83 (CH), 
128.49, 129.90, and 130.16 (3 x A r m ) ,  135.90 ( A r a ,  174.74 (C=O). 
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2-Amino-3-(l-naphthyI)propanoic acid, 2.74 
Prepared following the general method, using 2.67 (0.36g, 4.1 mmol) in dioxane (2ml) 
and water (10 mi). Work-up afforded pseudoephedrine (O.llg, 50%) and the title 
compound (0.16g, 76%). M.p. 185-186°C (lit.'" m.p. 179OC); Found: MH+ (ES') 
216.1022. Cl3Hl3NO2 requires: MH 216.1024; vmx/cm-l (KBr) 3100, 2600, 2300, 1675, 
1600, 1500, 1400, 1350, 1150, 800, 750; &(DzO) 3.17 and 3.78 (2H, 2 x dd, 55.3, 8.50 
and 14.5, CHz), 3.95 (lH, dd, 5 5.3 and 8.5, CH), 7.33-7.89 (7H, m, Ar); d z  (CI) 216 
(e, 20%), 170 (100) and 145 (40). 
2-Amino-4-(l-naphthyI)butanoic acid, 2.75 
H20/dioxane 
OH CH, 
2.68 
Prepared following the general method, using 2.68 (0.75g. 4.2 mmol) in dioxane (5ml) 
and water (20 mi). Work-up afforded the rifle compound (0.34g, 74%) as a hygroscopic 
solid and pseudoephedrine (0.19g. 58%), Found: e (ES') 230.1181. C~HisN0z 
requires: MH 230.1181; v,/cm-' (KBr) 3150, 2600, 2350, 1670, 1620, 1500, 1410, 
1350, 1150, 850; &I (DzO) 2.15 (2H, m, CHCH?), 3.2 (2H, m, CHz), 3.8 (IH, t, J 7.2, 
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CHCH2), 7.30-7.80 (7H, m, ArH); d z  229 @I) (M+, 12%), 167 (50), 141 (100) and 115 
(50). 
2-Amino-3-(2-pyridyl)propanoic acid, 2.76 
Prepared following the general method, using 2.69 (1.15g, 3.67 mmol) in dioxane (5ml) 
and water (20 mi). Work-up afforded the title compound (0.36g, 59%). M.p. 206-209°C 
(lit.Io6 210-21 1T). Found MH+ (ES+) 167.0820. C ~ H I O N ~ O ~  requires: MH 167.0820; 
v,,/cm.' (KBr) 3400,2950,2850,2500, 1600, 1450, 1050; 8" (D20) 3.30 and 3.45 (2H, 
2xdd overlapped, J5.0,7.6, and 14.0, CHCH2). 4.2 (IH, dd, J5.0 and 7.6, CWCHz), 7.40 
(2H, m, pyridyl H3 and H5), 7.85 (lH, m, pyridyl H4), 8.60 (lH, m, pyridyl H6). d z  
(CI) 167 (MH+, 3%), 148 (5), 121 @O), 93 (100) and 78 (15). 
2-Amino-3-(3-pyridyl)propanoic acid, 2.77 
._ 
I 
0" CH3 h 
2.70 w 
Prepared following the general method using 2.70 (l.Og, 3.66mmol) in dioxane (5ml) 
and water (20 mi). Work-up afforded the title compound (0.26g, 49%). M.p. 253-254°C 
(lit.'" 253-256OC). Found: MH+ (ES') 167.0820. C8H10N202 requires: MH 167.0820; 
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v,,,/cm-' (KBr) 3400,2900,2800,2500, 1600, 1400, 1050; 8" (DzO) 3.15 and 3.25 (2H, 
2 x dd overlapped, J 14.8, 5.6 and 7.5, CHCHz), 4.05 (lH, dd, J 5.6 and 7.5, CHCHz), 
7.38 (lH, m, pyndyl H5), 7.73 (lH, m, pyridyl H4), 8.38-8.40 (2H, m, pyridyl H2 and 
H6). d z  (CI) 167 ( M P ,  30%), 121 (loo), 93 (40) and 52 (38). 
%Amino-3-(4-pyridyl)propanoic acid, 2.78 
Prepared following the general method, using 2.71 (l.Og, 3.66mmol) in dioxane (5ml) 
and water (20 mi). Work-up afforded the title compound (0.21g, 40%). M.p. 239-241°C 
(lit.'06 246-248OC). Found: MH+ (ES') 167.0821. CsHlfl2Oz requires: MH 167.0820 
vmax/cm-' (KBr) 3350, 2900, 2750, 2500, 2200, 1600, 1400, 1300, 1050; S, (D20) 3.06 
and3.12(2H,2xdd,J5.9,7.5and14.5,CHCH2),4.05(1H,dd,J5.9and7.5,CHCHz), 
7.24-7.40 (4H, m, pyridyl H); 6~ @20) 38.3 (CHz), 57.6 (CHCHz), 128.4 and 130.4 (2 x 
ArCH), 137.3 (quaternary C), 174.0 (C=O); d z  @I) 166 (M', loo%), 150 (5 ) ,  121 (12), 
88 (5) and 52 (28). 
2-Amino-3-(2-phenylphenyl)propanoic acid, 2.79 
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Prepared following the general method, using 2.72 (1.54g, 3.95 mmol) in dioxane (5ml) 
and water (20 mi). Work-up afforded pseudoephedrine (0.69, 78%) and the title 
compound (0.46g, 48%). M.p. 190-191°C. Found MH+ (ES') 242.1189. Ci5Hi~N02 
requires: MH 242.1181; vmx/cm-' (KBr) 3400, 3000, 1600, 1500, 1450, 1400, 1350, 
1150, 800, 750, 700; S"(D20) 2.9 (lH, dd, J7.2 and 10.8, CHz), 3.62 (IH, dd, J3.9 and 
11.1, CHz),  3.69 (lH, dd, J 3.9 and 7.2, CHCHz), 7.3-7.6 (9H, m, Ar); & @zO) 36.0 
(CHz), 56.4 (CHCHz), 128.0, 128.3, 129.6, 129.7, 130.3, 130.8 and 131.7 (ArCH), 134.7, 
142.5 and 144.1 (ArC), 173.83 (C=O); d z  (CI) 242 (W, 28%) and 196 (100). 
2-Amino-3-(3,5-dimethylisoxazol-4-yl)propanoic acid, 2.80 
H20/dioxane 
2.80 Ho>N 
Prepared following the general method , using 2.73 (2.938, 8.84 mmol) in dioxane (5 
mi) and water (20 mi)). Work-up afforded pseudoephedrine (1.21, 62%) and the title 
compound (0.96g, 59%). M.p. 216-217°C. Found MH' (ES') 185.0927. C8HizN203 
requires: MH 185.0926; v,/cm-' (KBr) 3400, 2950, 2600, 2050, 1650, 1500, 1450, 
1400, 1200; S, (D20) 2.09 and 2.20 (2 x 3H, 2 x s, isoxazole CH3), 2.69-2.88 (2H, 2 x 
ddoverlapped, J7.0 and 15.4, CHz), 3.63 (lH, t, J7.0, CH); 6c(D20) 10.06 (CH3), 11.08 
( C H 3 )  24.48 (CHz), 55.05 (CH), 109.26, 161.86, and 169.16 (3 x A r o ,  174.22 (C=O); 
d z  (CI) 185 (MH', 20%), 141 (50) and 124 (100). 
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General method for conversion of an amino acid into its (S)-2-methoxy-2-phenyl- 
3,3,3-trifluoropropanamide Nosher amide) derivative 
HO%"' 
R 
0 CF3 
k O M e  
i) ¡i) EtOHIHCI (ß)-MTPA-CI * E t 0 5 "  Ph 
'U 
Acetyl chloride (10 mol equiv.) was added dropwise at 0°C to a stirred solution of the 
amino acid (-50 mg) in ethanol (-40 mi). The mixture was then stirred overnight at 25"C, 
heated at reflux for 4 h, cooled and the solvent evaporated under reduced pressure to give 
the ethyl ester hydrochloride salt which was further dried under vacuum overnight. (R)-2- 
Methoxy-2-phenyl-3,3,3-tnfluoropropanoyl chloride (MTPA-C1) (100 mg) was added 
dropwise at room temperature to the ester hydrochloride stirred in chloroform (4 cm3) and 
pyridine (4 cm3). The mixture was stirred overnight, water (20 cm3) was added and the 
mixture extracted with diethyl ether (3 x 20 cm3). The combined ethyl acetate layers were 
washed with saturated sodium hydrogen carbonate solution (3 x 10 an3), dned (h4gSO4) 
and evaporated under reduced pressure to afford the product amide that was directly 
analysed by I9F NMR spectroscopy for the determination of enantiomeric punty. 
(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-3- 
phenylpropanoate, 2.59 
0 CF3 
i) EtOWHCI E to%Nh:Me 
i¡) (U)-MTPA-CI 
2.59 0 
Prepared as above using 2.51 (-50 mg). õ~ -69.087 (major diastereoisomer, 93.5%), - 
69.141 (minor diastereoisomer, 6.5%); ex.  87%. 
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(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-3-(1- 
naphthyl)propanoate, 2.81 
CF3 
i) EtOWHCI 
i¡) (R)-MTPA-CI 
Prepared as above using 2.74 (-50 mg). 8~ -68.009 (major diastereoisomer, 93.5%), - 
68.085 (minor diastereoisomer, 6.5%); e.e. 87%. 
(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-4-(1- 
naphthyl)butanoate, 2.82 
Prepared following the general method using 2.75 (-50 mg). õp 48.076 (minor 
diastereoisomer, 19.5%), -67.959 (major diastereoisomer, 80.5%); c e .  61%. 
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(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl~no)-3-(2- 
pyridyl)propanoate, 2.83 
H+3 2.76 /
i) EtOWHCI 
¡i) (R)-MTPA-CI 
2.83 
Prepared following the general method using 2.76 (-50 mg). õ~ -69.146 (major 
diastereoisomer, 55%), -69.518 (minor diastereoisomer, 45%); e.e. 10%. 
(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-3-(3- 
pyridyl)propanoate, 2.84 
H73 2.77 ' i) EtOWHCi ¡i) (R)-MTPA-Ci 2.84 
Prepared following the general method using 2.77 (-50 mg). ¿i~ 48.851 (minor 
diastereoisomer, 13%), -69.166 (major diastereoisomer, 87%); e.e. 74%. 
(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-3-(4- 
pyridyl)propanoate, 2.85 
H %  2.78 H N  
0 CF3 
i) EtOWHCI * E t o q N h : M e  
¡i) (ß)-MTPA-Ci 
2.85 t2 
Prepared following the general method using 2.78 (-50 mg). ¿i~ 48.947 (minor 
diastereoisomer, 16%), -69.146 (major diastereoisomer, 84%); e.e. 68%. 
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(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyla~no)-3-(2 
-phenylphenyl)propanoate, 2.86 
i) EtOWHCI 
¡i) (R)-MTPA-CI 
Prepared following the general method, using 2.79 (-50 mg). 6~ 48.011 (major 
diastereoisomer, 87%), -68.125 (minor diastereoisomer, 13%); e.e. 74%. 
(2'S)-Ethyl2-(3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl~no)-3-(3,5- 
dimethylisoxazol-4-yI)propanoate, 2.87 
H>N 2.80 
O CF3 
i) EtOWHCI E,o%Nh:M' 
il) (R)-MTPA-CI / 
2.87 
Prepared following t.: general method, using 2.80 (-50 mg). 6~ -68.869 (major 
diastereoisomer, 87%), -69.003 (minor diastereoisomer, 13%); e.e. 74%. 
Nó-Boc-Adenine. 2.88 
adenine 2.88 
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Adenine (5g, 37.0 mmol) and triethylamine (4.12g, 41 mmol) were vigorously stirred in 
DCM (100ml). After 30 min, di-ter?-butyldicarbonate (9.8g, 41 mmol) in 
dichloromethane (20 mi) was added dropwise to the reaction mixture. The mixture was 
then heated at reflux overnight. The reaction was cooled to room temperature and 
concentrated in vucuo to give a white solid which was purified by column 
chromatography (DCM:MeOH, 73:7, v/v) to yield the title compound (6.528, 75%) as 
white solid. M.p.>25O0C; & 1.6 (9H, s, CMe3), 8.2 (lH, s, 2-H), 8.4 (lH, s, 8-H); h 2 7 . 9  
(CMe3), 86.7 (CMe3). 120.0 (CH), 139.4 (CH), 149.8, 155.0 and 155.7 (3 x adenine 
quaternary C), 165.0 (C=O). 
N9-(2-Bromoethyl)adenine, 2.89 
NHBoc "2 I 
* 
DIAD, Ph,P, bromoethanol 
2.88 2.89 (, 
Br 
DIAD(5.16g, 25.5mmol) in dioxane (20ml) was added dropwise to a suspension of N6- 
Boc-adenine (5.0g, 21.3mmol), 2-bromoethanol (3.19g, 25.5mmol) and 
triphenylphosphine (6.69g, 25.5mmol) in dioxane (100ml) at 0°C. The mixture was 
stirred overnight to give a cloudy yellow solution. The solvent was removed and the 
yellow residue purified by column chromatography (DCM:MeOH, 10:0.5, v/v) to yield 
the title compound (2.51g, 21%) as a white crystalline solid. M.p.192-193°C (lit.'07 195- 
197T); 6" (CD30D) 3.8 and 4.6 (each 2H, t, J 5.9, CHzCHz), 8.05 and 8.1 (each lH, s, 
adenine H); 6~ 30.9 and 46.6 (CHzCHz), 120 and 143 (CH), 143.0, 150.6 and 153.7 
(quaternary C); d z  243 (EI) (M+ "Br, lo%), 109 (40). 
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Attempted synthesis of (IR, 2R, 2S')-2'-Amino-4'-(N9- 
adeninyl)butanoylpseudoephedrine, 2.90 
.. 
I 
Br 
I\- OH CH3 
LDA, LICI 
2.89 
2.90 // 
This was attempted following the general method using (lR,2R)-pseudoephednne 
glycinamide (0.58 g, 2.61 mmol), lithium chloride (0.67 g, 15.8 mmol), LDA (2.58 ml, 
5.16 mmol) and N9-(2-bromoethyl)adenine (0.7 g, 2.89 mmoi). Work-up of the reaction 
mixture in the usual manner afforded N9-ethenyiadeni11e'~' as a white solid (0.36 g, 
77%). M.p. 200-201°C (lit.'07 201-203OC); 8" (CD30D) 5.2 (lH, dd, J 7.6 and 1.5, 
CH=CHz), 6.0 (lH, dd, J 16.0 and 1.5, CH=CH*), 7.25 (2 (lH, dd, J 16.0 and 7.6, 
CH=CHz), 8.2 (lH, s, adenine CH), 8.4 (lH, s, adenine CH). 
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NHCOCHMe2 
I 
adenine 2.91 
Adenine (10 g, 74 mmol) was stirred with 2-methylpropanoic anhydride (36.8 cm3, 35.1 g, 
222 mmol) in DMF at 160°C for 6 h. After evaporation of the solvent, the residue was 
taken up in EtOH-H20 (200 cm3, 1:l v/v) and the mixture heated under reflux for 1 h. The 
solvents were evaporated under reduced pressure and the residue subjected to column 
chromatography (DCM:MeOH, 9:1 v/v) to afford the title compound 3.40 as a white solid 
(10.8 g, 71%), m.p. 223-224°C; 15" (300MHz; DMSO-&) 1.20 (6H, d, J 6.8 Hz, CHMeZ), 
2.97 (lH, septet, J 6.8 Hz, CHMeZ), 8.48 and 8.69 (each lH, s ,  2-CH and 8-CH), 11.2 and 
12.3 (NHCO and NH) ; & (75 M H z ;  DMSO-&) 19.2 (CH3). 34.2 (CHMeZ), 113.85 and 
144.5 (ArC), 145.7 and 151.2 (C-2 and C-8), 161.3 (ArC) and 177.2 (CO). 
2.91 2.92 i 
CI 
DIAD (2.538, 12.5mmol) in dioxane (10ml) was added dropwise to a suspension of N6- 
(2-methylpropanoyl)aminopurine (2.14g, 10.4mmol). 2-chloroethanol (l.Og, 12.4mmol) 
and triphenylphosphine (3.298, 12.5mmol) in 50ml of dry dioxane at 0°C under nitrogen. 
The mixture was stirred at room temperature overnight to yield a clear pale yellow 
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solution. The solvent was removed and the residue purified by recrystallisation from 
ethanol to give the title compound as white solid (1.98g, 71%). M.p. (decomp.) 160- 
162°C; Found: M+ (EI) 267.0886; CIIHI~CINSO requires: M' 267.0887. vm/cm-' (KBr) 
3246, 2972, 1686, 1602, 1576, 1520, 1338, 1228, 1195, 955; SH 1.26 (6H, d, J 5.1, 
CHMeZ), 3.28 (lH, septet, J 5.1, CHMeZ), 3.91 and 4.57 (each 2H, t, J 4.2, CHzCHz), 
8.13 and 8.66 (each lH, s, 2-CH and 8-CH), 9.19 (lH, s, COW); & 19.25 (CH,), 35.95 
(CHMeZ), 42.27 (CH2C1), 45.87 (NCHz), 122.57 and 143.45 (quaternary C), 149.56 and 
151.47 (C-2 and C-û), 152.56 (quaternary C) and 176.75 (CO); d z  267 (EI) (M', 22%), 
197 (30) and 135 (100). 
Attempted synthesis of ( l R ,  2R, 2S')-2'-Amino-4'-[N6-(2-methylpropanoyl)-N9- 
adeninyl] butanoylpseudoephedrine, 2.93 
HN 
I 
2.92 
CI 
K- ÖH CH3 LDA, LiCI OH AH3 
2.36 
2.93 
This was attempted following the general method using (lR,2R)-pseudoephedrine 
glycinamide (0.58 g, 2.61 mmol), lithium chloride (0.67 g, 15.8 mmol), LDA (2.58 ml, 
5.16 mmol) and N6-(2-methylpropanoyl)-N9-(2-chloroethyl)adenine (0.7 g, 2.89 mmol). 
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Work-up in the usual manner afforded N6-(2-methylpropanoyI)-N9-vinyladenine (0.36 g, 
77%) as part of an inseparable mixture with N6-(2-methylpropanoyI)-N9-(2- 
chloroethy1)adenine. Found MH+ (ES') 232.1201. ClIH13N50 requires: MH 232.1120; 
8" 1.26 (6H, d, J 5.1, CHMeZ), 3.28 (IH, septet, J 5.1, CHMeZ), 5.20 (lH, d, J 8.8, 
CH=CHz), 5.90 (lH, d, J 12.0, CH=CH2), 7.19 and 7.25 (lH, 2 x d, J 8.8 and 12.0, 
CH=CH2), 8.24 and 8.71 (each lH, s, 2-CH and 8-CH), 9.26 (lH, s, CO"); & 19.25 
(CH3), 35.95 (CHMeZ), 105.24(CH=CHz), 122.19 (quaternary C), 126.27 (CH=CHz), 
140.23 (quaternary C), 149.62 and 150.82 (C-2 and C-8), 153.06 (quaternary C), 176.75 
(C=O). m/z @I) 231 (M', SO%), 161 (70) and 134 (100). 
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Experimental 2 Radical approach 
(2S,4R)-3-Benzyloxycarbonyl-2-tert- butyl-4-(methylsulfonylmethyl)oxazolidin-5-0ne, 
3.21, and the (2R,4R)-isomer, 3.22 
* $ " e  72 i) NaOH, i-CI, Bu3CH0, ¡i) Oxone 
+ Z N y O  
,,Y0 BU' hexane, DCM BU' 
3.21 3.22 
H2N xSMe COON 
(R)-S-Methylcysteine (27 g, 0.2 mol) was treated with aqueous sodium hydroxide (8.0 g, 
0.2 mol, in 130 cm3 water), and after 5 min the solution was evaporated to dryness under 
reduced pressure to leave a white solid. A solution of pivaldehyde (21.7 cm3, 17.2 g, 0.2 
mol) in hexane (300 cm3) was added and the suspension stirred and heated under reflux 
with Dean-Stark water removal for 24 h. The reaction mixture was then evaporated to 
dryness under reduced pressure and the white solid suspended in dry dichloromethane (250 
cm3). Benzyl chloroformate (42.8 cm3, 51.1 g, 0.3 mol) was added dropwise to the stirred 
suspension at O°C over 3 h. After stimng the mixture at room temperature for a further 36 
h, aqueous sodium hyärogen carbonate (10% wlv, 100 cm3) was added and rapid stimng 
was continued for 4 h. The layers were then separated and the dichloromethane solution 
was dried (MgSOb), filtered and evaporated. The residue was dissolved in acetonitrile (200 
cm3) and oxone8 (95 g, 0.15 mol) in water (500 cm3) was added. After 24 h at room 
temperature, water (200 cm3) was added, the mixture extracted with dichloromethane (3 x 
200 cm'), and the combined extracts dried (MgSOd), filtered and evaporated. Careful 
purification by column chromatogaphy(hexane:ethyl acetate, 9:1 to 3: 1 vív) gave the title 
compounds (42 g, 57% overall yield); syn-diastereoisomer 3.21 as an oil that gave white 
crystals from hexane, m.p. 151-152'C (38.19 g, 52%), and the anti-diastereoisomer 3.22 as 
a clear oil (3.80 g, 5%). (2S,4R)-3-Benzyloxycarbonyl-2-tert-butyl-4- 
(methylsulfonylmethyl)oxazolidin-5-one 3.21 (syn diastereoisomer): [ a ] ~ ~ *  +27.0 (c, 2.00 
in EtOH); Found MH+ 370.1323. C L ~ H ~ ~ N O ~ S  requires: MH 370.1324; v,(film/cm-') 
3056, 2980, 2877, 1796, 1729, 1635, 1397, 1316, 1266, 1131 and 1041; 6~ 0.95 (9H, s, 
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CMe3), 3.11 (3H, s, SOzMe), 3.41 (lH, dd, J3.8, 15.2, CHHSO2Me), 3.59 (lH, dd, J 8.0, 
15.2, CHHSOZMe), 4.99 (lH, dd, J 3.8, 8.0, CHCH2), 5.18-5.27 (2H, 2 x d, J 11.9, 
CHzPh), 5.62 (IH, s, CHCMe3) and 7.33-7.43 (5H, m, ArH); SC 24.6 (CMe3), 37.2 (CMe3), 
42.5 (SOzMe), 53.5 (CHCHz), 57.2 (CHzSOzMe), 68.9 (CHzPh), 96.8 (CHO), 128.7, 128.8 
and 128.8 (ArCH), 134.8 (ArC), 155.3 and 170.65 (CO). (2R,4R)-3-Benzyloxycarbonyl-2- 
ter~-butyl-4-(methylsulfonylmethyl)oxazoli~n-5-one 3.22 (anti-diastereoisomer): [ a ] ~ ~ ~  
+72.8 (c, 0.32 in EtOH); Found: MHf 370.1319. C I ~ H ~ ~ N O ~ S  requires: MH 370.1324; 
v,,(film/cm-') 3056,2973,2877, 1797, 1713, 1639, 1413, 1354, 1317, 1266, 1127, 1035, 
1015 and 975; 6, 0.94 (9H, s, CMe3), 2.91 (3H, s, SOzMe), 3.57 (2H, d, J 14.1, 
CHzSOzMe), 4.45 (lH, br s, CHCHz), 5.12-5.29 (2H, 2 x d, J 11.9, CH2Ph), 5.68 (IH, s, 
CHCMe3) and 7.23-7.47 (5H, m, ArH); SC 24.7 (CMe3), 39.3 (CMe3), 43.7 (S02CH3), 53.6 
(CHCHz), 61.2 (CHzS02Me), 68.3 (CHzPh), 96.0 (CHO), 128.7, 128.7 and 129.0 (ArCH), 
134.9 (ArC), 152.9 and 170.4 (CO). 
(2S)-3-Benzyloxyearbonyl-2-fert-butyl-4-methyleneox~olidin-S-one 3.23 
3.21 3.23 
(2S,4R)-3-Benzyloxycarbonyl-2-re~-butyl-4-(methylsulfonylmethyl)ox~olidin-5-one 
3.21 (2.85 g, 7.72 mmol) in dry dichloromethane (40 cm3) was treated dropwise with DBU 
(1.39 cm3, 1.41 g, 9.27 mmol) and stirred at 0°C for 1 h before addition of water (40 cm3). 
The layers were separated and the dichloromethane solution was washed with water, dried 
(MgSOb), filtered and evaporated under reduced pressure. The crude product was filtered 
through a short column of silica gel to give a colorless oil that crystallized from hexane to 
yield the title compound 3.23 (2.13 g, 95%) as a colorless crystalline solid, m.p. 69-71'C, 
[a]1>~'-65.4 (c, 0.4 in EtOH); Found MH+ 290.1394. Cl,jH1gN04 requires: MH 290.1392; 
v,,(KBr/cm-') 3093,3068,3052, 1790, 1724, 1680, 1391, 1369, 1329, 1272, 1257, 1162, 
1133, 1095, 1036 and 1012; & 0.93 (9H, s, CMej), 5.27 (2H, s, CHzPh), 5.63 (2H, s, 
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C=CHz), 5.71 (lH, s, CHCMed, 7.26-7.39 (5H, m, ArH); & 24.3 (CMej), 38.6 (CMe3), 
68.7 (CHzPh), 93.9 (CHCMe3), 104.2 (C=CHz), 128.65, 128.7 and 128.81 (AKH), 130.2 
and 134.7 (2 x quaternary C), 152.3 and 164.5 (C=O). 
N3-Benzoylthymine 3.24 and N3-benzoyluracil 3.29 were prepared by the method of 
Reese er N6-(2-Methylpanoyl)adenine 2.9117 and N2-acetyl-06-[2-(4- 
nitrophenyl)ethyl]guanine 3.44'" were prepared according to the methods of Shevlin er 
al. 
N3-Benzoylthymine 3.24" 
3.24 
Benzoyl chloride (2.55 cm', 3.09 g, 22 mmol) was added dropwise at room temperature to 
a stirred suspension of powdered thymine (1.26 g, 10 mmol) in acetonitrile (10 cm3) and 
pyridine (4 cm3). The mixture was then stirred at room temperature overnight before the 
solvents were removed under reduced pressure. The residue was treated with potassium 
carbonate in dioxane-water (0.25M, 20 cm3, 1:l vlv) for 2 h. The solution was then 
filtered, washed with acetonitrile (10 cm') and dried under vacuum for 24 h to afford the 
title compound 3.24 as a white solid (1.54 g, 67%), m.p. 168-17O'C (lit.93 150-152'C); 
Found: M+ 231.0769. C12HloN203 requires: M 231.0766; v,(KBr/cm-') 3119, 1754, 
1746, 1694, 1650, 1434, 1364 and 1193; 6" (300MHz; DMSO-&) 1.81 (3H, s, CH3), 7.52 
(3H, m, ArH), 7.76 (1H, m, ArH), 7.93 (2H, m, ArH) and 11.36 (lH, d, J5 .3  Hz, NH); & 
(75 m; DMSO-&) 11.7 (CH3), 107.9 (C-5), 129.3, 129.5, 130.2 and 135.3 (C-6 and 
ArCH), 138.8 (Ar€), 163.6, 167.3 and 170.1 (CO); d z  231 (I@, 25%), 146 (53). 105 
(loo), 77 (70) and 51 (34). 
139 
General procedure for the Mitsunobu reaction in the preparation of N-(m 
bromoalkyl) nucleobase derivatives (method A) 
To a suspension of a suitably protected nucleobase (1 mol equiv.), triphenylphosphine (1.2 
mol equiv.) and the o-bromoalcohol (1.2 mol equiv.) in dry dioxane at 0°C was added 
DIAD (1.2 mol equiv.) dropwise over 3 h. The mixture was then stirred under argon at 
room temperature overnight to yield a clear solution. The solvent was removed and the 
residue purified by column chromatography to give the N-(o-bromoalkyl) nucleobase 
derivative. 
General procedure for conversion of the N-(mbromoalkyl) nucleobase derivatives 
into N-(o-iodoalkyl) derivatives (method B) 
The N-(o-bromoalkyl) nucleobase derivative (1 mol equiv.) and dry sodium iodide (5 mol 
equiv.) were heated in dry acetone (100 cm3) at reflux under argon overnight in the dark 
(aluminium foil). After cooling, the acetone was removed under reduced pressure and the 
residue taken up in ethyl acetate (100 cm3) and water (100 cm3). The organic layer was 
separated and washed with aqueous sodium thiosulfate solution (2% wlv, 2 x 50 cm3). The 
solution was dried (MgS04) and the solvent removed under reduced pressure to yield the 
N-(o-iodoalkyl) derivative. 
N3-Benzoyl-N1-(2-bromoethyl)thymine, 3.25 
HO)\)ür, DIAD, PhJP 
w Ph 
Ph 
H Dioxane 
3.24 3.25 
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Prepared following method A, using N3-benzoylthymine 3.24 (4.0 g, 17.4 mmol), 
triphenylphosphine (5.47 g, 20.9 mmol), 2-bromoethanol (1.48 cm3, 2.61 g. 20.9 mmol), 
dioxane (150 cm3) and DIAD (4.11 cm3, 4.22 g, 20.9 mmol). Purification by column 
chromatography (hexawethy1 acetate 6:4 v/v) gave the title compound 3.25 as a white 
amorphous solid (5.22 g, 89%). m.p. 183-184°C; Found: MN&+ (79Br; CI) 354.0453. 
C14H129BrNz03 requires: M N h  354.0455; v,,(KBr/cm-') 2926,2854,2723,1752,1700, 
1659, 1441, 1378 and 1360; & 1.95 (3H, d, J 1.1, CH3), 3.64 and 4.09 (each 2H, t, J 5.9, 
CHzCHz), 7.18 (lH, q. J 1.1, CH=CCH3), 7.50 (ZH, m, ArH), 7.65 (lH, m, ArH) and 7.92 
(ZH, m, ArH); 6c 12.35 (CH3), 29.3 and 50.7 (CHJ, 110.3 (C-5). 129.2, 130.4, 131.4 and 
135.2 ( M H  and C-6), 140.9 (ArC), 149.6, 163.1 and 168.8 (CO); m/z (EI) 339.1 (MH; 
"Br, loo%), 337.1 (MH, 7%r, 96), 310.1 (93), 308.1 (loo), 268.1 (28), 266 (31). 
N3-Benzoyl-N1-(2-iodoethyl)thymine 3.26 
w 
Na1 
Acetone 
Ph 
I 
I 
3.25 3.26 
Prepared following method B, using N3-benzoyl-N1-(2-bromoethyl)thymine 3.25 (4.0 g, 
11.4 mmol) and sodium iodide (8.56 g, 57.1 mmol) to yield the title compound 3.26 as a 
yellow powder (4.32 g, 95%), m.p. 138-139°C. Found MH+ 385.0049. c14H13mzo3 
requires: MH 385.0053; v,,(KBr/cm-') 3119, 1754, 1746, 1694, 1650, 1434, 1364 and 
1193; S, 1.95 (3H, s, CH3). 3.4 and 4.07 (each 2H, t, J 6.2, CHzCHz), 7.14 (lH, s, 
CH=CCH3), 7.52 (ZH, m, AH), 7.66 (lH, m, ArH) and 7.93 (ZH, m, ArH); S, 12.35 
(CH3), 41.85 and 50.85 (CHz), 110.4 (C-5), 129.2, 130.4, 131.4 and 135.1 (ArCH and C- 
6), 141.1 (ArC), 149.7, 163.1 and 168.7 (CO); m/z 385 (m, 62%), 356 (loo), 314 (18), 
229 (20) and 202 (60). 
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N3-Benzoyl-N1-(3-bromopropyl)thymine, 3.27 
C 
Il 
Ph 
HO-Br, DIAD, Ph3P 
I w Ph 
O 4  H 
I Dioxane 
3.24 ( 3.27 
Br 
Prepared following method A, using N3-benzoylthpine 3.24 (3.0 g, 13.0 mmol), 
triphenylphosphine (4.11 g, 15.7 mmol), 3-bromo-1-propanol (1.42 cm3, 2.18 g, 15.7 
mmol) in dry dioxane (150 cm3) and DIAD (3.08 cm3, 3.17 g, 15.7 mmol). Purification by 
column chromatography (hexane:ethyl acetate 1:l v/v) gave the title compound 3.27 as a 
white solid (4.20 g, 92%), m.p. 89-90°C. Found: MH' (CI) 351.0343. C,sH,sBrN203 
requires MH 351.0344; v,,,(KBr/cm-') 3079, 2966, 1753, 1698, 1664, 1648, 1597, 1463, 
1348, 1257 and 1179; S, 1.97 (3H, d, J 0.9, CH3), 2.28 (2H, apparent quintet, J 6.6, 
CH2CH2CH2), 3.91 (2H, t, J 6.2, CHZBr), 4.09 (2H, t, J 6.8, NCHz), 7.18 (IH, q. J 1.0, 
CH=CCH3), 7.50 (2H, m, ArH), 7.65 (lH, m, ArH) and 7.92 (2H, m, ArH); 6~ 12.35 
(CH3), 29.3, 31.0 and 50.7 (CHz), 110.3 (C-5). 129.2, 130.4, 135.2 and 131.4 (ArCH and 
C-6), 140.9 (ArC), 149.6J63.1 and 168.8 (CO). ndz 351 (M', IO%), 322 (IOO), 282 (40), 
243 @O), 229 (10) and 216 (25). 
N3-Benzoyl-N1-(3-iodopropyl)thymine, 3.28 
Na1 
- 
Acetone 
Ph 
I 
3.27 3.28 
Prepared following method B, using N3-benzoyl-N1-(3-bromopropyl)thymine 3.27 (4.0 g, 
11.4 mmol) and sodium iodide (8.56 g, 57.1 mmol) to yield the title compound 3.28 as a 
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yellow powder (4.32 g, 95%), m.p. 91-92°C. Found: MH'399.0213. C15HlJN203 requires 
399.0205; v,, (KEWcm.') 3479, 1746, 1651, 1600, 1439, 1353, 1239 and 1176; 6" 1.97 
(3H, s, CH3), 2.25 (2H, quintet, J 7.9, CH2CHJ), 3.21 (2H, t, J6.4, CHzI), 3.82 (2H, t, J 
6.8, NCHz), 7.17 (lH, S ,  CH=CCH3), 7.45 (2H, t, J7.9, M H ) ,  7.62 (lH, t, J7.9, ArCH), 
7.93 (2H, d, J 6.4, ArCH); 6, 1.62 (CH2I) 12.37 (CH3), 31.82 and 49.48 (Gli2) ,  110.92 
(CH=CCH3), 129.12 and 130.38 and 131.51 (ArCH), 135.02 and 140.21 (C-CH3 and ArC), 
149.78, 163.02 and 168.90 (C=O); d z  M+ 398 (is%), 370 (30), 328 (20), 277 (loo), 243 
(60) and 167 (18). 
N3-Benzoyluracil 3.2993 
3.29 
Prepared using the method described above for N3-benzoylthymine 3.24, using benzoyl 
chloride (6.83 cm3, 8.28 g, 58.9 mmol), uracil (3.0 g, 26.8 mmol) in acetonitrile (50 cm3) 
and pyridine (20 cm3) and then potassium carbonate in dioxane-water (0.25~, 100 cm3, 
1:l v/v). Filtration, washing the solid with acetonitrile (20 cm3) and drying under vacuum 
afforded the title compound 3.29 as a white solid (3.58 g, 62%), m.p. 168-170 "C (lit.93 
148-149'C); Found: MH+ 217.0613. CilHsN203 requires: MH 217.0613; & (300 MHz; 
DMSO-~~)~.~~(~H,~,J~.~H~,CH=CHCO),~.~~(~H,~,J~.~HZ,A~CH),~.~O(~H,~,J 
7.9 Hz, CH=CHCO), 7.30 (1H, t, J7.3, ArH), 7.53 (2H, d, J7.2, ArH), 11.17 (lH, s, NH); 
6c (75 M H Z ;  DMSû-d6) 100.1 (C-5), 129.5, 130.3, 131.4 and 135.4 (C-6 and ArCH) 143.3 
(Arc), 150.1, 163.0 and 170.1 (CO); d z  217 (MH', is%), 139 (60), 130 (loo), 122 (40), 
113 (50) and 52 (48). 
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N3-Benzoyl-N1-(2-bromoethyl)uracil, 3.30 
Ho%Br, DIAD, Ph,P 
D Ph 
Ph 
I 
H Dioxane 
3.29 < 3.30 
Br 
Prepared following method A, using N3-benzoyluracil 3.29 (4.2 g, 19.4 mmol), 
triphenylphosphine (6.12 g, 23.3 mmol) and 2-bromoethanol(l.65 cm3, 2.92 g, 23.3 mmol) 
in dry dioxane (150 cm3) and DIAD (4.59 cm3, 4.72 g, 23.3 mmol). Purification by column 
chromatography (hexane:ethyl acetate 6:4 v/v) gave the title compound 3.30 as a white 
solid (5.15 g, 82%), m.p. 183-184°C. Found: (h4Nh'; 79Br) (ES') 340.0290. 
C13H1~~~BrN203 requires: M"4 340.0297; v-(KBr/cm-') 31 10, 1744, 1699, 1664, 1449, 
1349 and 1258; OH 3.65 and 4.13 (each 2H, t, J 5.9, CHzCHz), 5.74 and 7.31 (each lH, d, J 
7.7, CH=CHCO), 7.48 (2H, m, ArH), 7.65 (lH, m, ArH), 7.93 (2H, m, ArH); S, 29.4 and 
51.1 (CH2), 101.8 (C-6), 129.25, 130.5, 131.3 and 135.3 (AtCH and C-5), 144.9 (Arc), 
149.6, 162.3 and 168.45 (CO); m/z 324 (MHf, 100%). 
N3-Benzoyl-N1-(2-iodoethyl)uracil, 3.31 
Ph K"4 Na1 * Ph JìN5 
A N  
Acetone AN 
I 
3.31 
Br O ?  O ?  
3.30 
Prepared following method B, using N3-benzoyl-N1-(2-bromoethyl)uraci13.30 (5.0 g, 15.5 
mmol) and sodium iodide (11.64 g, 77.6 mmol) to yield the title compound 3.31 as a 
yellow powder (5.52 g, 96%), m.p. 190-191'C. Found: MH' (CI) 370.9892. C13HiiIN203 
requires: MH 370.9892; v,,(KBr/cm-') 3109, 1743, 1700, 1663, 1447, 1344 and 1178; SH 
3.44 and 4.13 (each 2H, t, J 6.2, CHlCHz), 5.84 and 7.23 (each lH, d, J 7.9, CH=CHCO), 
7.49 (2H, m, ArH), 7.66 (lH, m, ArH) and 7.95 (2H, m, ArH); S, 21.9 and 
144 
51.5 (CHz), 101.9 (C-5), 129.25, 130.5, 131.3, 135.2 ( A S H  and C-6). 144.3 (AS),  149.5, 
162.25 and 168.44 (CO); d z  371 (m, 4%), 342 (loo), 277 (30), 215 (40), 188 (60) and 
155 (50). 
N3-Benzoyl-N1-(3-bromopropyl)urac¡l, 3.32 
H-Br, DIAD, PbP 
* Ph Ph 
Dioxane 
3.29 ( 3.32 
Br 
Prepared following method A, using N3-benzoyluracil 3.29 (3.5 g, 16.2 mmol), 
triphenylphosphine (5.10 g, 19.4 mmol) and 3-bromo-1-propanol (1.77 cm3, 2.70 g, 19.4 
mmol) in dry dioxane (150 cm') and DIAD (3.08 cm3, 3.83 g, 19.4 mmol). Purification by 
column chromatography (hexane:ethyl acetate, 1:l v/v) gave the title compound 3.32 as a 
white solid (4.57 g, 84%), m.p. 89-90°C. Found: MH' (CI) 337.0188. C&3BrN203 
requires: MH 337.0188; v,,(KBr/cm-') 1738, 1699, 1654, 1598, 1446, 1389, 1341 and 
1256; 6" 2.28 (2H, apparent quintet, J 6.4, CHzCHzCHz), 3.44 (2H, t, J 6.1, CHZBr), 3.94 
(2H, t, J 6.6, NCHz), 5.80 and 7.35 (each lH, d, J 8.1, CH=CHCO), 7.51 (2H, m, ArH), 
7.65 (lH, m, ArH) and 7.93 (2H, m, ArH); & 29.7, 30.95 and 47.9 (CHz), 102.2 (C-5), 
129.2 and 130.45 (ASH), 131.4 ( A S ) ,  135.2 and 144.5 ( A S H  and C-6), 149.8, 162.35 
and 168.75 (CO); d z  337 (m, 40%), 276 (30), 259 (40), 172 (loo), 155 (46), 139 (44) 
and 105 (34). 
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N3-Benzoyl-N1-(3-iodopropyl)uracil, 3.33 
Br 
3.32 
I 
3.33 
Prepared following method B, using N3-benzoyl-Nl-(3-bromopropyl)uracil 3.32 (4.5 g, 
13.4 mmol) and sodium iodide (10.0 g, 67.0 mmol) to yield the title compound 3.33 as a 
yellow gum (5.0 g, 96%); Found: MH+ 385.0052. C1fi1@izO3 requires: h4H 385.0049; 
v,,(KBr/cm-') 3056, 1751, 1708, 1669, 1440 and 1266; 6" 2.21 (2H, apparent quintet, J 
6.6, CHzCH2CH2) 3.14 (2H, t, J6.6, CHzI), 3.82 (2H, t, J6.8, NCHz), 5.74 and 7.33 (each 
IH, d, J 8.0, CH=CHCO), 7.49 (2H, m, ArH), 7.65 (lH, m, ArH) and 7.91 (2H, m, ArH); 
& 1.53, 31.7 and 49.7 (CHz), 102.0 (C-5), 129.2 and 130.3 (ArCH), 131.3 (Arc), 135.2 
and 144.6 (ArCH and C-6), 149.7, 162.3 and 168.8 (CO); m/z 384 (hf, 8%), 356 (50), 328 
(8), 314 (10). 263 (100) and 257 (65). 
N1-(3-Hydroxypropyl)cytosine, 3.34 
N5 
O A N  H 
NaH, H O w B r  
DMF 
OH 
3.34 
This was prepared using a modified procedure of K e e ~ e ~ ~ .  NaH (0.319 g, 13.3 mmol) was 
added portionwise to cytosine (1.48 g, 13.3 mmol) suspended in DMF (50 mi). After 
stirring at room temperature for 1 h, 3-bromo-1-propanol (1.20 ml, 1.85 g, 13.3 mmol) in 
DMF (5 mi) was added dropwise over 2 h (syringe pump) to the clear solution and the 
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mixture stirred for a further 16 h. Methanol was then added and the solvents were 
evaporated. The solid obtained was dissolved in methanol and silica gel was added. The 
mixture was dned and submitted to flash chromatography (DCM/MeOH/Et3N, 93/5/2, v/v) 
to yield the title compound 3.34 as a white gum (1.46 g, 65%). Found (&) (ES+) 
274.1194. C I ~ H I ~ N ~ O ~  requires (MH) 274.1191; v,,(KBr/cm-') 3420, 3170, 3100, 3040, 
2930, 2850, 1705, 1640, 1500, 1435, 1380, 1260, 1235, 1160, 1070, 101.5, 990; 6~ 
@MSO-d6) 1.76 (2 H, quintet, J 6.5, CHZCH~CHZOH), 3.44 (2 H, t, J 6.1, CH20H), 3.74 
(2 H, t, J 7.0, NCHz), 4.61 (lH, broad s, CHzOH), 5.71 (1 H, d, J 7.2, ArCH), 7.06 (2 H, 
broad s, NHz), 7.59 (1 H, d, J 7.2, ArCH); S, 31.79 (CHzCHzCHz), 46.01 (CH20H), 57.66 
(NCHz), 93.18 (ArCH), 146.23 (ArCH), 156.02 (Arc), 165.96 (C=O). 
Attempted preparation of N1-(3-bromopropyl)cytosine, 3.35 
on 
3.34 
Ph3P, NBC 
DCM 
3.36 
NBS (1.31 g, 7.36 m o l )  was added portionwise to a stirred solution of 1-(3- 
hydroxypropy1)cytosine 3.34 (1.13 g, 6.69 mmoi) and triphenylphosphine (1.93 g, 7.36 
mol) in dichloromethane at -1OOC (ice-salt bath). The mixture was stirred at -10°C for 3 h. 
The solvent was removed and the crude product purified by flash chromatography 
(DCM/MeOH/Et,N, 93/5/2, v/v and 70/30, v/v MeOWAcOH) to yield unreacted starting 
material (0.76 g, 67%) and the cyclised starting material 3.36 as a gum (0.21 g, 19%). 8, 
(DMSO-d,) 2.23 (2 H, quintet, J 5.3, CH$H,CqO), 4.08 (2 H, t, J 5.9, CH,), 4.57 (2 
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H, t, J 5.3, CH,), 6.56 (1 H, d, J 7.1, ArCH), 7.94 (1 H, d, J 7.1, ArCH); S, 48.15 
( C K q C K ) ,  67.99 ( q O ) ,  101.91 ( N q ) ,  146.39 (ArCH), 155.67 (AKH), 165.04 
(ArC), 172.0 (C-O). 
N4-Benzoyl-N1-(3-hydroxypropyi)-cytosine, 3.37 
HN K Ph 
I 
H 
HN K Ph 
I 
3.37 on 
This was prepared using a modified procedure of K e e ~ e ~ ~ .  NaH (0.310 g, 12.9 mmol) was 
added portionwise to N4-benzoylcytosine (2.78 g, 12.9 mmol) suspended in DMF (50 mi). 
After stimng at room temperature for 1 h, 3-bromo-1-propanol (1.17 ml, 1.80 g, 12.9 
mmol) in DMF (5 mi) was added dropwise over 2 h (syringe pump) and the mixture stirred 
for a further 16 h. Methanol was then added and the solvents evaporated. The solid 
obtained was dissolved in methanol and silica gel was added. The mixture was dried and 
submitted to flash chromatography (DCM/MeOH, 95/5) to yield the title compound 3.37 as 
a white solid (2.14 g, 61%), m.p. 156-157°C; Found (m) 274.1194 (ES') C&5N303 
requires (MH) 274.1191; vmx (KBr/cm-') 3531, 3387, 3151, 3067, 2968, 1696, 1651, 
1626, 1604, 1583, 1504, 1320, 1251, 1173, 1090, 796, 700; SH (DMSO-&) 1.84 (2 H, 
quintet, J 6.6, CHZCH~CHZ), 3.45 (2 H, q, J 5.1, CHIOH), 3.92 (2 H, t, J 7.2, NCH2), 4.65 
(1 H, LJ4.9, CHzOH), 7.30 (1 H, d, J7.2, ArCH), 7.52 (1 H, t, J7.7, ArCH), 7.63 (2 H, t, 
J 7.3, ArCH), 8.03 (2 H, d, J 8.3, ArCH), 8.13 (1 H, d, J 7.3, ArCH), 11.18 (1 H, s, 
CO"); Sc 31.16 (CH~CH~CHZ), 47.19 (CHzOH), 57.62 (NCHz), 95.69, 128.32, 128.34 
and 132.55 (Arm) ,  133.21 (Arc), 150.33 (ArCH), 155.11 (C=O), 162.79 (Arc), 167.29 
(C=O); d z  273 (w, 50%), 244 (60). 229 (90). 196 (loo), 178 (30), 138 (70). 
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N4-Benzoylcytosine-Nl-(3-bromopropropyl)cytosine, 3.38 
HN K Ph 
3.37 
PhaP, NBC 
- 
DCM 
HN a Ph 
3.38 
NBS (4.02 g, 22.6 mmol) was added portionwise to a stirred soIution of N4-benzoyl-N1-(3- 
hydroxypropy1)cytosine 3.37 (5.60 g, 20.5 mmol) and triphenylphosphine (5.92 g, 22.6 
mol) in &chloromethane at -10°C (ice-salt bath). The mixture was stirred at -1OOC for 3 h. 
The solvent was removed and the crude product purified by flash chromatography 
(DCMMeOH, 97/3, v/v) to yield the title compound 3.38 as a white amorphous solid 
(4.92g, 72%), m.p. 162-163OC; Found ( M w )  336.0356 (ES') C I ~ H I ~ ~ B ~ N ~ O Z  requires 
(h4H) 336.0347; vmx (KBr/cm-') 3156, 3058, 3005, 1674, 1661, 1626, 1553, 1485, 1361, 
1298, 1265, 809,703; & (DMSO-d6) 2.24 (2 H, quintet, J 6.8, CH~CHZCH~), 3.47 (2 H, t, 
J6.6, CHzBr), 3.95 (2H, t,J7.0,NCHZ),), 7.31 (I H, d,J6.4,  ASH), 7.52 (1 H, t,J7.7, 
AicH), 7.63 (1 H, t, J7.3, ASH), 8.03 (2H, d.Jf3.3, ArCH), 8.13 (1 H, d,J7.2,  ArCH), 
8.66 (lH, d, J7.3, ArCH), 11.20 (1 H, s, CONH); & 31.04 (CH~CHZCHZ), 31.32 (CHzBr), 
48.57 (NCHZ), 95.87 (Arm) ,  128.32, 128.77 and 132.07 (ArCH), 132.56 (ArC), 150.22 
(ArCH), 155.32 (C=O), 162.85 (Aro ,  167.34 (C=O); d z  336 (M+H, loo%), 306 (90). 
258 (90), 229 (90), 178 (60). 138 (90). 
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N4-Benzoyl-N1-(3-iodopropyl)cytosine, 3.39 
Na1 
D 
I 
acetone 
I 
Br 3.38 < 3.39 
This was prepared following method B using N4-benzoyl-N1-(3-bromopropyl)cytosine 
3.38 (3.04 g, 9.07 mmol) and dry sodium iodide (6.80 g, 45.4 mmol) to yield the title 
compound 3.39 as a yellow powder (3.14 g, 90%), m.p. 169-170OC. Found (MHf) 
384.0216 (ES') C1&14IN302 requires (MH) 384.0209 ; v, (KBr/cm-') 3208, 3070, 1693, 
1657, 1625, 1553, 1489, 1348, 1260, 803, 787, 699; 6" (DMSO-& 2.18 (2 H, quintet, J 
7.0, CHzCHzCHz), 3.25 (2 H, t, J 7.0, CHzI), 3.89 (2 H, t, J 7.2, NCH2),), 7.31 (1 H, d, J 
6.5, ArCH), 7.49 (1 H, t, J 7.7, ArCH), 7.61 (1 H, t, J 7.3, ArCH), 8.15 (2 H, d, J 8.0, 
ArCH),8.13(1H,d,J7.2,ArCH),8.65(1H,d,J7.3,ArCH),11.19(1H,~,CONH)~~- 
19.03 (CHzI), 49.74 (CHzCHzCHzI), 69.24 (NCHz), 105.06 (ArCH), 128.32, 128.53, 
132.05 ( A r a ) ,  133.45 ( A r o ,  151.88 ( A r a ) ,  156.24 ( A r o ,  163.23, 167.53 (C=O); d z  
383 (M', 40%), 354 (30). 306 (20), 256 (60), 226 (66), 178 (loo), 122 (90), 151 (50). 
N9-(2-Bromoethyl)-N6-(2-methylpropanoyl)adenine, 3.40 
NHCOCHMe, NHCOCHMe, 
b 
Ph,P, DIAD 
n Dioxane 
2.91 \ 3.40 
Br 
Prepared following method A, using N6-(2-methylpropanoyI)adenine 2.91 (5.0 g, 24.4 
mmol), tnphenylphosphine (7.68 g, 29.3 mmol) and 2-bromoethanol (2.07 cm3, 3.66 g, 
150 
29.3 mmol), dioxane (150 cm3) and DIAD (5.76 cm3, 5.92 g, 29.3 mmol). Purification by 
column chromatography (hexane:ethyl acetate, 4:l vlv) gave the title compound 3.40 as a 
white solid (5.76 g, 76%), m.p. 148-149°C (from ethanol); Found: MH' 312.0462. 
CllH14BrN50 requires: MH 312.0460; vM(KBr/cm-') 3339, 3281, 3117, 2973, 1689, 
1611, 1516, 1489, 1201 and 1152; SH 1.34 (6H, d, J6.93, CHMeZ), 3.28 (IH, septet, J6.9, 
CHMeZ), 3.79 and 4.69 (each 2H, t, J 5.9, CH2CH2), 8.12 and 8.70 (each lH, s, 2-CH and 
8-CH), 9.06 (lH, s, CO"); SC 19.4 (CH3), 29.65 (CHZBr), 36.0 (CHMeZ), 45.8 (NCHz), 
122.3 and 143.0 (ArC), 149.5 and 151.4 (C-2 and C-8). 152.6 (A<) and 176.4 (CO); d z  
313 (M', lOO%), 311 (M+, iOO%), 270 (12) and 268 (20). 
N9-(2-Iodoethyl)-N6-(2-methylpropanoyl)adenine, 3.41 
NHCOCHM+ NHCOCHMQ 
1 
3.41 
acetone 
Er 
3.40 
Prepared following method B, using N9-(2-bromoethyl)-N6-(2-methylpropanoyl)adenine 
3.40 (5.0 g, 16.1 mmol) and sodium iodide (12.0 g, 80.4 mmol) to yield the title compound 
3.41 as a yellow powder (4.96 g, 86%), m.p. 162-163°C; Found: MH+ 360.0315. 
CllH1JN50 requires MH 360.0321; v,,(KBr/cm-l) 3339, 3064, 3040, 2971, 2928, 2871, 
1794, 1611, 1527, 1471, 1348, 1322, 1237, 1191, 1152 and 1111; SH 1.33 (6H, d, J 6.9, 
CHMeZ), 3.24 (lH, septet, J6.9, CHMeZ), 3.63 and 4.64 (each 2H, t, J6.5, CHZCH~), 8.14 
and 8.71 (each lH, s, 2-CH and 8-CH) and 8.93 (lH, s, "CO); & 19.5 (CH3), 20.05 
(CHzI), 36.0 (CHMeZ), 45.8 (NCHz), 122.5 and 143.1 (ArC), 149.6 and 151.3 (C-2 and C- 
8), 152.7 (AK) and 176.4 (CO); d z  359 (M', 20%), 289 (20). 205 (20). 135 (100) and 
108 (15). 
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N9-~3-Bromopropyl)-~66-(2-methylpropanoyl)adenine, 3.42 
YHCOCHMe, YHCOCHMB, 
Ho\/\/Br Ph3P, DIAD 
Dioxane 
2.91 ( 3.42 
Br 
Prepared following method A, using N6-(2-methylpropanoyi)adenine 2.91 (4.5 g, 22.0 
mmol), triphenylphosphine (6.91 g, 26.3 mmol), 3-bromo-1-propanol (2.39 cm3, 3.66 g, 
26.3 mmol), dioxane (170 cm3) and DIAD (5.19 cm3, 5.33 g, 26.3 mmol). Purification by 
column chromatography (hexane:ethyl acetate 4:l v/v) gave the title compound 3.42 as a 
white solid (5.42 g, 76%), m.p. l l O - l l l ~ C  (from toluene). Found: MH' (ES') 326.0621. 
CIzH16BrN50 requires: MH 326.0616; v-(KBr/cm-') 3283, 3137, 3068, 3047, 2970, 
2930, 1689, 1663, 1485, 1406, 1350, 1234 and 1227; SH 1.31 (6H, d, J 6.5, CHMeZ), 2.49 
(IH, septet, J 6.5, CHMeZ), 3.30 (2H, apparent quintet, J 6.8, CHZCHZCHZ), 3.37 (2H, t, J 
6.2, CHzBr), 4.49 (2H, t, J 6.6, NCHz), 8.14 and 8.73 (each lH, s, 2-CH and 8-CH) and 
8.85 (IH, s, "CO); 19.25 (CH3). 29.5 and 31.7 (CH2), 36.0 (CHMez), 42.3 (CH2), 
122.4 (Arc), 143.1 (CH), 149.5 and 151.7 (A&), 152.5 (CH) and 176.6 (CO); m/z 325 
(M+, 20%), 257 (20), 205 (20), 176 (40), 149 (100) and 71 (38). 
N9-(3-Iodopropyl)-N6-(2-methylpropanoyl)adenine, 3.43 
NHCOCHMe, NHCOCHM% 
Na1 +J I\ 
b 
I "i 3.43 acetone Br 3.42 
Prepared following method B, using N9-(3-bromopropyl)-N6-(2-methylpropanoyl)adenine 
3.42 (5.3 g, 16.3 mmol) and sodium iodide (12.2 g, 81.5 mmol) to yield the title compound 
3.43 as a yellow gum (4.93 g, 81%). Found: MH+ (ES') 374.0473. Cdi16IN50 requires: 
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MH 374.0478; v,(film/cm-') 3413, 2981, 1610, 1588, 1459 and 908; SH 1.31 (6H, d, J 
6.7, CHMeZ), 2.43 (lH, septet, J6.7, CHMeZ), 3.12 (2H, t, J6.6, CHiI), 3.24 (2H, apparent 
quintet, J 6.6, CHZCHZCH~), 4.42 (2H, t, J 5.6, NCHz), 8.09 and 8.73 (each lH, s, 2-CH 
and 8-CH), 8.75 (lH, s, NHCO); 6~ 1.65 (CHz), 19.2 (CH3), 32.3 (CHz), 36.1 (CHMeZ), 
44.5 (CHZ), 122.3 (ArC), 142.9 (CH), 149.4 and 151.6 (ArC), 152.57 (CH) and 176.9 
(CO); d z  373 (M+, lo%), 277 @O), 199 (28), 149 (54) and 77 (100). 
F) 
* ANA?? ii)Ho/\/PNP PhaP, DIAD N 
H H 
A 
DMF, dioxane 
H2N "3) N 1 
3.44 
To a suspension of guanine (10 g, 66.2 mmol) in DMF (150 cm') acetic anhydride (18.7 
cm', 20.27 g, 198.5 mmol) was added dropwise at room temperature. The mixture was 
then heated at reflux for 4 h to yield a clear solution. After evaporation of the solvents 
under reduced pressure, the residue was washed with saturated aqueous sodium hydrogen 
carbonate (100 cm3) and cold ethanol (25 cm'), and dried with P205 under vacuum 
overnight. The solid was suspended with 2-(4-nitrophenyl)ethanol (16.6 g, 99.3 mmol ) 
and triphenylphosphine (26.0 g, 99.3 mmol) in dioxane (200 cm') and DIAD (20.1 g, 19.6 
cm', 99.3 mmol) was added dropwise at 0°C under argon over 3 h. The mixture was stirred 
at room temperature overnight to yield a pale yellow solution to which water (100 cm') 
was added and the mixture heated at reflux for 2 h. After cooling, solvents were evaporated 
under reduced pressure and the residue purified by column chromatography (DCMMeOH, 
90:lO vív) to afford the title compound 3.44 (12.0 g, 53%), m.p. >250"C; 6~ (300 MHz;  
DMSO-&) 2.17 (3 H, s ,  CH3), 3.32 and 4.77 (each 2H, t ,  J 6.8 Hz, CHzCHz), 7.66 (2H, d, 
J8.3IIz,ArH),8.04(1H,s,9-NH),8.17(3H,m,8-CHandArH),10.31(1H,s,CONH). 
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N9-(2-Bromoethyl)-N2-acetyl-06-[2-(4-nitrophenyl)ethyl]~~ine, 3.45 
3.44 ( 3.45 
Er 
Prepared following method A, using N2-acetyl-06-[2-(4-nitrophenyl)ethyl]guanine 3.44 
(5.0 g, 14.6 mmol), 2-bromoethanol (1.24 cm3, 2.19 g, 17.5 mmol), triphenylphosphine 
(4.6 g, 17.5 mmol), dioxane (100 cm3) and DIAD (3.54 g, 3.45 cm3, 17.5 mmol). 
Purification by flash chromatography (EtOAc:hexane, 4: 1 v/v) gave the title compound 
3.45 as a white solid (4.39 g, 67%), m.p. 181-182°C. Found: MH' (FAB) 449.0573. 
Ci7H~?9BrN604 requires: MH 449.0579; v,,(KBr/cm-') 3206, 3133, 1665, 1610, 1589, 
1510, 1460, 1415, 1383, 1352, 1327, 1309, 1226 and 1025; S, (DMSO-&) 1.97 (3H, s, 
CH3), 3.28 (2H, t,J6.8, ArCHz), 3.95 and4.55 (each 2H, t ,J6.0,  NCHZCHzBr),4.77 (2H, 
t, J6.8, OCHz), 7.60 and 8.20 (each 2H, d, J 8.2, ArH), 8.29 (lH, s, 8-CH), 10.42 (lH, s, 
"CO); 6c (DMSO&) 24.7 (CH3), 31.0, 34.2, 44.85 and 66.4 (CHz), 116.65 (Arc), 
123.4, 130.3 and 142.8 (ArCH), 146.21, 146.4, 152.0, 152.9 and 159.6 ( A S )  and 169.10 
(CO); d z  449 (MH+, 65%), 343 (20), 300 (75), 258 (35), 178 (50), 151 (100) and 133 
(52). 
N2-acetyl-N9-(2-Iodoethyl)-06-[2-(4-nitrophenyl)ethyl]~anine, 3.46 
A LI O N' 
11 I, 
/ 
Er 
3.45 
I 
1 
3.46 
Prepared using a modification of method B. N2-Acetyl-N9-(2-bromoethyl)-06-[2-(4- 
nitrophenyl)ethyl]guanine 3.45 (0.77 g, 1.72 mmol) and dry sodium iodide (1.29 g, 8.58 
mmol) in dry acetone (50 cm3) was heated at reflux in the dark (aluminium foil) under 
argon overnight. After cooling, the acetone was removed under reduced pressure and the 
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residue taken up in dichloromethane (50 cm3) and water (50 cm3). The organic layer was 
separated and washed with aqueous sodium thiosulfate solution (2% wlv, 2 x 25 cm3), 
dried (MgS04) and the solvents were removed under reduced pressure to yield the title 
compound 3.46 as a yellow gum (0.72 g, 85%). Found: IvlH+ (FAB) 497.0412. 
C17H17m604 requires: MH 497.0408; v,,,(KBr/cm-') 3387, 3093, 1685, 1677, 1656, 1605, 
1515, 1493, 1381, 1344, 1327, 1213, 1048 and 1023; SH (DMSO-&) 2.25 (3H, s, CH3), 
3.32 (2H, t, J6.8, A G I 2 ) ,  3.70 and4.51 (each 2H, t, J6.6,  NCH2CH21), 4.79 (2H, t, J6.8, 
OCH?), 7.56 and 8.18 (each 2H, d, J 8.3, ArH), 8.26 (1 H, s, 8-CH), 10.42 (lH, s, "CO); 
6c (DMSO-ds) 3.65 (CHz), 24.7 (CH3), 34.2, 45.3 and 66.35 (CHz), 116.8 (Arc), 123.3, 
130.3 and 142.6 (ArCH), 146.2, 146.4, 152.9, 152.8 and 159.6 (ArC) and 169.0 (CO); wdz 
497 (MH', 75%), 348 (55), 279 (26), 193 (65), 151 (100) and 107 (73). 
General procedure for conjugate radical addition to oxazolidinone 3.23 (method C) 
Tributyltin hydride (1.2 mol equiv.) was added dropwise via syringe pump over 2 h to the 
appropriate iodoalkyl derivative (1 .O mol equiv.), (2S)-3-benzyloxycarbonyl-2-tert-butyl- 
4-methyleneoxazolidin-5-one 3.23 (1.2 mol equiv.) and AIBN (0.1 mol equiv.) in degassed 
toluene (200 cm3), at 80°C and under a positive atmosphere of argon. Heating and stirring 
were continued until reflux and for a further 12 h. After cooling, the toluene was removed 
under reduced pressure and the residue purified by flash column chromatography 
(EtOAc:hexane, 1:4 to 4:l v/v) to give the conjugate adduct. 
General procedure for conjugate radical addition to oxazolidinone 3.23 (method D) 
The appropriate iodoalkyl derivative (1 .O mol equiv.), (2S)-3-benzyloxycarbonyl-2-re~- 
butyl-4-methyleneoxaolidin-5-one 3.23 (2 moi equiv.), tributyltin chloride (0.3 mol 
equiv.), sodium cyanoborohydnde (2 mol equiv.) and AIBN (0.1 mol equiv) in tea-butanol 
(40 cm3/g of 3.23) were heated at reflux under a positive atmosphere of argon for 40 h. 
After cooling, the solvent was removed under reduced pressure and the residue purified by 
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flash column chromatography (EtOAc:hexane, 1:4 to 4:l v/v) to yield the conjugate 
adduct. 
(2S,4S)-4-[3-(3-Benzoyl-l-thy~nyl)propyl]-3-benzyloxycarbonyl-2-~e~-butyl 
oxazolidin-5-one, 3.47 
3.26 zNyò 3.47 3.48 
Bu' 
Performed following method C, using N3-benzoyl-N1-(2-iodoethyl)thymine 3.26 (0.66 g, 
17.2 mmol), (2S)-3-benzyloxycarbonyl-2-te~-butyl-4-methyleneox~olidin-5-one 3.23 
(497 mg, 17.2 mmol), AIBN (ca. 10 mg) and tributyltin hydride (0.555 cm3, 0.60 g, 20.6 
mmol) to give the conjugate adduct 3.47 as a colourless oil (244 mg, 26%) and 3-benzoyl- 
I-ethylthymine 3.48 as a white solid (106 mg, 24%), m.p. 169-171OC. (2S,4S)-4-[3-(3- 
Benzoyl- l-thyminyl)propyl]-3-benzyloxycarbonyl-2-te~-butyloxazolidin-5-one, 3.47: 
Found (CI) 548.2387. C&33N307 requires: MH 548.2397; v-(film/cm-') 3431, 
2361, 2342, 1790, 1749, 1701, 1657, 1440 and 1266; SH 0.94 (9H, s, CMe3), 1.74-2.04 
(7H, m, 2 x NCHzCHzCHz and CH=CCH3), 3.69 and 3.81 (each lH, m, NCHz), 4.31 (lH, 
t, J6.8, CHCHz), 5.17 (2H, S ,  CHZPh), 5.56 (lH, S, CHBU'), 7.11 (lH, S, CH=CCH3), 7.34- 
7.38 (5H, m, ArH), 7.49 (2H, m, ArH), 7.64 (lH, m, ArH) and 7.91 (2H, m, ArH); & 12.4 
(CH=CCH3), 24.9 (CMe3), 25.8 (NCHZCHZCHZ), 29.9 (CHCHz), 36.9 (CMe3), 47.7 
(NCHz), 56.6 (CHCHz), 68.7 (CHZPh), 96.5 (mu ' ) ,  110.9 (CH=CCH,), 128.6, 128.8, 
128.8, 129.1, 130.4 and 131.7 (AKH), 134.95 and 135.0 (ArC), 139.9 (CH=CCH3), 149.8, 
156.1, 163.1, 169.0 and 172.3 (CO); d z  @I) 547 (M+, loo%), 490 (50), 442 (30), 395 
(60), 315 (70) and 286 (45). N3-Benzoyl-NI-ethylfhymhymine 3.48: Found: (m) (CI) 
259.1083. C ~ ~ H I $ ~ , O ,  requires: MH 259.1082; v,,(KBr/cm-') 3192, 3080, 3069, 2984, 
2960, 2744, 2620, 2464, 2095, 1986, 1693, 1644, 1366, 1346, 1266, 1248 and 1193; SH 
1.30 (3H, t, J 7.2, CHzCHj), 1.95 (3H, S, CH=CCH3), 3.77 (2H, q, J 7.2, CHZCH~), 7.12 
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(1H, s, CH=CCH3), 7.49 (2H, m, ArH), 7.64 (lH, m, ArH) and 7.91 (2H, m, ArH); dz 258 
(M', 15%), 230 (100) and 188 (40). 
(2S,4S)-4-[3-(3-Benzoyl-l-thyminyl)propyl]-3-benzyloxycarbonyl-2-tert- 
butyioxazolidin-5-one, 3.47 and (2S,4S)-3-benzyioxycarbonyl-2-tert-butyi-4-[3-(1- 
thyminyl)propyl]oxiIidin-5-one, 3.49 
I 
- Bu,SnCl,NaBH3CN, AIBN 
'Buon 
+ 
1 
BU' 
3.26 3.41 3.49 
I 
BU' 
Performed following method D, using N3-benzoyl-N1-(2-iodoethyl)thymine 3.26 (1.13 g, 
2.94 mmol), (2S)-3-benzyloxycarbonyl-2-te~-butyl-4-methyleneoxaolidin-5-one 3.23 
(1.70 g, 5.89 mmol), tributyltin chloride (0.239 cm3, 0.287 g, 0.882 mmol), sodium 
cyanoborohydnde (0.370 g, 5.89 mmol) and AIBN (0.29 mmol), but heating at reflux for 
16 h to yield the conjugate adduct 3.47 as a colourless oil (1.29 g, 24%) identical with the 
sample prepared by method C, and the debenzoylated conjugate adduct 3.49 as a white 
solid (0.391 g, 30%), m.p. (decomp.) 7840°C. No reduced products were isolated. (2S,4S)- 
3-Benzyloxycarbonyl-2-te>-r-butyl-4-[3-( 1 thyminyl)propyl]oxaolidin-5-one, 3.49: Found 
MH+ (CI) 444.2132. C23HzgN306 requires: MH 444.2134; v,(KBr/cm-') 3204, 3037, 
2964, 1792, 1708, 1680, 1467, 1397, 1363, 1348, 1229, 1198 and 1125; 6" 0.95 (9H, s, 
CMe3), 1.85-1.99 (7H, m, CH2CHz and CH=CCH3), 3.68 and 3.76 (each lH, m, NCHz), 
4.32 (lH, t, J 6.8 Hz, CHCH2), 5.17 and 5.18 (2H, 2 x d, J 11.9, CHZPh), 5.56 (lH, s, 
CHBu'), 7.00 (lH, s, CH=CCH3), 7.34-7.38 (5H, m, ArH) and 9.57 (lH, s, NH); & 12.3 
(CH=CCH3), 24.9 (CMej), 25.8 (NCHZCH~CHZ), 29.8 (CHCHZ), 36.9 (CMe3), 47.4 
(NCH2), 56.7 (CHCHz), 68.6 (PhCHz), 96.5 (CHBu'), 110.8 (CH=CCH3), 128.6, 128.7 and 
128.8 (ArH), 135.0 (Arc), 140.2 (CH=CCH3), 172.3, 171.2, 164.5 and 156.1 (CO); d z  
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(EI) 443 (M+, 60%), 386 (70). 308 (75), 286 (loo), 264 (35), 250 (35), 208 (80) and 194 
(48). 
When the reaction time was extended to 40 h, using N3-benzoyl-N1-(2-iodoethyl)thymine 
3.26 (6.84 g, 17.8 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-4-methyleneox~o~i~n- 
5-one (10.3 g, 35.6 mmol), tributyltin chloride (1.45 cm3, 1.74 g, 5.34 mmol), sodium 
cyanoborohydride (2.24 g, 35.6 mmol) and AIBN (1.78 mmol), purification by column 
chromatography gave only the adduct 3.49 as a white solid (3.68 g, 47%), data as above. 
Reduced products were not isolated. 
(2S,4S)-3-Benzyloxycarbonyl-4-[4-( l-tbyminyl)butyl]-2-tert-butyloxazolidin-5-one, 
3.50 
"+ Mo O A "9 "Y0 
A N  
+ L o  + 
phAJy BU' 
O A N  Bu3SnCI, NaBHSCN, AIBN 
'BuOH 
3.51 B U' 3.50 
,,Y0 ci 
3.28 
Prepared following method D, using N3-benzoyl-N1-(3-iodopropyl)thymine 3.28 (3.12 g, 
7.84 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-4-me~yleneox~olidin-5-one 3.23 
(4.53 g, 15.7 mmol), tributyltin chloride (0.638 cm3, 0.765 g, 2.35 mmol), sodium 
cyanoborohydride (0.98 g, 15.7 mmol) and AIBN (0.78 mmol) to yield the debenmylafed 
conjugate adduct 3.50 as a thick oil (900 mg, 25%) and N1-propylthymine'08 3.51 as a 
white solid (276 mg, 21%), m.p. 134-135°C. (2S,4S)-3-Benzyloxycarbony1-4-[4-(1- 
thyminyl)butyl]-2-tert-butyloxazolidin-5-one 3.50: Found: MH+ 458.2287. Cdi31N306 
requires: MH 458.2291; v,,(film/cm-') 3489,3201, 3068,2964, 1789, 1710, 1690, 1480, 
1398, 1348, 1289, 1269, 1225, 1125, 1043 and 1013; 6 ~ 0 . 9 5  (9H, s, CMe3). 1.56-2.05 (9H, 
m, CH(CH2)3CH2N and CH=CCH3), 3.49-3.69 (2H, m, NCH2), 4.23-4.28 (lH, t, J 6.8, 
CHCHz), 5.17 (2H, S, CHzPh), 5.55 (lH, S ,  CHBU'), 6.89 (lH, S, CH=CCH3), 7.32-7.44 
(5H, m, ArH) and 9.08 (lH, s, NH); 6~ 12.3 (CH=CCH3), 23.2 (CHz), 24.9 (CMe3), 28.4 
and 32.6 (CHZ), 37.0 (CMe3), 48.2 (NCHz), 56.8 (CHCHz), 68.5 (CHzPh), 96.4 ( m u t ) ,  
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110.7 (CCH3), 128.5, 128.55 and 128.7 (ArCH), 135.2 (ArC), 140.4 (CH=CCH3), 150.8, 
156.0, 164.3 and 172.6 (CO); d z  457 @I) (M', lo%), 400 (20), 300 (30), 91 (25), 84 
(100) and 47 (20). N1-Propylthymine 3.51Io8: Found: @ 169.0980. CsHlzNz02 requires: 
h4H 169.0977; v,,(KBr/cm-') 3163,3099,3027,2970, 1704, 1649 and 1245; h 0 . 9 4  (3H, 
t, J 7.5, CHZCH~), 1.71 (2H, apparent sextet, J 7.3, NCHZCHZCH~), 1.93 (3H, s,  
CH=CCH3), 2.91 (2H, t, J6.3, NCHzCHz), 6.99 (lH, s, CH=CCH3) and 9.37 (lH, s, NH); 
6c 10.9 (cH2CH3), 12.3 (CH=CCH3), 22.35 (CHZCH~), 50.05 (NCHz), 110.5 (CH=CCH3), 
140.5 (CH=CCH3), 151.1 and 164.4 (CO); d z  (EI) 168 (M', 90%). 126 (90), 96 (100). 55 
(37) and 41 (40). 
(2S,4S)-4-[3-(3-Benzoyi-l -uracilyl)propyl]-3-benzyloxycarbonyl-2-tert- 
butyloxazolldin-5-one, 3.52 
I 
3.31 
Bu' 
Bu' 
3.53 
BusCnCI, NaüyCN, AIBN 
'BUOH 
3.52 
Prepared following method D, using N3-benzoyl-N1-(2-iodoethyl)uracil 3.31 (0.76 g, 2.05 
mmol), (2S)-3-benzyloxycarbonyl-2-te~-butyl-4-methyleneox~olidin-5-one 3.23 (1.19 g, 
4.11 mmol), tributyltin chloride (0.167 cm3, 0.201 g, 0.616 mmol), sodium 
cyanoborohydnde (0.258 g, 4.11 mmol) and AIBN (0.205 mmol) ), but heating at reflux 
for 7 h to yield the conjugate adduct 3.52 as a colourless oil (510 mg, 47%) and N3- 
benzoyl-NI-ethyluracil 3.53 as a white amorphous gum (230 mg, 46%) that was 
incompletely characterized. No debenzoylated products were observed in the mixture. 
(2S,4S)-4-[3-(3-Benzoyl- 1-uracilyl)propyl]-3-benzyloxycarbonyl-2-~e~-butylox~oli~n-5- 
one 3.52 Found MH* (CI) 534.2237. CzgH31N307 requires: MH 534.2240; v,,(film/cm-') 
3404, 3369, 1790, 1749, 1704, 1665, 1497, 1439, 1392, 1347, 1255, 1235 and 1041; ¿iH 
0.94 (9H, s, But), 1.82-2.01 (4H, m, CHCH~CHZ), 3.69-3.85 (2H, m, NCHz), 4.30 (lH, t, J 
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6.8, CHCHz), 5.16 (2H, S, CHzPh), 5.56 (lH, S, CHBU'), 5.75 (lH, d, J7.9, CH=CHCO), 
7.24-7.40 (6H, m, ArH and CH=CHCO), 7.46-7.52 (2H, m, ArH), 7.61-7.67 (lH, m, ArH) 
and 7.90 (2H, m, ArH); 6~ 24.9 (CMe3), 25.7 (CHzCHzCHz), 29.8 (CHCHz), 36.9 (CMe3), 
48.0 (NCHz), 56.6 (CHCHz), 68.7 (CHZPh), 96.5 (mu ' ) ,  102.15 (CHCO), 128.4, 128.6, 
128.8, 128.8, 129.2 and 130.4 (ArCH), 131.5 and 135.1 (ArC), 144.1 (CH=CHCO), 149.8, 
156.1, 162.4, 168.8 and 172.3 (CO); d z  533 (@, 20%), 476 (30), 404 (25), 376 (50), 
301 (40) and 198 (50). N3-Benzoyl-N1-ethyluracil3.53: v,,,(fildcm~') 3413, 3058, 2984, 
2328, 2178, 1788, 1749, 1665, 1601, 1485, 1439, 1391, 1346, 1266, 1178 and 1122; 6" 
1.29 (3H, t, J 7.2, NCHZCH~), 3.79 (2H, q, J 7.2, NCHZCH~), 5.81 (IH, d, J 7.9, 5-CH), 
7.20-7.52 (4H, m, ArH and 6-CH), 7.89 (2H, m, ArH); d z  244 (W, 5%), 216 (30), 199 
(20), 183 (15), 105 (100) and 77 (88). 
(2S,4S)-3-Benzyloxycarbonyl-4-[3( l-uracilyl)propyl]-2-tert-butyloxazolidin-5-one, 
3.54 
'BUOH 
I 
3.31 
"y" k 3.54 
Bu' 
Prepared following method D, using N3-benzoyl-N1-(2-iodoethyl)uracil 3.31 (5.45 g, 14.7 
mmol), (2S)-3-benzyloxycarbony1-2-tert-butyl-4-methyleneox~oli~n-5-one 3.23 (8.51 g, 
29.5 mmol), tributyltin chloride (1.20 cm3, 1.44 g, 4.42 mmol), sodium cyanoborohydride 
(1.85 g, 29.5 mmol) and AIBN (1.47 mmol) to yield the debenzoylated conjugate adduct 
3.54 as a colourless oil (3.24 g, 51%). No benzoylated product was isolated; reduction 
product was present but not purified from this experiment. (2S,4S)-3-Benzyloxycarbonyl- 
4-[3-(1-uracilyl)propyl]-2-rerr-butyloxazolidin-5-one 3.54: Found mf (ES+) 
447.2255. C~~H27N306 requires: MN& 447.2244; v,,(fildcm-') 3691, 3055, 2360, 2342, 
1791, 1713, 1689 and 1266; 6~ 0.92 (9H, s, Bu'), 1.83-2.10 (4H, m, CHCHZCH~), 3.26- 
3.82 (2H, m, NCHz), 4.43 (lH, t, J 6.8, CHCHz), 5.16 (2H, s, CHZPh), 5.54 (lH, s, 
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CHBu'), 5.82 (lH, d, J 7.5, CH=CHCO), 7.32-7.34 (6H, m, ArH and CH=CHCO) and 9.92 
(lH, s, NH); 6c 24.9 (CMe3), 26.7 (CH~CH~CHZ), 28.9 (CHCHz), 36.8 (CMe3), 47.6 
(NCHz), 56.7 (CHCHz), 68.9 (CHZPh), 96.8 (CHBU'), 102.5 (CHCO), 128.7, 135.0 
(ACH), 146.15 and 147.1 (AZ), 151.4 (CH=CHCO), 156.4, 165.5, 171.0 and 173.3 
(CO); d z  430 (MW, 30%), 279 (20), 254 (loo), 238 (30) and 220 (90). 
(2S,4S)-4-[4-(3-Benzoyl-l-uracilyl)butyl]-3-benzyloxycarbonyl-2-~e~-butylox~olid¡n- 
s-one, 3.55 
- Bu3SnCI, NaBH,CN, AiBN 
EtOH 1 
Iiyb BU' 
3.33 3.55 3.56 
Prepared following a modified method D, using N3-benzoyl-N1-(3-iodopropyl)uracil 3.33 
(2.40 g, 6.25 mmol), (2S)-3-benzyloxycarbonyl-2-ter1-butyl-4-methyleneoxazo~idin-5-one 
3.23 (1.51 g, 5.21 mmol), tributyltin chloride (0.424 cm3, 0.509 g, 1.56 mmol), sodium 
cyanoborohydride (0.427 g, 6.79 mmol) and ALBN (0.52 mmol) but heated at reflux in 
degassed ethanol (SO cm3) for 8 h to yield the conjugate adduct as a colourless oil (598 mg, 
21%) and 3-benzoyl-1-propyluracil as a white gum (362 mg, 27%) that was incompletely 
characterized. (2S,4S)-4-[4-(3-Benzoyl- 1 -uracilyl)butyl]-3-benzyloxycarbonyl-2-ter1- 
butyloxazolidin-5-one 3.55: Found: MH+ (CI) 548.2390. C30H33N307 requires: MH 
548.2397; v,,(KBr/cm-') 2962, 2362, 1791, 1749, 1703, 1664, 1438, 1371, 1348, 1256 
and 1235; ¿i" 1.00 (9H, s, CMe3), 1.64-2.02 (6H, m, CH(CH2)3CH2), 3.74 (2H, m, NCHz), 
4.31 (IH, t, J7.0, CHCHz), 5.21 (2H, s, CHzPh), 5.60 (lH, s, CHBu'), 5.81 and 7.25 (each 
IH, d, J 7.4, CH=CHCO), 7.42-7.44 (5H, m, ArH), 7.55 (2H, m, ArH) 7.70 (IH, m, ArH) 
and 7.97 (2H, m, ArH); & 22.0 (CH2). 24.8 (CMe3), 28.1 and 32.4 (CHz), 36.81 (CMe3,), 
48.7 (NCH2). 53.4 (CHCH2), 68.3 (CH2Ph), 96.3 (CHBU'), 101.9 (CHCO), 128.4, 128.6, 
128.7, 129.1 and 130.3 (AtCH), 131.4 (Arc), 135.0 (ArCH), 135.1 (AC), 144.2 
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(CH=CHCO), 149.6, 155.8, 162.35, 168.8 and 172.4 (CO); ndz 547 w, 20%). 490 (50), 
446 (30). 418 (50), 390 (60), 286 (40) and 198 (100). N3-Benzoyl-N1-propyluracil3.56 6, 
0.96 (3H, t, J7.5, CHZCH~), 1.72 (2H, apparent sextet,J7.3, NCH2CH2CH3), 3.68 (2H, t, J 
7.3, NCHz), 5.80 and 7.20 (each lH, d, J 7.1, CH=CHCO) and 7.47-7.68 (5H, m, ArH). 
(2S,4S)-3-Benzyloxycarbonyl-4-[4-(l-uracilyl)butyl]-2-tert-butyloxazolidin-5-one, 3.57
O 
O 
U 
I 
BU' 
3.33 3.57 3.58 
Prepared following method D, using N3-benzoyl-N1-(3-iodopropyl)uracil 3.33 (1.98 g, 
5.16 mmol), (2~-3-benzyloxycarbonyl-2-tert-butyl-4-methyleneoxazolidin-5-one 3.23 
(2.98 g, 10.3 mmol), tributyltin chloride (0.420 cm3, 503 mg, 1.55 mmol), sodium 
cyanoborohydnde (648 mg, 10.3 mmol) and AIBN (0.516 m o l )  to yield the 
debenzoylated conjugate adduct 3.57 as an amorphous solid (1.00 g, 44%). m.p. (decomp.) 
151-i53"C, and N1-propyluracil'og 3.58 as a white gum (0.405 g, 51%). (2S,4S)-3- 
Benzyloxycarbonyl-4-[4-( 1 -uracilyl)butyl]-2-tert-butyloxazolidin-5-one 3.57: 
Found M" 444.2125. C23HzgN306 requires: MH 444.2134; SH (CD3OD) 0.93 (9H, s, 
CMe3), 1.52-2.01 (6H, m, CH(CH&CH2N), 3.58-3.73 (2H, m, NCHz), 4.35 (lH, t, J7.5, 
CHCHz), 5.16 (2H, s, CHzPh), 5.56 (lH, s, CHBu'), 5.62 (lH, d, J 7.7, CH=CHCO) and 
7.30-7.50 (6H, m, ArH and Cii=CHCO); 6c (CD30D) 24.2 (CHz), 25.4 (CMe3), 29.2 and 
33.8 (CHz), 37.8 (CMe3,), 48.5 (NCHz), 58.2 (CHCHZ), 69.4 (CH2Ph), 97.8 ( m u ' ) ,  
102.2 (CH=CHCO), 128.75, 129.5 and 129.6 (ArCH), 137.1 (Arc), 147.3 (CH=CHCO), 
152.8, 157.9, 166.8 and 174.6 (CO); d z  444 (m, 80%) and 430 (20). N1-Propyluracil 
3.58'09: Found: M+ (EI) 154.0734. C7Hl&02 requires: M 154.0742; 6" 0.91 (3H, t, J 7.3, 
CHZCH~), 1.72 (2H, sextet, J 7.3, CHZCHZCH~), 3.70 (2H, t, J 7.3 Hz, NCHz), 5.72 (lH, 
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d, J 7.9, CH=CHCO), 7.16 (IH, d, J 7.9, CH=CHCO) and 9.20 (IH, s, NH); & 10.9 
(CHZm3), 22.3 (mzCH3), 50.45 (NCHz), 102.0 (C-5), 144.7 (C-6), 164.0 and 171.2 
(CO); d z  154 (M', SO%), 126 (15), 112 (60), 82 (IOO), 69 (50) and 55 (40). 
This experiment was repeated using N3-benzoyl-N1-(3-iodopropyl)uracil 3.33 (1.98 g, 
5.16 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-4-methyleneox~oli~n-5-one 3.23 
(7.45 g, 25.8 mmol, 5 mol equiv.), tributyltin chloride (0.420 cm3, 503 mg, 1.55 mmol), 
sodium cyanoborohydride (648 mg, 10.3 mmol) and AIBN (0.516 m o l )  to yield the 
debenzoylated conjugate adduct 3.57 as an amorphous solid (1.42 g, 62%), identical to the 
above sample. 
3-Benzoyloctahydropyrrolo[l,2-c]pyrimidine-2,4-dione, 3.59 
3.33 3.59 
Prepared following method D, using N3-benzoyl-N1-(3-iodopropyl)uracil 3.33 (0.86 g, 
2.24 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-4-methyleneox~o~i~n-5-one 3.23 
(777 mg, 2.69 mmol), tributyltin chloride (0.182 cm3, 219 mg, 0.67 mmol), sodium 
cyanoborohydride (42 mg, 0.67 mmol) and AIBN (0.2 mmol) but heated at reflux for 30 
min. to yield recovered oxazolidinone 3.23 (640 mg, 82%) and uracil 3.33 (690 mg, SO%), 
and the title compound 3.59 (99 mg, 17%; 87% based on recovered uracil 3.33) as a white 
amorphous solid, m.p. 157-158'C; Found: MH' (CI) 259.1084. CiJIi$r1203 requires: MH 
259.1083; v,,(KBr/cm-') 2963, 2926, 1743, 1704, 1681, 1438, 1370, 1349, 1278, 1258, 
1240 and 980; 6" 1.64-1.76 (1H, m, COCHzCHCHH), 1.94-2.00 and 2.09-2.15 (each IH, 
ddddd, J2.4, 4.8, 7.0, 9.7 and 11.9, NCHzCHz), 2.32-2.38 (lH, m, COCH2CHCHH), 2.57 
(lH, dd, J 13.2 and 15.9 Hz, COCHH), 2.95 (lH, dd, J3 .9  and 16.0, COCHH), 3.50-3.71 
(2H, m, NCHz), 3.91-3.95 (IH, m, NCH), 7.49 (2H, m, ArH), 7.62 (IH, m, ArH) 
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and 7.89-7.92 (2H, m, ArH); & 23.2 (NCHZCH~CHZ), 33.2 (CHCHz), 38.3 (COCHz), 45.3 
(NCHz), 52.9 (CH), 129.2 and 130.5 (ArCH), 132.7 (ArC), 134.5 (ArCH), 149.9, 168.9 
and 170.0 (CO). 
An experiment following method C, using N3-benzoyl-N1-(3-iodopropyl)uracil 3.33 (0.43 
g, 1.12 mmol), AIBN (ca. 10 mg), toluene (150 mi) and tributyltin hydride (0.361 cm3, 
0.391 g, 1.34 mmol), but without using the chirai acceptor 3.23, gave the title compound 
3.59 as a colourless oil (152 mg, 53%), having spectral data as above. No reduced N3- 
benzoyl-N1-propyluracil was observed. 
N1-(2-Bromoethyl)thymine, 3.60 
Br 
3.25 
$I 
3.60 
N3-Benzoyl-N1-(2-bromoethyl)uraciI 3.25 (0.5 g, 1.41 mmol) and sodium 
cyanoborohydride (0.2 g, 2.82 mmol) were heated at reflux in tert-butanol(20 mi) for 40h. 
The solvent was removed in vacuo and the crude product was extracted with ethyl acetate 
(2 x 20 mi), washed with brine and dried over MgS04. The solvent was removed to yield 
only the title compound107 3.60 as a white solid (0.31 g, 94%), m.p. 166-167°C (lit.lo7 164- 
165OC). 1.96 (3H, d, J 1.2, CH3), 4.30 (2H, t, J 8.5, CHZBr), 4.75 (2H, t, J 8.5, NCHz), 
7.55 (lH, d, J 1.2, CH), 9.90 (lH, broad s, NH). 
164 
Attempted preparation of (2S,4S)-4-[N4-(4-benzoyl-l-cytosinyl)butyl]-3- 
benzyloxycarbonyl-2-tert-butyloxazolidin-S-one, 3.61
BU' 
Bu3SnCI, NaBYCN, AIBN 
I 
BU' 
This was attempted following method D using N1-iodopropyl-N4-benzoylcytosine 3.39 
(3.14 g, 8.20 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-N4-methyleneoxazoli~n-5- 
one 3.23 (4.74 g, 16.4 mmol), tributyltin chloride (0.667 ml, 801 mg, 2.46 mmol), sodium 
cyanoborohydride (1.03 g, 16.4 mmol) and AIBN (0.8 mmol) heated at reflux in tert- 
butanol over 16 h. Purification of the residue by flash chromatography was attempted. A 
mixture of the ritle compound 3.61, the reduced starting N1-propyl-N4-benzoylcytosine 
and unknown products was isolated and could not be purified further. This mixture was 
therefore used directly in the next step. 
(2S,4S)-3-Benzyloxycarbonyl-2-tert-butyl-4-{3-[~6-(2-methylpropanoyl)-9- 
adeninyllpropyl}oxazolidin-5-one, 3.62, and (2S,4S)-4-[3-(9-adeninyl)propy11-3- 
benzyloxycarbonyl-2-fert-butyloxazolidin-S-one, 3.64 
NHCOCHMe2 
'BUOH 
'i zN,ò 
3.41 
1 
Bu' 
3.62 3.63 
I 
Bu' 
3.64 3.65 
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Prepared following method D, using N9-(2-iodoethyl)-N6-(2-methylpropanoyl)adenine 
3.41 (3.29 g, 9.16 mmol), (2S)-3-benzyloxycarbonyl-2-~e~-butyl-4-methyleneoxazolidin- 
5-one 3.23 (5.30 g, 18.3 mmol), tributyltin chloride (0.746 cm3, 895 mg, 2.75 mmoi), 
sodium cyanoborohydnde (1.15 g, 18.3 mmol) and ABN (0.92 m o l )  but heated at reflux 
for 16 h to yield the conjugate adducr 3.62 as a colourless oil (1.17 g, 26%), a mixture of 
deacylared conjugate adduct 3.64 (580 mg, 14%, calculated from the following hydrolysis 
step) and N9-ethyl-N6-(2-methyIpropionyl)adenine 3.63 (360 mg, 17%, calculated from 
the hydrolysis step), and N9-ethyladenine 3.65 (280 mg, 19%) as a white solid, m.p. 180- 
182°C (lit."o 184-186°C). (2S,4S)-3-Benzyloxycarbonyl-2-tel?-butyl-4-{3-[N6-(2- 
methylpropanoyl)-9-adeninyl]propyl}oxazolidin-5-one 3.62: Found: h4H+ 523.2670. 
C27H3&,05 requires: MH 523.2669; 6~ 0.91 (9H, s, CMe3), 1.33 (6H, d, J 7.0, CHMez), 
1.87-2.24 (4H, m, CHCHzCHz), 3.28 (lH, septet, J 7.0, CHMez), 4.27-4.34 (3H, m, 
CHCHz and NCH2), 5.15 (2H, s, CHZPh), 5.52 (lH, s, CHBu'), 7.26 (5H, m, ArH), 8.12 
and 8.71 (each lH, s, adenine-H), 9.74 (lH, s, NH); & 19.0 (CHMeZ), 24.6 (CMe3), 26.7 
(CHCHzCHz), 29.0 (CHCHz), 33.85 (CHMeZ), 35.8 (CMe3), 43.2 (NCHz), 56.5 (CHCHz), 
68.6 (CHZPh), 96.5 (CHBu'), 122.0 (ArC), 128.5, 128.65 and 128.7 (ASH), 134.9 (AS),  
143.0 (ArCH), 149.55 and 151.7 (ArC), 152.4 (ArCH), 156.1, 172.25 and 176.8 (CO); d z  
522 (M', 2%), 395 (2), 359 (25) and 91 (100). (2S,4S)-4-[3-(9-Adeninyl)propyl1-3- 
benzyloxycarbonyl-2-tert-butyloxazolidin-5-one 3.64 (data from the mixture of 3.64 and 
3.63): 6" 0.91 (9H, s, CMe3), 1.79-2.25 (4H, m, CHCHzCHz), 4.22 (2H, t, J 7.0, NCH2), 
4.36 (lH, m, CHCHz), 5.15 (2H, s, CHZPh), 5.56 (lH, s, CHBu'), 7.26-7.38 (5H, m, ArH), 
7.83 and 8.36 (each lH, s, adenine-H). N9-Ethyl-N6-(2-methylpropanoyl)adenine 3.63 
(data from the mixture of 3.65 and 3.63): SH (CD30D) 1.26 (6H, d, J 7.0, CHMeZ), 1.51 
(3H, t, J7 .3 ,  CHzCH3) 2.91 (lH, septet, J7.0, CHMez) and 4.31 (2H, q, J 7.3, CHzCHi), 
8.37 and 8.63 (each lH, s, 2-CH and 8-CH); S, (CD30D) 15.6 and 19.7 (CH3), 37.1 
(CHMeZ), 40.3 (azcH3) ,  127.05 (AS),  145.3 (C-2 or C-8), 150.6 (ArC), 152.9 (C-8 or 
C-2), 153.2 (ArC) and 178.23 (CO). N9-Ethyladenine"O 3.65: Found: M (EI) 163.0857. 
C7HgNs requires: M 163.0858; v,,(KBr/cm-') 3268, 3191, 1675, 1601, 1573, 1480, 1415, 
1327, 1308, 1249, 1214 and 1197; 6" 1.62 (3H, t, J 7.3, CHZCH~), 4.26 (2H, q, J 7.3, 
CH2CH3), 6.09 (2H, s, NH), 7.86 and 8.37 (each lH, s, 2-CH and 8-CH); S, (CD30D) 
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15.55 (CH3), 38.9 (CHz), 121.0 (ArC), 140.0 (C-2 or C-8), 150.4 (Arc), 152.8 (C-8 or C-2) 
and 155.5 (Arc); ndz 163 (M', 60%), 135 (100) and 108 (70). 
(2S,4S)-3-Benzyloxycarbonyl-2-tert-butyl-4-{ [N6-(2-methylpropanoyl)-9- 
adeninyllbu tyl}oxazolidin-5-one, 3.66 
N H C O C H M e, 
WO 
NHCOCHMe, 
- Y!!J \ i "Y0 BU' BbSnH, AIBN toluene 
3.61 
I 
BU' 3.66 3.43 
Prepared following method C, using N9-(3-iodopropyl)-N6-(2-methylpropionyi)adenine 
3.43 (0.3 1 g, 8.3 1 mmol), (2S)-3-benzyloxycarbonyl-2-ter?-butyl-4-methyleneox~olidin- 
5-one 3.23 (240 mg, 8.31 mmol), AIBN (ca. 10mg) and tributyltin hydride (0.268 mi, 
0.290 g, 9.97 mmol) to give the conjugate adduct 3.66 as a colourless oil (102 mg, 23%) 
and N6-(2-methylpropanoyl)-N9-propyladenine 3.67 as a white gum (92.4 mg, 45%). 
(2S,4S)-3-Benzyloxycarbonyl-2-ter?-butyl-4- [ [N6-(2-methylpropanoyl)-9- 
adeninyllbutyl}oxazolidin-5-one 3.66: Found MH+ 537.281 1. C~gH36Ns05 requires: MH 
537.2747; v,,(KBr/cm-') 3343, 3055, 2975, 2875, 2359, 1790, 1718, 1615, 1586, 1462, 
1402, 1372, 1349 and 1267; 8 ~ 0 . 9 4  (9H, s, CMe?), 1.31 (6H, d, J 6.9, CHMez), 1.52-2.03 
(6H, m, CHCHzCHzCHz), 3.22 (lH, septet, J6.9, CHMe2). 4.18-4.26 (3H, m, CHCH2 and 
NCHz), 5.15 (2H, s, CHzPh), 5.54 (lH, s, CHBu'), 7.29-7.39 (5H, m, ArH), 7.92 and 8.55 
(each lH, s, 2-CH and 8-CH) and 8.72 (lH, s, CO"); SC (CD30D) 19.7 (CHMe2), 24.4 
(CHCHzCHz), 25.6 (CMe3), 30.2 (CHCHZCHZCH~), 33.65 (CHCHz), 37.15 (CHMez), 37.8 
(CMe3), 44.75 (NCHz), 58.1 (CHCHz), 69.3 (CHzPh), 97.7 (CHBu'), 129.5, 129.6 and 
129.9 (ArCH), 137.0 (Arc), 143.0 (ArCH), 149.8 and 150.7 (ArC), 153.1 (AKH), 153.4 
(AK), 157.8, 174.55 and 176.25 (CO); d z  537 (I"+, 100%). 515 (6). 379 (13,260 (16), 
202 (16) and 148 (25). N6-(2-MethylpropanoyI)-N9-propyladenine 3.67: Found M€I+ 
248.1511. C I ~ H I ~ N S O  requires: MH 248.1516; & (CD30D) 0.94 (3H, t, J 7.2, CHZCH~), 
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1.38 (6H, d, J6.9,  CHMez), 1.88 (2H, sextet,J7.2, CH~CHZCH~), 3.31 (1H, septet, J6.9, 
CHMez), 4.29 (2H, t, J 7.2, NCHZCHZ), 8.38 and 8.62 (each IH, s, 2-CH and 8-CH); Sc 
(CD30D) 11.3 (CHZm3), 19.65 (CHMez), 24.2 (CH2CH3), 37.1 (CHMez), 46.7 (NCHz), 
124.0 (AS),  145.75 (ASH), 150.65 (ArC), 152.9 (ArCH), 153.4 ( A S )  and 178.2 (CO); 
d z  247 (h4+, 50%), 177 (60), 149 (58), 138 (loo), 108 (30) and 84 (30). 
(2S,4S)-3-Benzyloxycarbonyl-2-tert-butyl-4-{4-[~6-(2-methylpropanoyl)-9- 
adeninyllbutyl}oxazolidin-5-one, 3.66 and (2S,4S)-4-[4-(9-Adeninyl)butyl1-3- 
benzyloxycarbonyl-2-tert-butyloxazolidin-5-one, 3.68 
BU' BU' 
3.43 3.66 3.67 3.68 3.69 
Prepared following method D, using N9-(3-iodopropyl)-N6-(2-methylpropanoyl)adenine 
3.43 (1.86 g, 4.99 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl-4-methyleneoxazolidin- 
5-one 3.23 (2.88 g, 9.97 mmol), tributyltin chloride (0.406 cm3, 487 mg, 1.50 mmol), 
sodium cyanoborohydride (627 mg, 9.97 mmol) and AIBN (0.5 mmol) but heated at reflux 
for 16 h to yield the conjugate adduct 3.66 as a colourless oil (0.31 g, 12%), deacylated 
conjugate adduct 3.68 as a colourless oil (0.22 g, 14%), N6-(2-methylpropanoyI)-N9- 
propyladenine 3.67 as a white gum (0.13 g, 11%) and NI)-propyladenine 3.69 also as a 
white gum (0.2 g, 23%). Data for (2S,4S)-3-benzyloxycarbonyl-2-terl-butyl-4-{4-[N6-(2- 
methylpropionyl)-N9-adeninyl]butyl]oxazolidin-5-one 3.66 and for N6-(2- 
methylpropionyl)-N9-propyladenine 3.67 were identical to those given above. (2S,4S)-4- 
[4-(~-Adeninyl)butyI]-3-benzyloxycarbonyl-2-tert-butylox~o~idin-5-one 3.68: Found: 
@ (ES') 467.2401. C24H3&04 requires: MH 467.2407; vm(KEWcm-') 3323, 3300, 
2874, 1790, 1718, 1645, 1600, 1481, 1396, 1348 and 1082; & (CD30D) 0.91 (9H, s, 
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CMe3), 1.35-2.22 (6H, m, CHCHZCH~CH~), 4.15 (2H, t, J 7.0, NCH2), 4.32 (lH, t, J 7.0, 
CHCH2), 5.10 (2H, s ,  CHZPh), 5.54 (lH, s, CHBu'), 7.24-7.35 (5H, m, ArH), 8.04 and 8.19 
(each lH, s ,  adenine-H); 6c (CD30D) 24.4 (CHCHZCHZ), 25.4 (CMq), 30.4 
(CHCHZCHZCH~), 33.7 (CHCHz), 37.8 (CMe3), 44.6 (NCHz), 58.15 (CHCHz), 69.3 
(CHzPh), 97.7 ("Bu'), 120.1 (Arc), 129.5, 129.6 and 129.9 (ArCH), 137.0 (ArC), 142.7 
(ArCH), 150.7 (ArC), 153.7 (ArCH), 157.3 (ArC), 157.8 and 174.55 (CO); d z  466 (w, 
SO%), 409 (loo), 365 (40) and 287 (70). N9-Propyladenine 3.69: Found: MIi+ (ES') 
178.1091. C ~ H I I N ~  requires: MH 178.1092; v,(film/cm-') 3408, 3055, 2985, 2361, 1636, 
1474, 1418, 1327, 1266 and 896; SH 0.94 (3H, t, J 7.2, CHZCH~), 1.90 (2H, sextet, J 7.2, 
CHZCH~CH~), 4.20 (2H, t, J 7.2, NCH2). 6.23 (2H, s, NHz), 7.82 and 8.35 (each lH, s, 2- 
CH and 8-CH); 8~ (CD30D) 11.2 (CHZm3), 22.8 (CHZCH~), 46.6 (NCHz), 119.6 (Arc), 
140.45 (ArCH), 150.1 (ArC), 152.9 (ArCH) and 155.7 (ArC); d z  177 (M+, 55%), 148 
(88), 135 (100) and 108 (60). 
(2S,4S)-4-(3-{N2-Acetyl-06-[2-(4-nitropbenyl)etbyl]-N9-~~inyl}propyl)-3- 
benzyloxycarbonyl-2-tert- butyloxazolidin-5-one, 3.70 
,\ ,- 
N 
.. 
Bu3SnH, AIBN 
3.46 3.70 3.71 
This was prepared following method C, using N2-acetyl-N9-(2-iodoethyl)-û6-[2-(4- 
nitrophenyl)ethyl]guanine 3.46 (1 .O g, 2.02 mmol), (2S)-3-benzyloxycarbonyl-2-tert-butyl- 
4-methyleneoxazolidin-5-one 3.23 (587 mg, 2.02 mmol), AIBN (ca. 10mg) and tnbutyltin 
hydride (0.651 cm3, 0.704 g, 2.42 mmol) ) in toluene (200 cm3) to give the conjugate 
adduct 3.70 as a yellow oil (279 mg, 21%) and N2-acetyl-9-ethyl-06-[2-(4- 
nitrophenyl)ethyZ]guanine 3.71 as a white solid (149 mg, 20%) m.p. (decomp.) 194- 
196°C). (2S,4S)-4-(3-(N2-Acetyl-~6-[2-(4-nitrophenyl)ethyl]-N9-guaniny~}propyl)-3- 
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benzyloxycarbonyl-2-tert-butyloxazolidin-5-one 3.70: Found MH+ (CI) 660.2787. 
C33H37N708 requires: MH 660.2782; & 0.91 (9 H, s, CMe3), 1.72-2.13 (4 H, m, 
CHCHZCH~), 2.53 (3H, s, CH3CO), 3.32 (2H, t, J6.7,  CH2Ar), 4.18 (2H, m, NCHz), 4.37 
(lH, LJ7.5,  CHCHz), 4.79 (2H, t,J6.7, OCHz), 5.16 (2H, S ,  CHZPh), 5.56 (lH, S ,  CHBU'), 
7.29-7.35 (5H, m, ArH), 7.50 (2H, d, J 8.6, ArH), 7.77 (lH, s, guanine-H), 7.85 (lH, s, 
CONH) and 8.19 (lH, d, J 8.62 Hz, ArH); & 24.9 (CMe3), 25.2 (coCH3), 26.6 
(CHCHZCHZ), 30.05 (CHCHz), 35.1 (CHz), 36.9 (CMe3). 43.1 (NCHz), 56.5 (CHCHz), 
66.9 (CHz), 68.7 (CHZPh), 96.5 (CHBu'), 117.75 (ArC), 123.8, 128.6, 128.7 and 128.8 
(ArCH) 128.9 (AS) ,  130.0 (ArCH), 134.9 (AS),  141.6 (ArCH), 145.7, 146.9, 152.0 and 
153.15 (Ar€), 156.1, 160.6 and 172.25 (CO); m/z 660 (m, 20%), 602 (loo), 511 (60), 
480 (401, 410 (401, 368 (30), 261 (70) and 193 (SO). N2-Acetyl-N9-ethyl-û6-[2-(4- 
nitrophenyl)ethyl]guanine 3.71: Found M' (EI) 370.1390. Ci7HisN6O4 requires: M 
370.1390; v,,(KBr/cm-'); SH 3.60 (3H, t, J 7.3, CHZCH~), 2.53 (3H, s, CH3CO). 3.31 (2H, 
t, J6.6, CHzAr), 4.22 (2H, 9. J7.3, CHZCH~), 4.78 (2H, t, J6.6, OCHz), 7.50 (2H, d, J8.6, 
ArH), 7.82 (lH, s, guanine-H), 7.87 (lH, s, CO") and 8.18 (2H, d, J 8.56, ArH); d z  370 
(m, loo%), 341 (20), 328 (70), 277 (50), 262 (40) and 234 (84). 
General procedure for conversion of 4-substituted oxazolidinones into N- 
benzyloxycarbonyl-@)-amino acids by base hydrolysis (method E) 
The oxazolidinone conjugate adduct in THF-water (3:l v/v, 40 cm3) was cooled in an ice- 
bath and treated with lithium hydroxide monohydrate (2 mol equiv.). After stimng for 1 h 
at o"C, water (50 cm3) was added and the THF removed under reduced pressure. The 
solution was acidified to pH 2-3 by careful addition of 1M hydrochloric acid, and the 
mixture was extracted with ethyl acetate (3 x 50 cm3). The combined organic extracts were 
dried (MgS04), filtered, and evaporated to give the @)-amino acids. 
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(S)-5-(N3-benzoyl-N1-thyminyl)-2-benzyloxycarbonyla~nopen~noic acid, 3.72 
Ph Ph 
b 
LiOH 
THF-Hi0 
ZHN OH 
I 
Bu' 
3.47 3.72 
Prepared following method E, using (2S,4S)-4-[3-(N3-Benzoyl-Nl-thyminyl)propyl]-3- 
benzyloxycarbonyl-2-tert-butyloxazolidin-5-one 3.47 (210 mg, 0.384 mmol) and lithium 
hydroxide monohydrate (0.768 mmol, 32 mg) to yield the rifle compound 3.72 (0.170 g, 
92%) as a thick colourless oil that was incompletely characterized; -13.3 (c, 0.24 in 
EtOH); v,,(film/cm-') 3436, 3057, 2987, 2686, 2306, 2096, 1654, 1511, 1439, 1345, 
1266, 1179, 896, 740; 6" 1.62-1.96 (7H, m, CHCH2CH2 and CH=CCH3], 3.65-3.74 (2H, t, 
J 6.6, NCH2), 4.20 (lH, m, NHCHCH2), 5.10 (2H, s, CH2Ph), 5.58 (lH, d, J 7.9, 
NHCHCHz), 7.09 (1 H, s, CH=CCH3), 7.30-7.34 (5H, m, ArH), 7.44 (2H, m, ArH), 7.61 
(lH, m, ArH), 7.87 (2H, m, ArH); 6~ 12.3 (CH=CCH3), 24.8 (CH2CH2CHz), 29.2 
(CHzCHzCHz), 48.1 (CHzN), 53.0 (CHCHz), 67.2 (CHZPh), 110.0 (CH=CCH3), 125.3, 
128.1, 128.2, 128.6, 129.0 and 129.2 (ArCH), 130.4 and 135.15 (ArC), 140.4 (CH=CCH3), 
150.0, 156.3, 163.3, 169.1 and 175.0 (CO). 
171 
(S)-2-Benzyloxycarbonylamino-5-(N1-thyminyl)pentanoic acid, 3.73 
THF-H,O 
I 
BU' 
3.49 3.73 
Prepared following method E, using (2S,4S)-3-benzyloxycarbonyl-4-[3-(Nl- 
thyminyl)propyll-2-rert-butyloxazolidin-5-one 3.49 (210 mg, 0.474 mmol) and lithium 
hydroxide monohydrate ( 0.948 mmol, 40 mg) to yield the title compound 3.73 (0.170 g, 
96%) as a white amorphous solid, m.p. (decomp.) 199-100°C; [u]D** -11.3 (c, 0.32 in 
EtOH); Found: MN&+ (ES') 393.1777. C1gH21N306 requires: 393.1774; 
v,,(KBr/cm-') 3306,3191,3062,3035,2959,2827,2602,2366,2345,2252, 1654, 1531, 
1358, 1217, 1133, 1066 and 910; 8~ 1.55-1.84 (7H, m, CHCHzCHz and CH=C(CH3), 3.65- 
3.81 (2H, t, J 6.6, NCHz), 4.27 (1H, m, NHCHCHZ), 5.02 (2H, s, CHZPh), 5.99 (lH, d, J 
7.7, NHCHCHz), 7.00 (lH, s, CH=CCH3), 7.23-7.47 (5H, m, ArH), 10.25 (lH, s, CO"); 
6c 12.2 (CH=CCH3), 21.1 (CHzCHzCHz), 29.2 (CHzCHzCHz), 48.0 (CHzN), 53.2 
(CHCHz), 67.0 (CHZPh), 110.95 (CH=CCH3), 128.0, 128.2 and 128.5 (ArCH), 136.2 
(ArC), 141.0 (CH=CCH3), 151.5, 165.2, 156.4 and 151.5 (CO); d z  393 (MNL', lOO%), 
376 @O), 349 (55) ,  332 (40) and 285 (70). 
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(S)-2-Benzyloxycarbonylamino-6-(N1-thyminyl)hexanoic acid, 3.74 
Lo LiOH THF-Hi0 
ZHN OH 
BU' 
3.74 
Lo 
,,Y0 
3.50 
Prepared following method E, using (2S,4S)-3-benzyioxycarbonyl-4-[4-( 1 -thyminyl)butyl] 
-2-tea-butyloxazolidin-5-one 3.50 (3 10 mg, 0.678 mmol) and lithium hydroxide 
monohydrate (85 mg, 2.04 mmol) to yield the title compound 3.74 as a thick colourless oil 
(230 mg, 87%); Found: MN&+ 407.1940. C19H23N306 requires: MN& 407.1931; 
v,,(film/cm-') 3430, 2959, 2348, 1657, 1546, 1501, 1467, 1129 and 1070; 6" 1.21-1.88 
(9H, m, CH(CHZ)~CHZN and CH=CCH3), 3.66 (2H, m, NCHz), 4.37 (lH, m, CHCHz), 
5.79 (lH, d, J 7.9, NHCH), 6.98 (lH, s, CH=CCH3), 7.26-7.37 (5H, m, ArH) and 10.17 
(lH, s, CONH); 6c 12.2 (CH=CCH3), 21.7, 28.35 and 31.7 (CHz), 48.0 (NCHz), 53.4 
(CHCHz), 67.0 (CHzPh), 110.9 (CH=CCH3), 128.0, 128.15 and 128.5 (ArCH), 136.3 
(Arc), 140.9 (CH=CCH3), 151.45, 156.2, 165.1 and 175.6 (CO); m/z 390 ( I d ,  75%). 363 
(90), 346 (100). 299 (88) and 282 (80). 
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(S)-2-Benzyloxycarbonylamino-5-(N1-uracilyl)pentanoic acid, 3.75 
LiOH 
b 
THF-HZ0 
3.54 3.75 
Prepared following method E, using (2S,4S)-3-benzyloxycarbony1-4-[3-(-Nl- 
uracilyl)propyl]-2-te~-butyioxazolidin-5-one 3.54 (2.34 g, 5.45 mmol) and lithium 
hydroxide monohydrate (687 mg, 16.4 m o l )  to yield the title compound 3.75 (1.35 g, 
69%) as a thick oil; [ a ] ~ ~ ~  -71.6 (c. 0.10 in EtOH); Found: MH+ 362.1352. C17H19N306 
requires: MH 362.1352; v,,,(film/cm-') 3426, 3056, 2988, 2686, 2361, 2339, 2307, 2300, 
2245, 2095, 1660 and 1266; 6" (CD30D) 1.55-1.82 (4H, rn, CHCHzCHz), 3.65 (2H, t, J 
6.4, NCHz), 4.11 (lH, rn, CHCHz), 4.98 (2H, s, CHZPh), 5.52 (lH, d, J7.8,  CH=CHCO), 
7.17-7.26 (5H. m, ArH) and 7.51 (lH, d, J 7.8 Hz, CH=CHCO); 6c (CD30D) 21.5 
(CHzCHzCHz), 29.65 (CHZCHZCH~), 48.7 (CHzN), 54.8 (CHCHz), 67.6 (CHzPh), 102.3 
(CH=CHCO), 128.8, 129.0 and 129.5 (ACH), 138.2 ( A S ) ,  147.15 (CH=CHCO), 152.8, 
158.6, 166.7 and 175.4 (CO); m/z 361 (M+, loo%), 344 (40), 318 (55 )  and 296 (20). 
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(S)-6-(N3-Benzoyl-N1-uracilyl)-2-benzyloxycarbonylam~nohexanoic acid, 3.76 
P h ' N 5  Ph JN4 
O A O A N  
.- L o  
LiOH 
THF-H,O 
ZHN OH 
Bu' 
3.55 3.76 
,,Y0 1,
Prepared following method E, using (2S,4S)-4-[4-(3-benzoyl-l-uracilyl)butyl]3- 
benzyloxycarbonyl-2-te~-butyloxazolidin-5-one 3.55 (1 12.6 mg, 0.206 mmol) and lithium 
hydroxide monohydrate (17 mg, 0.412 mmol) to yield the title compound 3.76 as a thick 
colourless oil (95 mg, 96%); Found M"4' 497.2038. C Z ~ H Z ~ N ~ O ~  requires: I~~ML, 
497.2036; v,,(KBr/cm-') 3436, 3057, 2989, 2686, 2306, 2096, 1654 and 1266; 6" 1.23- 
2.04 (6H, m, CHCHzCHzCHz), 3.66 (2H, m, NCHz), 4.32 (lH, m, CHCHz), 5.02 (2H, s, 
CHZPh), 5.59 and 6.98 (each lH, d, J 8.0, CH=CHCO), 7.13-7.32 (5H, m, ArH), 7.46 (2H, 
m, ArH) 7.72 (lH, m, ArH) and 7.87 (2H, m, ArH); 6~ 21.8, 28.1 and 31.4 (CHZ), 48.6 
(NCHz), 53.3 (CHCHz), 67.1 (CHzPh), 101.8 (CRCHCO), 128.0, 128.2, 128.5, 129.2 and 
130.3 (ASH), 131.2 (ArC), 135.2 (ArCH), 136.0 (ArC), 144.6 (CH=CHCO), 149.7, 
156.2, 162.8, 168.8 and 175.38 (CO). m/z 479 (M', 15%), 374 (20), 153 (25) and 121 
(100). 
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(S)-2-Benzyloxycarbonylamino-6-(N1-uracilyl)hexanoic acid, 3.77 
LiOH 
THF-H*O 
I 
BU' 
3.57 3.77 
Prepared following method E, using (2S,4S)-3-benzyloxycarbonyl-2-rerf-butyl-4-[4-(N1- 
uracilyl)butyl]oxazolidin-5-one 3.57 (250 mg, 0.564 mmol) and lithium hydroxide 
monohydrate (47 mg, 1.13 mmol) to yield the rifle compound 3.77 as a white solid (110 
mg, 52%). m.p. (decomp.) 182-183'C; [a]," -150 (c, 0.032 in EtOH); Found: MH? 
376.1513. C~~HZIN~O~ requires: MH 376.1508; v,(KBr/cm-l) 3213, 2364, 1715, 1688, 
1541, 1466, 1364, 1257, 1200 and 1072; 6" (DMSO-&) 1.15-1.56 (6H, m, CH 
CHZCH~CH~), 3.62(2H, t, J6.8, NCHz), 3.89 (lH, m, CHCHz), 5.02 (2H, s, CHzPh), 5.50 
(lH, d, J7.9, CH=CHCO), 7.31-7.34 (5H, m, ArH), 7.55 (lH, d, J7.8, CH") 7.61 (lH, 
d, J 7.9, CH=CHCO) and 11.21 (lH, s, uracil-"); S, 22.4, 27.9 and 30.3 (CHz), 47.1 
(NCHz), 53.6 (CHCHz), 65.3 (CHzPh), 100.7 (CH=CHCO), 127.6, 127.7 and 128.2 
(ASH), 136.9 ( A S ) ,  145.55 (CH=CHCO), 150.8, 156.0, 163.6 and 173.7 (CO); d z  376 
(m, 80%), 332 (70), 285 (90), 268 (loo), 244 (100) and 226 (50). 
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(S)-6-(N4-Benzoyl-N1-cytosinyl)-2-benzyloxycarbonyla~nohexanoic acid, 3.78 
LiOH 
THF-HzO 
ZHN OH 
3.78 
I 
3.61 Bu' 
This was prepared following method E using crude (2S,4S)-4-[4-(N4-benzoyl-N1- 
cytosinyl)butyl]-3-benzyloxycarbonyl-2-~e~-butylox~olidin-5-one 3.61 to yield the crude 
title compound 3.78 which could not be purified despite several attempts using column 
chromatography ; Found (m) 479.1932, C2$i2&+06 requires MH 479.1930; m/z 479 
(@, 90%), 362 (loo), 271 (go), 254 (82), 243 (100). 230 (90), 220 (98). 
(S)-2-Benzyloxycarbonylamino-5-[N6-(2-methylpropanoyl)-~9-adeninyl]pen~noic 
acid, 3.79 
NHCOCHMQ NHCOCHMQ 
LiOH 
THF-HZO 
ZHN OH 
3.62 3.79 
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Prepared following method E, using (2S,4S)-3-benzyloxycarbonyl-2-tert-butyl-4-[ 3-[N6- 
(2-methylpropionyl)-N9-adeninyl]propyl}oxazolidin-5-one 3.62 (0.91 g, 1.74 mmol) and 
lithium hydroxide monohydrate (219 mg, 5.23 mmol) to yield the title compound 3.79 as a 
white amorphous solid (0.57 g, 72%), m.p. (decomp.) 147-15O'C; Found: MH' 455.2043; 
C Z Z H Z ~ N ~ O ~  requires: MH 455.2052; 6" 1.28 (6H, d, J 6.8, CHMeZ), 1.74-2.27 (4H, m, 
CHCHzCHz), 3.03 (lH, septet, 16.8, CHMeZ), 4.36 (2H, m, NCHz), 4.52 (lH, m, CHCHz), 
5.11 (2H, S, CHzPh), 5.73 (lH, d, J7.5, CH"), 7.33 (6H, m, 5 x ArH and NHCO), 8.17 
and 8.69 (each lH, s, 2-CH and 8-CH); öc 19.2 (CHMez), 25.5 (CHCHzCHz), 28.6 
(CHCHz), 36.0 (CHMez), 43.4 (NCHz), 53.5 (CHCHz), 67.1 (CHZPh), 122.0 (ArC), 128.1, 
128.3 and 128.6 (ArCH), 136.8 (ArC), 143.1 (ASH), 149.3 and 151.6 (ArC), 152.9 
(ArCH), 156.2, 172.8 and 176.5 (CO); d z  455 (@, 70%). 347 (loo), 277 (30). 206 (62) 
and 196 (70) 
(S)-5-(N9-Adeninyl)2-benzyloxycarbonyl~nopen~noic a id, 3.80 ' 
N% L i 5  
N%J I\N N 
* Lo LiOH THF-Hi0 
ZHN OH 
Bu' 
3.80 
Lo 
'"Y" 
3.64 
Prepared following a modified method E, using a mixture of (2S,4S)-4-[3-(N9- 
adeninyl)propyl]-3-benzyloxycarbonyl-2-tert-butylox~olidin-5-one 3.64 (580 mg, 1.28 
mmol), N9-ethyl-N6-(2-methyIpropionyl)adenine 3.63 (360 rng, 1.55 mmol) and lithium 
hydroxide monohydrate (162 mg, 3.85 rnmol), and extracting with dichloromethane (3 x 
20 cm3) to yield N9-ethyl-N6-(2-methylpropanoyl)adenine 3.63 (360 mg, 17% based on 
iodo compound 3.41). Acidification and extraction of the aqueous layer as usual gave the 
title compound 3.80 as a white solid (430 mg, 87%), m.p. 193-94°C; Found: @ (ES') 
385.1629. C ~ ~ H Z O N ~ O ~  requires: M H  385.1624; vm(KBr/cm-') 3395, 3104, 2876, 2366, 
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2346, 1970, 1611, 1542, 1459, 1408, 1323 and 1221; SH (CD30D) 1.61-2.05 (4H, m, 
CHCH~CHZ), 4.22 (lH, m, CHCHz), 4.43 (2H, m, NCHz), 5.02 (2H, s, CH2Ph), 7.23-7.31 
(5H, m, ArH), 8.50 and 8.58 (each lH, s, 2-CH and 8-CH); & (CD30D) 27.4 and 29.4 
(CH2), 45.1 (NCHz), 54.8 (CHCHz), 67.6 (CH2Ph), 119.8 (Arc), 128.6, 128.9 and 129.4 
(ASH), 138.0 (ArC), 145.1 and 145.7 (ASH), 150.0 and 151.2 (AS),  158.5 and 174.0 
(CO); d z  385 (m, is%), 251 (3, 190 (46), 126 (70), 111 (100) and 84 (90). 
(S)-6-[N6-(2-Methylpropanoyl)-N9-adeninyl]-2-benzyloxycarbonyla~nohexanoic 
acid, 3.81 
NHCOCHMe2 
I NHCOCHM% I 
> Lo LIOH THF-H2O ce ZHN OH =,Yo Bu' 
3.66 3.81 
Prepared following method E, using (2S,4S)-3-benzyloxycarbonyl-2-re~-butyl-4-{ 4-[N6- 
(2-methylpropanoyl)-N9-adeninyl]butyl)oxazolidin-5-one 3.66 (0.32 g, 0.597 mmol) and 
lithium hydroxide monohydrate (84 mg, 0.199 mmol) to yield the title compound 3.81 as a 
white amorphous solid (0.250 g, 89%), m.p. 147-150°C; Found: MH' (ES') 469.2208; 
C23Hz8N605 requires: MH 469.2199; v,,(KBr/cm-') 3322, 3054, 2974, 2556, 1723, 1683, 
1609, 1590, 1540, 1457, 1402, 1350, 1072, 1050 and 968; SH (CD3OD) 1.28 (6H, d, J 6.9, 
CHMez), 1.34-2.21 (6H, m, CHCH2CH2CH2), 2.91 (lH, septet, J6 .9 ,  CHMe2), 4.14 (lH, 
m, CHCHz), 4.31 (2H, t, J 7.0, NCHz), 5.04 (2H, s, CHZPh), 7.26-7.32 (5H. m, ArH), 8.35 
and 8.63 (each lH, s, 2-CH and 8-CH); & (CDiOD) 19.2 (CHMe2). 23.9, 28.9 and 32.11 
(CH2), 37.1 (CHMez), 44.8 (NCHz), 53.73 (CHCH2), 67.6 (CHZPh), 123.75 (Arc), 128.7, 
128.9 and 129.4 (ArCH), 138.15 (ArC), 145.6 (ASH), 150.5 (ArC), 152.9 (ArCH), 153.3 
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(ArC), 158.6, 175.7 and 178.2 (CO); d z  469 (m, loo%), 399 (40), 361 (50). 335 (30) 
and 291 (42). 
(S)-6-(N9-Adeninyl)-2-benzyloxycarbonyla~no~exanoic acid, 3.82 
* Lo LiOH THF-HZO 
ZHN OH 
Bu' 
3.82 
,Y0 
3.68 
Prepared following method E, using (2S,4S)-4-[4-(N9-adeninyl)butyl1-3- 
benzyloxycarbonyl-2-tert-butyloxazolidin-5-one 3.68 (0.27 g, 0.579 mmol) and lithium 
hydroxide monohydrate (73 mg, 1.74 mmol) to yield the title compound 3.82 as a white 
amorphous gum (0.197 g, 86%); Found: MH+ (ES') 399.1778. Cl9H22N604 requires: MH 
399.1781; v,,(KBr/cm-') 3327, 2971, 2361, 2342, 1704, 1515, 1266 and 1202; SH 
(CD30D) 1.38-1.98 (6H, m, CHCHzCHzCHz), 4.14 (lH, m, CHCHz), 4.25 (2H, t, J 7.0, 
NCHz), 5.06 (2H, s ,  CHZPh), 7.25-7.33 (5H, m, ArH), 8.18 and 8.26 (each IH, s ,  2-CH and 
8-CH); 6c (CD30D) 23.9 (CHCHzCHz), 30.45 (CHCHzCHzCHz), 32.1 (CHCHz), 44.9 
(NCHz), 55.0 (CHCHz), 67.6 (CHzPh), 126.15, 128.8, 129.0 and 129.5 (ArCH), 138.2, 
139.2 and 143.9 (ArC), 150.2 (ArCH), 155.0 (ArC), 158.6 and 176.15 (CO); d z  399 
( M P ,  loo%), 355 (15), 291 (60), 265 (60) and 247 (40). 
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(S)-5-{N2-Acetyl-06-[2-(4-nitrophenyl)ethyl]-N9-guaninyl}-2- 
benzyloxycarbonylaminopenîanoic acid, 3.83 
WPNP 
O 
I 
D b? LiOH THF-HzO 
ZHN OH 
I 
Bu' 
3.70 3.83 
Prepared following method E, using (2S,4S)-4-(3-(~2-acetyl-O6-[2-(4-nitrophenyl)ethyl]- 
N9-guaninyl]propyl)-3-benzyloxycarbonyl-2-te~-butyloxazolidin-5-one 3.70 (60 mg, 
0.091 mmol) and lithium hydroxide (10 mg, 0.18 mmol) to yield the title compound 3.83 
as a yellow solid (47 mg, 87%), m.p. 143-144'C; Found MH' 592.2156. C28H29N708 
requires; MH 592.2154; v,,(KBr/cm-') 3466, 2961, 2363, 2345, 1719, 1687, 1664, 1610, 
1518, 1345 and 1236; & (DMSO-&) 1.45-1.85 (4H, m, CHCH~CHZ), 2.20 (3H, s, 
CHiCO), 3.35 (2H, t, 56.7, CHzAr), 3.60 (lH, m, CHCHz), 4.20 (2H, m, NCHz), 4.75 (2H, 
t, J6.7, OCHz), 4.97 (2H, br s, CHzPh), 5.80 (lH, d, J7.5, CH"), 6.43 (lH, s, guanine- 
H), 7.20-7.40 (5H, m, ArH), 7.60 and 8.19 (each 2H, d, J 8.6, ArH) and 10.35 (lH, s, 
CONH); d z  592 (m, 60%), 562 (40). 546 (38). 516 (loo), 484 (40) and 428 (65). 3.83 
was too insoluble in DMSO-& for I3C spectra analysis and interpretation. 
General procedure for removal of a benzyloxycarhonyl group (Z) by hydrogenolysis 
to afford amino acids (method F) 
The Z-protected amino acid (1 mol equiv.) in ethanol (140 cm3) and water (60 cm3) was 
degassed with a stream of argon for 15 min. Palladium-charcoal catalyst (10 mol%, 0.1 
mol equiv.) was added and a stream of hydrogen was passed through the solution under 
vigorous stirring for 8h. The solution was again degassed with a stream of argon for 15 
min, and the catalyst was filtered and washed with a small amount of ethanol and water. 
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The solvents were removed under reduced pressure, toluene (20 cm3) was added and 
removed under reduced pressure (3 times) to eliminate traces of water. The crude residue 
was dried under vacuum to yield the free amino acid. 
(S)-2-Amino-5-(N1-thyminyl)penîanoic acid, 3.84 
3.73 
Prepared following 
Hz, PCVC 
* 
EtOH-HZO 
3.84 
method F, using (S)-2-benzyloxycarbonylamino-5-(Nl- 
thyminy1)pentanoic acid 3.73 (1.61 g, 4.29 mmol) and PdC (200 mg) to yield the title 
compound 3.84 as a white solid (760 mg, 74%), m.p. (decomp.) 124-125°C; Found: MH+ 
(ES') 242.1144. Cla1~N304 requires: MH 242.1141; v,,(KBr/cm-') 3448, 3153, 3034, 
2362, 1685, 1674, 1600, 1475, 1460, 1420 and 1220; &I (DzO) 1.57-1.91 (7H, m, 
CHCHzCH2 and CH=CCH3), 3.57-3.71 (2H, m, NCHz), 3.85 (lH, t, J 5.5, CHCHz) and 
7.29 (1 H, S ,  CH=CCH3); S, (DIO) 11.7 (CH=CCH3), 24.3 (CHCHzCHz), 27.2 (CHCH2), 
48.2 (CHzN), 53.45 (CHCH2), 111.3 (ArC), 143.4 (CH=CCH3), 152.7, 167.3 and 173.1 
(CO); d z  242 (MHf, 50%). 198 (loo), 169 (53), 146 (52), 127 (54), 113 (44) and 70 (70). 
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(S)-2-Amin0-6-(Nl-thyminyl)hexanoic acid, 3.85 
3.74 3.85 
Prepared following method F, using (2S)-benzyloxycarbonylamino-6-(N1- 
thyminy1)hexanoic acid 3.74 (1.32 g, 3.39 rnrnol) and PdíC (300 rng) to yield the title 
compound 3.85 as a white solid (680 mg, 79%), m.p. 219-220°C; Found: MH' (ES') 
256.1296. C11H,7N3O4 requires: MH 256.1297; v,,(KBr/crn-') 3432, 3050, 2955, 2362, 
1685, 1476, 1413, 1356 and 1130; OH (DIO) 1.21-1.29 (2H, rn, CHCH2CHz), 1.52-1.62 
(2H, apparent quintet, J 7.4, CHCHZCHZCHZ), 1.66-1.75 (5H, m, CHCHz and CH=CCH3), 
3.48 (lH, t, J 6.6, CHCHZ), 3.61 (2H, t, J 7.0, NCHi) and 7.33 ( i  H, s, CH=CCH3); ¿ic 
@zO) 12.1 (CH=CCH3), 22.2 (CHCHzCHz), 28.6 (CHCHzCHzCHz), 30.9 (CHCHz), 48.9 
(CHzN), 55.2 (CHCHz), 111.5 (ArC), 144.0 (CH=CCH3), 153.2, 167.9 and 175.6 (CO); 
m/z 256 (m, 70%), 212 (loo), 197 (30), 183 (34), 169 (60), 146 (28), 127 (28) and 84 
(42). 
(S)- 2-Amino-5-(N1-uracilyl)penîanoic acid, 3.86 
3.75 3.86 
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Prepared following method F, using (S)-2-benzyloxycarbonylamino-5-(N1- 
uracily1)pentanoic acid 3.75 (1.23 g, 3.41 m o l )  and Pd/C (150 mg) to yield the title 
compound 3.86 as a white solid (580 mg, 75%), m.p. 208-209'C; Found [M-HI- (ES-) 
226.0833. CgH13N304 requires: M-H 226.0828; v,,(KBr/cm-') 3513, 3457, 3090, 1692, 
1673, 1609, 1418, 1387, 1249 and 1237; (DzO) 1.47-1.82 (4H, m, CHCHzCHz), 3.59 
(IH, t ,  J 5.9, CHCHz), (2H, m, NCHz), 5.67 and 7.48 (each IH, d, J 7.8, CH=CH); S, 
@ 2 0 )  24.6 (CHCH~CHZ), 27.9 (CHCHz), 48.9 (CHzN), 54.9 (CHCHz), 102.2 and 147.8 
(CH=CH), 152.9, 167.5 and 174.8 (CO); d z  226 (M-H, 58%), 183 (20), 153 (30), 121 
(loo), 11 (40) and 90 (60). 
(S)- 2-Amino-6-(N1-uracilyl)hexanoic acid, 3.87 
3.77 3.87 
Prepared following method F, using (S)-2-benzyloxycarbonyIamino-6-(Nl- 
uracily1)hexanoic acid 3.77 (110 mg, 0.293 mmol) and PdC (30 mg) for 5 h to yield the 
title compound 3.87 as a white solid (60 mg, 90%), m.p. (decomp.) 187-205'C, that was 
incompletely characterized; v,,,(KBr/cm-') 3515, 3460, 3091, 1694, 1675, 1615, 1419, 
1389, 1249 and 1235; SH @ 2 0 )  1.26-1.93 (6H, m, CHCHzCHzCHz), 3.67 (lH, t, J 6.4, 
CHCHz), 3.74 (ZH, t, J 7.3, NCHz), 5.75 and 7.58 (each lH, d, J 7.8, CH=CH); S, (D20) 
22.1 (CHCHzCHz), 28.5 (CHCHzCHzCHz), 30.8 (CHCHz), 49.3 (CHzN), 55.4 (CHCHz), 
102.3 and 148.1 (CH=CH), 153.2, 167.7 and 175.4 (CO). 
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(S)-2-Amino-6-(5,6-dihydro-l-uracilyl)hexanoic a id, 3.88 
H2, PCVC 
- 
EtOH-H20 
3.77 3.88 
This was prepared following method F, using (S)-2-benzyloxycarbonylamino-6-(N1- 
uracily1)hexanoic acid 3.77 (150 mg, 0.40 mmol) and PcüC (100 mg) but for 16 h to yield 
the rifle compound 3.88 as a white solid (86 mg, 88%), m.p. (decomp.) 219-220°C; Found: 
MH+ (ES') 244.1297. C10H17N304 requires: MH 244.1297; v,(KBr/cm-') 3484, 2954, 
2931, 2344, 2362, 1729, 1466, 1288, 1275, 1044 and 971; &I @ 2 0 )  1.10-1.75 (6H, m, 
CHCH~CH~CHZ), 2.63 (2H, LJ7.2, CHzCO), 3.22 (2H, t, J7.3, CHzN), 3.35 (2H, t,J7.2, 
CH2CHiCO) and 3.94 (IH, m, CHCH2); & @O) 22.5 (CHCHZCH~), 27.1 
(CHCHZCH~CH~), 30.7 (CHzCO), 31.5 (CHCHz), 42.5 (CHZCH~CO), 47.5 (CHzN), 51.4 
(CHCH2), 148.0, 155.0 and 175.1 (CO); m/z 244 (m, is%), 198 (20), 155 (30), 141 
(40), 116 (34) and 84 (100). Traces of (S)-2-amino-6-(N1-uracilyl)hexanoic acid 3.87 were 
also isolated. 
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(S)-2-Amino-6-(N4-benzoyl-N1 cytosinyl)hexanoic acid, 3.89 
HN K Ph 
Hi, PCVC 
EtOH-b0 
HN 'Ph 
3.78 3.89 
This was prepared following method F, using a crude mixture of (S)-6-(N4-benzoyl-N1- 
cytosinyl)-2-benzyloxyca1bonylaminohexanoic acid 3.78 and excess Pd/C (200mg) in 
EtO-O 200 ml, 7/3, v h ) .  The NMR data of the crude sample was complicated and no 
definite assignment of the peaks could be made, the crude amino acid 3.89 was therefore 
used in the next step without purification. 
(S)-2-Amino-5-[N6-(2-methylpropanoyl)-N9-adeninyl]pentic a id, 3.90 
NHCOCHMq I THCOCHMe, 
3.79 3.90 
Prepared following method F, using (S)-5-[N6-(2-methylpropanoyl)-N9-adeninyl]-2- 
benzyloxycarbonylaminopentanoic acid 3.79 (190 mg, 0.419 mmol) and PdC (200 mg) to 
yield the title compound 3.90 as a white solid (100 mg, 75%), m.p. (decomp) 110-112'C; 
Found: MH+ (ES') 321.1680. C ~ ~ H Z O N ~ O ~  requires: M H  321.1675; v,,(KBr/cm-') 3386, 
2971, 2934, 2377, 1794, 1774, 1611, 1459, 1219 and 966; 6" (D20) 1.13 (6H, d, J 7.0, 
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CHMez), 1.58 (2H, m, CHCHZCHZ), 1.77 (2H, m, CHCHz), 2.75 (lH, septet, J 7.0, 
CHMez), 3.35 (lH, m, CHCHz), 4.22 (2H, m, NCHz), 8.27 and 8.53 (each lH, s, 2-CH and 
8-CH); 6c (CD30D) 26.9 (CHCHZCHZ), 29.3 (CHCHZ), 37.1 (CHMeZ), 44.65 (NCHz), 
49.0 (CHCHz), 124.5 (ArC), 128.8 and 129.4 (ACH), 145.7 and 151.0 (ArC), 153.0 and 
178.0 (CO); m/z 321 (m, 35%). 206 (30), 165 (55), 152 (65), 133 (64) and 115 (72). 
(S)-Z-Amino-6-[N6-(2-methylpropanoyl)-N9-adeninyllhexanoic acid, 3.91 
NHCOCHMe, 
I 
NHCOCHMe, 
I 
t 
H2, PCVC 
THF-H,O 
3.81 3.91 
Prepared following method F, using (S)-2-benzyloxycarbonyiamino-6-[N6-(2- 
methylpropanoyl)-N9-adeninyl]hexanoic acid 3.81 (230 mg, 0.491 mmol) and PdC (200 
mg) to yield the title compound 3.91 as a white hygroscopic solid (100 mg, 61%); Found: 
MH+ (ES+) 335.1824. C I ~ H Z Z N ~ O ~  requires: MH 335.1831; 6" @ 2 0 )  0.60 (6H, d, J 6.9, 
CHMeZ), 1.28 (2H, m, CHCHZCHZ), 1.06-1.31 (4H, m, CHCH2 and NCHzCHz), 2.20 (lH, 
septeLJ6.9, CHMez), 3.07 (IH, t, J5.9, CHCHz), 3.61 (2H, t, J7.2, NCHz), 7.66 and 7.87 
(each lH, s, 2-CH and 8-CH); 6c (DzO) 19.25 (CHCHZCHZ), 22.4 (NCHZCHZCH~), 30.7 
(CHCHi), 36.7 (CHMez), 44.5 (NCHz), 55.3 (CHCHz), 123.6 (ArC), 146.1 (ArCH), 149.2 
(ArC), 152.0 (ArCH) 152.2 (ArC), 176.5 and 181.2 (CO); m/z 335 (m, SO%), 291 @ O ) ,  
265 (loo), 221 (90), 204 (60), 178 (100). 149 (40) and 136 (80). 
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General method for conversion of an amino acid into its (S)-3,3,3-trifluoro-2- 
methoxy-2-phenylpropanamide (Mosher amide) (method G) 
Acetyl chloride (10 mol equiv.) was added dropwise at O'C to the amino acid (-50 mg) 
stirred in ethanol (-40 mi). The mixture was then stirred overnight at 25"C, heated at reflux 
for 4 h, cooled and the solvent evaporated under reduced pressure to give the ethyl ester 
hydrochloride salt which was further dned under vacuum Overnight. (R)-3,3,3-Trifluoro-2- 
methoxy-2-phenylpropanoyl chloride (MTPA-CI) was added dropwise at room 
temperature to the ester hydrochloride stirred in dichloromethane (4 cm3) and triethylamine 
(4 cm3). The mixture was stirred overnight then water (20 cm3) was added and the mixture 
extracted with ethyl acetate (3 x 20 cm3). The combined ethyl acetate layers were washed 
with saturated sodium hydrogen carbonate solution (3 x 10 cm3), dned (MgS04) and 
evaporated under reduced pressure. The crude material was purified by column 
chromatography (ethyl acetate/hexane, 50/50) to yield the desired Mosher amide. 
Ethyl (S)-2-amino-S-(Nl-thyminyI)pentanoate (S)-MTPA amide, 3.92 
i) EtOH, HCI 
¡i) (R)-MTPA-CVESN-DCM 
3.84 3.92 
Prepared following method G from amino acid 3.84 to yield the rifle compound 3.92 as a 
colourless oil; Found MH' (ES') 486.1856. C22H26F3N306 requires: MH 486.1852; 6" 
major and minor* diastereoisomers: 1.30 and 1.26* (3H, t, J7.1, CHZCH~), 1.53-1.96 (7H, 
m, CHCH2CH2 and CH=CCH3), 3.45 and 3.35* (3 H, s, OCH3), 3.56-3.78 (2H, m, NCHz), 
4.24 (2H, q. J 7.1, CH2CH3), 4.66 (lH, dt, J 4.6 and 8.3, CHCHz), 6.85 and 
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7.05* (lH, s, CH=CCH3), 7.35-7.44 (4H, m, NHCH and ArH), 7.54-7.57 (2H, m, ArH), 
9.04 and 9.00* (lH, s, Ar"); 6~ 12.3 (CH=CCH3), 14.1 (CHZCH~), 24.9 (CHCH~CHZ), 
29.5 (CHCH2CHz), 47.4 (NCH2), 51.1 (CHCHz), 55.3 (OCH3), 62.1 (CH2CH3), 83.7 (CF3), 
110.8 (CH=CCH3), 125.4 (quaternary C), 127.2, 128.6 and 129.6 (AKH), 132.8 (Arc), 
140.2 (CH=CCH3), 150.8, 164.2, 166.7 and 171.2 (CO); d z  486 (M+, lo%), 296 (loo), 
268 (20), 222 (90), 189 (70) and 105 (80); & (minor diastereoisomer) 49.074, (major 
diastereoisomer) -68.790, e.e: 85%. 
Ethyl (S)-2-Amin0-6-(Nl-thyminyl)hexanoate (S)-MTPA amide, 3.93 and ethyl (S)-2- 
amin0-6-(Nl-thyminyl)hexanoaîe (S)-MTPA diamide, 3.94 
i) EtOH, HCI 
il) (R)-MTPA-CI/Et$VDCM 
3.85 
F&""/\ph 
Me0 
3.93 
F3C"'bph 
MeO 
3.94 
Prepared following method G from amino acid 3.85 to yield the title monoamide 3.93 and 
the ritle diamide 3.94, both as colourless oils. Ethyl (S)-2-Amino-6-(N1- 
thyminy1)hexanoate (S)-MTPA amide 3.93: Found: @ (ES') 500.2019. C23H28F3N306 
requires: MH 500.2008; 8" major and minor* diastereoisomers: 1.28 and 1.21* (3H, t, J 
7.2, CHZCH~), 1.59-1.97 (9H, m, CHCH2CH2CH2 and CH=CCH3), 3.34* and 3.54 (3H, s, 
OCH3), 3.61 (2H, t,J6.8, NCHz), 4.16 (2H, q. J7.2, CHZCH~), 4.56 (IH, dkJ5.1 and 8.2, 
CHCHz), 6.89 and 6.98* (lH, s, CH=CCH3), 7.10 (lH, d, J8.2, NHCH), 7.31-7.36 (3H, m, 
ArH), 7.61-7.63 (2H, m, ArH) and 8.51 (lH, s, imide NH); & 12.3 (CH=CC&), 14.1 
(CHZm3). 22.1, 28.3 and 31.6 (CHz), 47.8 (NCHz), 51.7 (CHCHz), 55.3 (OCH,), 61.84 
(CHZCH~), 84.0 (CF3), 110.8 (CH=CCH3), 125.4 (quaternary C), 127.2, 128.5 and 
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129.6 (ArCH), 133.0 (ArC), 140.1 (CH=CCH3), 150.7, 163.9, 166.45 and 171.5 (CO); d z  
499 (M', loo%), 426 (70) 374 (30), 354 (20), 338 (40) and 324 (28). SF minor 
diastereoisomer -69.325, major diastereoisomer -68.869, e.e: 88%. Ethyl (2S)-amino-6-(1- 
thyminy1)hexanoate (8-MTPA diamide 3.94: Found -+ (ES') 733.2668. 
C33H35F~N308 requires: M"4 733.2672; 6" major and minor* diastereoisomers: 1.26 and 
1.22* (3H, t, J 7.2, CHZCH~), 1.61-1.94 (9H, m, CHCHzCH2CH2 and CH=CCH3), 3.34* 
and 3.45 and 3.49 (6H, s, 2 x OCH3), 3.61 (2H, t, J 6.8, NCH2), 4.21 (2H, q, J 7.2, 
CH2CH3), 4.62 (lH, dt, J 5.1 and 8.2, CHCHz), 6.91 and 6.99* (lH, s, CH=CCH3), 7.17 
(lH, d, J 8.2, NHCH), 7.26-7.45 (6H, m, ArH), 7.54-7.57 (2H, m, ArH) and 7.68-7.71 (2H, 
m, ArH); & 12.3 (CH=CCH3), 14.1 (CHZCH~), 22.1, 28.2 and 31.85 (CH2), 48.4 (NCHz). 
51.6 (CHCHz), 54.7 and 55.3 (Om3), 61.9 (CH$2H3), 84.0 (CF3), 110.55 (CH=CCH3), 
121.6 (CF3), 124.8 and 125.4 (quaternary C), 127.3, 128.3, 128.5, 128.6, 128.7 and 129.65 
(ArCH), 131.2 and 132.8 (ArC), 139.9 (CH=CCH3), 149.2, 162.6, 166.4, 171.5 and 171.9 
(CO); d z  716 (M', 16%), 517 (100). 500(80), 468 (50), 391 (20). 337 (65) and 286 (70). 
SF (minor diastereoisomer) -69.206 and -70.136, (major diastereoisomer) -68.830 and - 
70.017, e.e: 88%. 
Ethyl (S)-2-arnino-5-(Nl-uracilyl)pentanoate (S)-MTPA amide, 3.95 
i) EtOH, HCI 
* 
¡i) (R)-MTPA-CUEtjN-DCM 
H2N OH 
3.86 3.95 
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Prepared following method G from 3.86 to yield the title compound 3.95 as a colourless 
oil; Found: M"S+ (ES+) 489.1959. C21H&N306 requires: MNH4 489.1961; 8" major 
and minor* diastereoisomer: 1.30 and 1.26* (3H, t, J 7.1, CHZCH~), 1.50-1.96 (4H, m, 
CHCHZCH~), 3.45 and 3.34* (3H, s, OCH3), 3.48-3.77 (2H, m, NCHz), 4.23 (2H, q, J 7.1, 
CH2CH3). 4.67 (lH, m, CHCHz), 5.54 and 5.69* (lH, d, J 1.8 and 7.8 or 7.9*, 
CH=CHCO), 6.92 and 7.21* (lH, J 7.8 and 7.9*, CH=CHCO), 7.34-7.59 (5H, m, ArH) 
and 9.38 (lH, s, imide NH); & 14.1 (CH2CH3), 24.6 (CHCHzCHz), 29.5 (CHCH2). 47.9 
(NCH2), 50.85 (CHCH2), 55.2 (OCH3), 62.2 (CH2CH3), 84.0 (CF3) 101.9 (CH=CHCO), 
121.6 (quaternary C), 128.55, 128.7 and 129.5 (ArCH), 132.6 (A<), 143.9 (CH=CHCO), 
149.1, 161.7, 166.8 and 171.1 (CO); d z  472 (m, 65%), 398 (loo), 346 (80) and 296 
(28); &(minor diastereoisomer) -68.444, (major diastereoisomer) 48.157, e.e: 88%. 
Ethyl (S)-2-Amino-6-(Nl-uracilyl)hexanoate (S)-MTPA amide 3.96 
3.87 
i) EtOH, HCI 
¡i) (R)-MTPA-CVEt,N-DCM 
3.96 
Prepared following method G from amino acid 3.87 to yield the title compound 3.96 as a 
colourless oil, incompletely characterized; Found MNH4' 491.21 17. C Z I H ~ ~ N ~ O ~ F ~  
requires: M W  491.21 11; 8~ (minor diastereoisomer) 49.134, (major diastereoisomer) - 
68.869, e.e: 89%. 
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Ethyl (S)-2-amino-6-(N4-benzoyl-Nl-cytosinyl)hexanoate ester MTPA amide, 3.97 
3.89 
i) EtOH, HCi 
i¡) (R)-MTPAGi/Et3N-DCM 
* 
MeO+ 3.91 
F3C Ph 
This was prepared following method G using crude (S)-2-amino-6-(N4-benzoyl-N1- 
cytosiny1)hexanoic acid to give ethyl (S)-2-amino-6-(N4-benzoyl-Nl-cytosinyl)hexanoate 
ester MTPA amide which was directly analysed by 19F Nh4R. 6, (major diastereoisomer) - 
68.830; (minor diastereoisomer) -69.369; e t .  81%. 
Ethyl (S)-2-amino-6-(N9-adeninyl)hexanoate (S)-MTPA diamide, 3.98 
i) EtOH, HCI 
il) (R)-MTPA-CUEbN-DCM 
b 
3.91 
F3C11*/jph 
Me0 
3.98 
Prepared following method G from 3.91 to give the title compound 3.98; Found M" 
(ES') 725.2516. C,,q4N606F6 requires: MH 725.2522; S,, minor* and major 
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diastereoisomers: 1.26* and 1.29 (3H, t, J 7.2, CH$H,), 1.58-1.91 (6H, m, 
CHCH,CH,CHJ, 3.32* and 3.46 (3H, s, OCH,), 3.47 and 3.52* (3H, s, OCHJ, 3.76 (2H, 
m, NCHJ, 4.22 (2H, q, J7.2, CH,CH,), 4.58 (IH, dt, J5 .3  and 8.2, NHCHCHJ, 7.13 (lH, 
d, J 8.2, CONHCH), 7.37-7.67 (lOH, m, ArH), 7.92 and 8.00* (IH, s, ArH), 8.78 and 
8.80* (lH, s, ArH) and 9.60 (lH, s, CONH); 8, 14.2 (CWCHJ, 22.4, 29.3 and 31.7 (CHJ, 
47.7 (NCHJ, 51.6 (CHCHJ, 55.3 and 55.6 (OCHJ, 110.6 and 113.3 (quaternary C), 84.4 
(CF,) 122.8 (ArC), 127.2, 127.7, 128.4, 128.5 and 128.75 (ArCH), 129.0 (CF,), 129.6 
(ArCH), 131.7 and 132.9 (ArC), 143.1 (ArCH), 148.2 and 152.2 (ArC), 152.5 (ArCH), 
163.7, 166.4 and 171.4 (CO); d z  725 (MZ,  loo%), 535 (5). 189 (20) and 105 (8); SF 
major diastereoisomer -68.871 and 49.423; minor diastereoisomer -69.181 and 49.277; 
e.e. 86%. 
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